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Abstract 
Polyketides are a class of secondary metabolites that includes compounds with 
antibiotic and anticancer properties. In type I polyketide synthesis, the individual 
activities are arranged into large polyproteins, while in type II polyketide synthesis 
enzymes are encoded separately. 
Streptomyces coelicolor actinorhodin acyl carrier protein synthase (AcpS) is a 
promiscuous enzyme involved in type II polyketide synthesis that catalyses the 
transfer of the phosphopantetheine chain from coenzyme A (CoA) to acyl carrier 
protein (ACP). 
The crystal structures of S. coelicolor apo-AcpS and of AcpS in complex with CoA 
and acetyl-CoA were solved. These holo-AcpSs are the first type I AcpS structures 
where a magnesium ion, essential for activity, is present in the active site. 
Analysis of crystal structures of AcpS in complex with CoA and acetyl-CoA 
reveals the presence of a defined hydrophobic cavity for the phosphopantetheine 
chain of CoA. Mobile loop ML2, that defines one side of this cavity, could enlarge 
this pocket allowing extended CoAs to bind. 
A model was made for S. coelicolor AcpS: ACP complex and used to interpret 
fluorescence binding studies of mutant ACPs. Conserved arginines were identified 
on helix al of AcpS which are proposed to interact with conserved aspartate and 
glutamate residues on helix a2 of ACP. The interaction between AcpS Arg15 and 
ACP Asp41 could be important for activity and is proposed to lock the ACP serine 
into a reactive conformation. 
His 110 and Asp 11 in the AcpS active site could deprotonate (in)directly the active 
ACP serine. Each was mutated to alanine, and the respective mutant proteins were 
crystallized and characterized biochemically. H11OA was inactive but ITC 
confirmed CoA binding, giving evidence of a possible role in catalysis. D 111A had 
reduced activity. The structure revealed that CoA binds in two alternative 
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INTRODUCTION 
Chapter 1 Introduction 
Chapter 1 
Introduction 
1.1 The modern pharmaceutical industry 
Pharmacology as we know it is a relatively recent field of investigation. It is only at 
the end of the Nineteenth century, with the discovery that an active compound 
could be not only reproduced in laboratory, but also modified so that it could 
trigger a specific physiological response, that an incredible leap forward in the 
treatment of many pathologies was made. Until that moment, treatment of diseases 
had been based solely on the use of mineral, vegetable and animal extracts. In a 
very prolific period for the chemical and pharmaceutical fields, the crucial event 
was the discovery of penicillin by Alexander Fleming in 1928. When he came back 
from a long holiday, the young Scottish researcher noticed that, on a plate 
previously inoculated with Staphilococcus bacteria, there was a zone around an 
invading fungus, the Penicillum notatum, where bacteria could not grow. He 
isolated and purified the extract, and investigated the antibacterial properties of the 
active agent that he called penicillin. Fleming published his discovery in 1929 in 
the British Journal of Experimental Pathology [1], but little attention was initially 
paid to his article. A few years later, Fleming's findings were elaborated further by 
Walter Florey and Ernst Chain. The two scientists managed to improve the 
purification protocol of penicillin in a stable form, and, after several clinical trials, 
they developed methods for mass production and distribution of the first antibiotic 
in 1945. For their massive contribution to the pharmaceutical industry, Fleming, 
Florey and Chain received the Nobel Prize in Medicine in 1945. 
Since the discovery of the first antibiotic, things have progressed quickly and 
nowadays there is a huge demand for new compounds, and an increasing interest in 
the possibilities they offer. Moreover, a number of classes of natural products, 
synthesized in bacteria and fungi [2], with similar properties to those of synthetic 
compounds, have been identified. 
2 
Chapter 1 Introduction 
1.2 Polyketide natural products 
Polyketide products are a broad class of secondary metabolites that exhibit great 
functional and structural diversities (Figure 1.1), and have a broad range of uses, 
including antibiotic (erythromycin A, rifamycin S), immunosuppressive 
(rapamycin), antifungal (amphotericin B), antiparasitic (avermectin), insecticidic 
(spinosyn A), as well as anticancer (doxorubicin) properties [3]. So, there is a great 
commercial interest in the production of polyketides because of their wide 
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Figure 1.1 Structural and functional diversity of polyketides. (Figure adapted from 
[3]). 
Since the serendipitous discovery of the aromatic orcinol by James Collie in 1893, 
the polyketide field has expanded considerably. The structures of numerous 
molecules have been elucidated, and in addition, the cloning, isolation and 
3 
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characterization of the enzymes responsible for their biosynthesis has begun. 
Polyketides are synthesized by a broad range of organisms, including bacteria, 
fungi, marine organisms and higher plants, via the iterative condensation of simple 
carboxylic acid precursors, a reaction similar to that of fatty acid biosynthesis. The 
most abundant source of polyketides is the Actinomycetales, in particular the 
Streptomycetes and Saccharopolyspora strains. Myxobacteria and Pseudomonads 
are also other important sources of bacterial polyketides. The precisely 
programmed polyketide synthases, in association with other chemical modifications 
that occur after the synthesis of the polyketide chain by the so-called tailoring 
enzymes, are responsible for the great chemical diversity. 
Early experiments revealed that the polyketide synthesis is very similar to fatty acid 
synthesis (FAS). The two pathways are characterized by a common pool of simple 
precursors and by similar enzymes that are used for chain assembly, and the 
chemistry carried out during the synthesis has the same nature [4]. Fatty acid 
synthesis could be described as a special case of polyketide synthesis, where the 
resulting polyketide is always fully reduced to an aliphatic chain. In addition, fatty 
acid synthesis has been studied for longer, and it is therefore a good basis for study 
to understand polyketide synthesis. 
1.3 The fatty acid synthesis 
1.3.1 FAS biosynthetic pathway 
Fatty acid biosynthetic pathway (Figure 1.2) consists of an iterative decarboxylative 
Claisen condensation between a starter unit and an extender unit to form a ß-keto 
thioester. An acetate unit is firstly transferred from acetyl-CoA to the acyl carrier 
protein (ACP) by the malonyl-acetyl transferase (MAT), then to the active site of 
the condensing enzyme, the ketosynthase (KS). A malonyl extender unit is 
transferred from malonyl-CoA to the ACP by MAT, and then the condensation 
reaction occurring between both the starter and extender units produces an extended 
chain that is bound to the ACP. The chain is then reduced by a ketoreductase (KR), 
dehydrated by a dehydratase (DH), and reduced again by an enoyl reductase (ER). 
Finally, the nascent chain is transferred to the condensing enzyme and the cycle is 
repeated several times, until the chain is passed to a thioesterase (TE), which 
releases a free acid or acyl ester [5]. Usually, the chain length reaches a maximum 
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of 16-18 carbon atoms, yielding palmitoyl or stearoyl derivates [6]. Further 
extension cycles beyond carbon C18 can occur, but the ultimate length rarely 
exceeds 24 carbons [7]. 
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Figure 1.2 Fatty acid biosynthesis. 
In this cycle, a starter acyl unit, usually acetyl, is condensed with a malonyl unit, 
which undergoes decarboxylation in order to provide the electrons for a new 
carbon-carbon double bond. These acyl participants are bound as thioesters to the 
enzymes involved in the chain extension. If the starter acyl is bound to a cysteine 
thiol of the ketosynthase, the condensing enzyme, the extender units are bound to a 
thiol that is not part of the primary sequence of the acyl carrier protein, but it is the 
terminus of the phosphopantetheine arm that is added to the ACP after post 
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translational modification. The organization of the different activities that 
characterize the fatty acid synthesis depends on the organism. Type II bacterial and 
plant fatty acid synthases are discrete proteins that can be isolated separately and 
reactions are carried out by these individual enzymes. On the other hand, type I 
animal synthases consist of different domains, each of them with a separate 
activity, linked covalently to form a large multifunctional enzyme [6]. 
1.3.2 Structure of type I mammalian FAS 
Structurally, mammalian type I FAS consists of two identical polypeptide chains 
organised as dimers, forming two active sites at the homodimer interface [8,9]. A 
model for the FAS organization was proposed, and it was based on a logical 
interpretation of the possible structure of a FAS monomer [10]. Observing that the 
bifunctional dibromopropane could cross-link the thiol of the N-terminal 
ketosynthase of one monomer with the C-terminal thiol of the ACP of another 
monomer, a model with two extended FAS monomers disposed in a head to tail 
antiparallel arrangement was proposed. The re-examination of the dibromopropane 
experiment [11] and functional complementation studies of baculovirus mutants 
[12] revealed new intra- and intermonomer interactions. Following these 
investigations, an alternative model for the FAS, in which the two monomers are 
intertwined and head to head contacts are formed (Figure 1.3), was proposed [13]. 
In particular, the two ACP domains can interact with the MAT or KS domains of 
either subunit. It was also proposed that the ACP interacts with MAT and KS of 
either subunit during substrate loading and the condensation reaction, while they 
interact only with one subunit during substrate processing and release [9]. It was 
also proved that a single wild-type subunit of the synthase, oligomerized with a 
mutant subunit where all the active sites have been destroyed by mutations, was 
still capable of synthesis, suggesting that, while the fatty acid synthase functions 
most efficiently when both the inter and intramolecular interactions are conserved, 
the synthesis can also occur when only one subunit is active [ 13]. Very recently, the 
X-ray structure of the mammalian FAS has been published at a resolution of 4.5 A 
[14]. Whilst it was not possible to identify individual residues or trace the 
polypeptide backbone, but secondary structure elements were identifiable. The 
overall structure is very similar to the EM reconstruction [15], and appears to be 
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asymmetric in clear contrast with the antiparallel model (Figure 1.4). The central 
portion of the FAS structure is composed by the ketosynthase (KS) domain, which 
is dimeric, and by the dehydratase (DH) and enoyl-reductase (ER) domains. As 
well as the KS, the ER domain is dimeric, while the DH domains adopt a pseudo- 
dimeric fold within each monomer. The malonyl-acetyl transferase (MAT) and 
ketoreductase (KR) domains protrude from this central portion. Both MAT and KR 
domains assume a pseudo-symmetric arrangement and are monomeric. The 
location of the ACP and thioesterase domains was not clearly identified. 
go, 
113 j, - Z0x- os Z m Aý substrates Bý 
Figure 1.3 Model of the functional contacts between FAS domains. During 
substrate loading and condensation (A), ACP interacts with the ketosynthase (KS) 
and the malonyl/acetyl transferase of either subunit, while during substrate 
processing and release ACP interacts with the enzymes of the same subunit (Figure 
adapted from [9]). 
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Figure 1.4 Organisation of the FAS active sites. The KS dimer forms the bottom 
part of the central portion, while MAT domains protrude from the bottom. DH and 
ER domains are located at the top of the central portion, and the KR domains 
extend from the top. White stars indicate the pseudosymmetry-related suggested 
attachment regions for ACP and TE (Figure adapted from [14]). 
1.3.3 Fungal type I FAS 
The architecture of vertebrates and fungal type I FAS are different. In fungi, the 
functional domains are organized in a 2.6-MDa barrel-shaped a606 dodecameric 
complex [ 16]. Two polyfunctional proteins, a and ß, assembly the fungal fatty acid 
synthase complex. In Saccharomyces cerevisiae, the 210 kDa a-chain contains a 
KS domain, a ketoacyl reductase and a phosphopantetheinyl transferase domain. In 
addition, it includes an N-terminal ACP, required for the transfer of intermediates 
between the different catalytic sites. The 230 kDa ß-chain contains an acetyl 
transferase and a malonyl/palmitoyl transferase domain, a dehydratase and an enoyl 
reductase domain. The structure for the S. cerevisiae FAS was recently solved [ 17- 
19]. In addition, Ban et al. presented an atomic model of the Thermomvices 
lanuginosus type I FAS at 3.1 A [20]. The organization of the S. cerevisiae FAS is 
illustrated in Figure 1.5. The barrel-shaped FAS complex is separated into two 
halves by a wheel-like structure at the equator formed by the a subunits. The dome 
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is formed by a trimer of ß subunits which lie on each side of the a subunit wheel. 
The ACP domain is located inside the hollow particle and presumably moves 














Figure 1.5 The S. cerevisiae type I FAS. A) The overall a606 dodecameric complex. 
B) The top view of the a subunit. C) The ß subunit trimer viewed from the top. 
Figure adapted from [ 19]. 
1.3.4 E. coli type 11 FAS 
In the E. coli type II FAS, each reaction is carried out by a discrete enzyme, 
encoded by a unique open reading frame. Malonyl-CoA: ACP transacylase (FabD, 
MCAT) catalyses the malonate transfer from malonyl-CoA to the acyl carrier 
protein, a step that is essential for the beginning of the reaction but also for each 
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elongation cycle. The crystal structure of FabD [21,22] revealed that this enzyme 
shares the same catalytic Ser-His dyad of serine hydrolases. The ß-ketoacyl-ACP 
synthase III (FabH), the condensing enzyme, starts the reaction using CoA 
thioesters as primers, while the elongation condensing enzymes FabB and FabF 
utilize acyl-ACPs [23]. FabG, a member of the short chain 
reductase/dehydrogenase superfamily [24], is involved in the following NADPH 
dependent reduction of the ß-ketoacyl-ACP. Analysis of the crystal structures of the 
plant Brassica papas FabG-NADPH complex and the apo protein from E. coli 
revealed that a conformational change occurs when the cofactor is bound, and ACP 
loop-2 region is associated to FabG recognition and binding [25]. FabA and FabZ, 
which vary only in their substrate specificities, catalyze the dehydration of the ß- 
hydroxyacyl-ACP, producing the trans-2-enoyl-ACP [26]. Finally, the NADH- 
dependent reductase Fabl reduces the enoyl-ACP [27,28]. The following 
elongation steps are then catalyzed by the ß-ketoacyl-ACP synthase I (FabB) and II 
(FabF), which are characterized by a His-His-Cys active site motif common to the 
thiolases. 
1.4 Polyketide biosynthesis 
Polyketide synthesis is very similar to fatty acid synthesis. It involves successive 
decarboxylative condensation cycles between simple acyl units to form a ß-keto 






KS ACP ACP 
Figure 1.6 Claisen condensation between the starter and the extender units. The 
acyl starter unit is bound to the ketosynthase, while the malonyl extender unit to the 
ACP. 
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In contrast to fatty acid synthesis, polyketide synthesis involves variable cycles, 
with more complex modifications, and it needs to be more programmed than the 
fatty acid synthesis. The choice of the building units, their order and 
stereochemistry, and the order of further modifications are predetermined. 
Moreover, the polyketide chains are in many cases cyclised to produce macrocyclic 
rings, and the presence of multiple chiral centres and other modifications, for 
example the addition of sugars, methyl and hydroxyl groups, increase their 
structural complexity. In comparison to the fatty acid synthesis, a wider range of 
acyl starter units and modifying enzymes, including cyclase, oxygenases, NADPH 
and FADH- dependent oxidoreductases, acyl transferases, glycosyltransferases and 
N-methyl transferases, are present [29] (Figure 1.7). 
KS, 
S-SH 
















Figure 1.7 Polyketide synthesis. Polyketide synthesis involves a minimal system, 
composed of the acyl carrier protein (ACP), the ketosynthase KS(0 and KSf; (called 
also chain length factor (CLF)). This complex catalyses the condensation reaction, 
while other enzymes, such as the ketoreductase (KR), the dehydratase (DH) or the 
enoyl reductase (ER) can modify the growing chain before the beginning of a new 
extension cycle. 
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1.4.1 Polyketide synthases 
Each polyketide is synthesized by its specific polyketide synthase (PKS). Three 
types of polyketide synthases can be identified on the basis of their structure and 
mechanism. Type I PKSs, such as the erythromycin synthase, are giant 
multienzymatic proteins carrying all the active sites required for the biosynthesis of 
reduced polyketides, and they can be modular or iterative type I PKS. Type II 
PKSs, for example the one responsible for the production of the actinorhodin from 
Streptomyces coelicolor, are made up from single mono-functional enzymes that 
catalyse the formation of aromatic compounds, but not extensively reduced. These 
PKSs are analogous to the bacterial fatty acid synthases and are involved in the 
biosynthesis of bacterial aromatic natural products such as actinorhodin, 
tetracenomycin and doxorubicin. Finally, bacterial or plant type III PKSs, such as 
the stilbene or chalcone synthases, are usually single peptides that behave like 
condensation enzymes, without using ACP domains and acting directly on the 
coenzyme A thioesters of simple carboxylic acids [30]. While type I and II PKSs 
are structurally different but share a high level of sequence similarity, type III PKSs 
act as condensing enzyme and show little sequence similarity to the ketosynthases 
of either type I or II PKSs [31-33]. 
1.4.2 Type I PKSs 
Type I PKSs are multimodular domains similar to the type I fatty acid synthase. 
This group can be subdivided in iterative type I PKSs, such as the lovastatin 
nonaketide synthase (LNKS) [34], and modular PKSs, for example the 6- 
deoxyerythronolide B synthase (DEBS). 
1.4.2.1 Iterative type I PKSs 
Iterative Type I synthases are commonly found in fungi, and consist of a single 
module that is used iteratively, so that at least some of the constituent enzymes act 
in every cycle. Examples are the synthases involved in the biosynthesis of the 6- 
methylsalicylic acid (6-MSA) and lovastatin. 
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1.4.2.1.1 6-Methylsalicylic acid synthase 
6-MSA is assembled from one molecule of acetate and 3 of malonate (Figure 1.8). 
The PKS responsible for its synthesis consist of KS, MAT, DH, KR and ACP (in 
this order). These domains act repeatedly catalysing three rounds of chain 
extension, with different levels of reduction at each stage, using a mechanism that 
is not known. For example, while the first condensation is followed by reaction 
with a second malonate, the second condensation is followed by reduction and 
dehydratation of the new keto group. After the third cycle, the polyketide chain is 
cyclised, dehydrated and enolised to yield the aromatic 6-MSA [35] A thioesterase 
is not included in this system, probably because the release of 6-MSA does not 
occur by hydrolysis. 
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Figure 1.8 6-MSA polyketide synthesis. 
1.4.2.1.2 Lovastatin polyketide synthesis 
Another example of the iterative type I PKS is the one responsible for the synthesis 
of the non aromatic lovastatin, a cholesterol lowering agent produced by the 
filamentous fungus Aspergillus terreus. Lovastatin is composed of two polyketide 
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chains joined via an ester linkage [36]: one chain is a nonaketide, synthesized by 
the lovastatin nonaketide synthase (LNKS), the other a diketide produced by the 
lovastatin diketide synthase (LDKS). Both PKSs generate their product using an 
acetate starter unit and malonate extender units, adding also a methyl group from S- 
adenosyl methionine (Figure 1.9). The LNKS is unimodular and contains KS, AT, 
DH, ER, KR and ACP domains in the same order as in the animal FAS, with the 
additional presence of a methyl transferase (MeT) and the substitution of the TE 
domain with a putative peptide synthetase elongation domain (PSED). It is believed 
that LNKS works in cooperation with the discrete type II protein LovC (a putative 
ER), to synthesize dihydromonacolin L [37]. Dihydromonacolin L is then tailored 
to monacolin J. LDKS, which produces (2R)-2-methylbutyrate, is also unimodular 
with the same organization of LNKS, but without the PSED domain and with an 
active ER. The synthesis of lovastatin is completed by the attachment of the (2R)-2- 




















Figure 1.9 Lovastatin polyketide synthesis. The nonaketide and diketide portions 
are generated by two independent polyketide synthases. 
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1.4.2.1.3 SQTKS 
Polyketides produced by fungi show a wide diversity of both structural motif and 
activity. In some fungal PKSs, such as Aspergillus oryzae, a methyltransferase 
(MeT) domain was also identified. Squalestatin SI (also known as zaragozic acid 
A) is a powerful inhibitor of squalene Synthase, identified as a metabolite of 
Phoma sp. and other filamentous fungi [38]. Squalestatin can be used in the 
treatment of diseases associated with a high level of serum cholesterol 
concentrations, and it is composed of 2 polyketide chains (Figure 1.10). The main 
chain is a hexaketide (chain A), composed of a benzoate derived starter unit and 
five acetate-derivate extender unit, while the side chain (chain B) is a tetraketide, 
with acetate as starter unit. Four other carbons are derived from succinate, forming 
the acid core. 
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Figure 1.10 Squalestatin Si (A) and its chain B (B). 
After several experiments, including the generation of cDNA and PCRs, a 8142 bp 
PKS (Phoma PKS1) contained KS, AT, DH, C-MeT, ER, KR and ACP domain 
encoding regions, was inserted into the expression vector pTAex3 forming a 15747 
bp expression construct [39]. This vector utilizes an amyB promoter, which is 
induced by starch or maltose and is repressed by glucose. The translated gene 
encodes a polypeptide of 2714 amino acids. After expression in Aspergillus oryzae, 
organic extraction and RP-HPLC analysis, a new compound was found to be 
expressed. The characterization revealed that it was the B chain of squalestatin, and 
the protein encoded by Phoma PKS 1 was named SQTKS (Squalestatin Tetraketide 
Synthase). It seems that all the PKS 1 domains are active. The biosynthesis must 
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involve 3 rounds of chain extension, with the MeT occurring after the first and 
second round, and KR and DH active in all rounds. ER and C-Met are not active in 
the final round. SQTKS so can be a great starting point for studying fungal type I 
PKSs. It is important to point out that the auxiliary domains are involved 
selectively in specific cycles during the polyketide production. 
1.4.2.2 Modular type I PKSs 
Modular PKS, for example the systems responsible for the synthesis of macrolides 
like erythromycin, rapamycin and rifamycin, consists of multiple active domains 
organised into modules. Each module is responsible for the decarboxylative 
condensation reaction, followed by a programmed reductive cycle. These modules 
are active only once during the production of the polyketide, and usually in a 
sequential way. In addition, a loading module carries the starter unit at the front of 
the first module and a thioesterase unloads the polyketide at the end of the last 
module. 
1.4.2.2.1 The erythromycin polyketide synthase 
One example of modular type I PKS is given by the synthase responsible for the 
synthesis of the polyketide portion of the antibiotic erythromycin, the 6- 
deoxyerythronolide B (6-dEB). 6-dEB is produced by sequential condensation of 
propionyl-CoA with 6 units of methylmalonyl-CoA as enzyme bound 
intermediates, followed by lactonisation to 6-dEB [40-42]. Three enormous open 
reading frames, responsible for the production of 6-dEB: eryAl, eryAI1 and 
eryAIII, encode for three huge multienzyme polypeptides, 6-deoxyerythronolide B 
synthase (DEBS) 1,2, and 3 (Figure 1.11). Linker regions between each domain are 
vital to maintain the correct topology. Each DEBS protein contains two functional 
modules, and each module is composed of the three essential catalytic domains, 
KS, AT and ACP, plus a variable set of other domains [43-45]. The three essential 
domains cooperate to catalyse the carbon-carbon bound by Claisen condensation, 
while the variable set of domains located between the AT and ACP (shown as a 
loop above the line of essentials domains in Figure 1.11) carry out the reductive 
modifications. No reductive domains are found in module 3, while the others 
incorporate a KR domain. Module 4 is characterized by a complete set of reductive 
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activities (DH, ER and KR). Structural studies of the DEBS proteins, including 
crosslinking experiments, have inspired a head to head homodimeric double helical 
structure [46] (Figure I. 12). 
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Figure 1.11 Domain organization of the erythromycin polyketide synthase. Each 
module incorporates the essential KS, AT and ACP domains, while all except one 
include optional reductive activities (Figure adapted from [3]). 
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Figure 1.12 Double helical "Cambridge model" for the erythromycin synthase. The 
ACP can cooperate with KS and AT in the other module (Figure adapted from [3]). 
1.4.3 Type 11 PKSs 
Type II PKSs are discrete enzymes that can be used several times during the 
production of a polyketide [5,47,48]. The products of these synthases are 
generally phenolic aromatic compounds. Polyketides are produced by the 
condensation of building blocks, and subsequent cyclization and aromatization of 
these chains occur. 
1.4.3.1 Type II PKS gene cluster organization 
The most studied type 11 PKS is the synthase involved in the production of 
actinorhodin by Streptomvices coelicolor, a gram positive bacterium that produces 
the polyketide antibiotics actinorhodin and methylenomycin, the 
immunosuppressive undecylprodigiosin, the non-ribosomal peptide antibiotic CDA 
and also the usual range of bacterial fatty acids. The gene cluster responsible for the 
actinorhodin biosynthesis was identified in 1992 by Fernandez-Moreno [49]. The 
identification of other type II gene clusters suggests a similar gene organization and 
consequently a similar evolutionary pathway (Figure 1.13). By using gene deletion 
experiments [50-53], it was discovered that a minimal set of three enzymes, 
encoded by the act! gene, is required in vivo for the catalysis: the acyl carrier 
protein, the ketosynthase a, the condensing enzyme, and the ketosynthase ß, also 
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known as chain length factor (CLF) or chain initiation factor (CIF) [54]. For 
example, the unnatural polyketides SEK 4 and SEK 4b, produced by the 
actinorhodin minimal PKS, are obtained after 8 condensation reactions followed by 
cyclization [53]. Then other enzymes, such as ketoreductases, aromatases and 
cyclases, modify the nascent polyketide to produce the final product. 
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Figure 1.13 Organisation of gene cluster for type Il PKSs. From the top: 
actinorhodin (act), tetracenomycin (tcm), oxytetracycline (otc) and daunorubicin 
(dps/dau). Figure adapted from [3]. 
1.4.3.2 Acyl Carrier Protein 
The biosynthesis of polyketide secondary metabolites takes place on large 
multienzymatic complexes starting from small building blocks [5]. In both 
polyketide [4,55,56] and fatty acid [8,57,58] synthesis, and in the biosynthesis of 
non-ribosomal peptides [59], specialized acyl carrier proteins (ACPs) hold the 
assembly intermediates during biosynthesis. So, the acyl carrier proteins are very 
important during type I and II fatty acid and polyketide biosynthesis. Their 
phosphopantetheine acts as a long flexible arm that carries and delivers the nascent 
chain to the right destination. ACP is expressed as the inactive apo-protein, that is 
then converted to the holo form by a post- translational modification [60]. The 4' 
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phosphopantetheinyl (P-pant) moiety is transferred from the coenzyme A (CoA) to 
a conserved serine on the ACP. The side chain of this serine acts as a nucleophilic 
group attacking the pyrophosphate linkage of CoA. This modification is guided by 
the acyl carrier protein synthase (AcpS) in a magnesium dependent reaction [611 
(Figure 1.14). The phosphopantetheine arm fulfils the two essential demands in 
fatty acid and polyketide biosynthesis: the intermediates remain covalently attached 
to the protein and the length and flexibility of the phosphopantetheine arm, 
approximately 20 A, allows the transport of the intermediate between the different 
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Figure 1.14 Phosphopantetheinylation of apo-ACP. The post-translational reaction 
is catalyzed by the Acyl carrier protein Synthase (AcpS) in the presence of CoA 
and magnesium. 
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ACPs share a high level of structural and amino acidic similarity. They can be 
described as a characteristic bundle of small negatively charged a-helices. Different 
ACPs, such as the E. coli [62] and B. subtilis [63] fatty acid ACPs, the actinorhodin 
polyketide ACP [64], the rat [65] and human [66] fatty acid ACP domain, and the 
oxytetracycline [67] and frenolicin [68] polyketide ACPs, have been solved by 
NMR and X-ray crystallography (Figure 1.15). Actinorhodin ACP from 
Streptomyces coelicolor was the first polyketide synthase ACP to be solved by ID 
and 2D NMR. It is a small protein composed of 86 amino acids, and it consists of 
three major helices, a shorter helix, and a large loop region that separates helices I 
and 2. The site of the phosphopantetheinylation, Sei-42, is located at the base of the 
negatively charged helix a2 [64,69]. 
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Figure 1.15 Structures of different apo-ACPs. Cartoon representation of. A) 
actinorhodin polyketide ACP (PDB code: 2af8); B) E. coli fatty acid ACP (1 acp) 
C) B. subtilis fatty acid ACP (lhy8) D) Rat fatty acid domain of ACP (2png). The 
active serine is shown as sticks. 
ý7 \ 
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It was also proved that the C 17S actinorhodin ACP mutant, expressed to prevent 
the formation of a disulphide bond between the phosphopantetheine thiol and 
Cys 17, can undergo self malonylation in vitro in the absence of a malonyl- 
CoA: ACP transferase [70]. This self-malonylation activity of act ACP is in contrast 
with what reported by Khosla and Hutchison. MCAT recruited from the fatty acid 
synthesis seems to be essential for the biosynthesis of polyketides in the 
actinorhodin and tetracenomycin minimal polyketide synthases [47,71]. However, 
more recent work carried out in the Department of Chemistry, Bristol, has shown 
that act ACP can self acylate with different unnatural starter units derived from ß 
keto N-acetylcysteamine (NAC) thiolesters, that are not substrates for the MCAT, 
giving further evidence of the self-acylation activity of actinorhodin ACP [72]. 
1.4.3.3 Acyl carrier protein Synthase 
The important phosphopantetheine arm of ACP is transferred from the coenzyme A 
(CoA) to a conserved serine residue of the ACP in a post-translational modification 
guided by the acyl carrier protein synthase (AcpS) [61,73]. AcpS belongs to the 
phosphopantetheinyl transferase superfamily, which can be classified into three 
groups, according to their sequence homologies and substrate spectrum. Group I 
contains bacterial proteins of about 120 residues, that transfer the 
phosphopantetheine arm onto fatty acids ACPs, and have been shown to accept 
type II PKS ACPs [74,75]. The enzymes responsible for the modification of the 
peptidyl carrier protein subunits of non-ribosomal peptide synthases, of which Sfp 
from Bacillus subtilis is an example [76], are members of group II, that are bigger 
proteins, usually composed of 240 amino acids. Sfp exhibits a broader substrate 
specificity than other type I AcpS, and it is able to modify fatty acid and polyketide 
ACPs [61,77]. The crystal structure reveals a two-domain enzyme, where each 
domain has a fold which is similar to the one of type I AcpS subunit [78] (Figure 
1.16). A mechanism was proposed whereby a water molecule involved in Mg2+ 
complexation will be replaced by the hydroxyl group of the serine residue of the 
substrate PCP. This hydroxyl group can be deprotonated and act as nucleophile for 
the ß-phosphate of CoA. In order to prevent self-hydrolization, the deprotonating 
base must be displaced by conformational change or must be provided by the PCP 
substrate [78]. 
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Figure 1.16 Surfactin syntethase-activating enzyme Sfp. Cartoon representation of 
the Sfp in complex with CoA, coloured in green (PDB code: l qrO). 
Group III includes proteins that are part of the heteromeric type I yeast and fungal 
FASs [79]. They seem to transfer the phosphopantetheine chain to their acceptor 
ACPs before the assembly of the protein complex they belong to. 
Typically, organisms use one phosphopantetheinyl transferase for each individual 
phosphopantetheine-dependent pathway. For example, Escherichia co/i has three 
phosphopantetheinyl transferases: the AcpS involved in the fatty acid synthesis, 
EntD that catalyses the synthesis of the siderophore enterobactin, and the product of 
the gene yhhU. Unlike Sfp, these AcpSs normally recognize their cognate ACPs 
[80]. 
The E. coli AcpS gene forms an operon with the upstream gene pdxJ, which 
function is required for the biosynthesis of vitamin B6 [81,82]. The AcpS gene was 
originally identified as dpi (downstream of pdxl). The gene, essential for the 
growth of E. co/i, encodes for a very low abundant small protein of about 14 kDa, 
and it was also shown that it can exhibit a discrete substrate specificity and can 
utilize a variety of ACPs [60,75,83-85]. 
Recently, the crystal structure of the acyl carrier protein synthase from Bacillus 
subtilis involved in fatty acid synthesis has been determined with and without the 
coenzyme CoA, and in complex with the B. subtilis type 11 holo-ACP [86] (Figure 
1.17). 
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Figure 1.17 B. subti/is FAS AcpS: ACP complex. Cartoon representation of the B. 
subtilis AcpS: ACP complex (PDB code: 1180). ACP is shown in yellow, AcpS in 
cyan, and the phosphopantetheine chain in green. 
The structure reveals a novel trimeric arrangement of molecules, resulting in three 
active sites. The cofactor CoA lies at the interface between two monomers. ACP 
interacts with the AcpS via salt bridges formed by arginines in helix al of AcpS 
and glutamate and aspartate residues on helix a2 of ACP (Figure 1.18). It was 
proposed that a water molecule in the AcpS active site, named "activating water", 
can be deprotonated by Asp35 of ACP or by a solvent water and then deprotonate 
the hydroxyl group of ACP Sei-36, the site for the attachment of the 
phosphopantetheine chain [86]. In addition, the structure of the Streptococcus 
pneumoniae AcpS has been solved in its apo form and in complex with the 3'-5'- 
ADP [87], and the structure of the human AcpS complexed with CoA and in 
ternary complex with CoA and human type I ACP has been recently determined 
[66] (Figure 1.19). S. pneumoniae AcpS is very similar to the B. subtilis 
phosphopantetheinyl transferase, with a trimeric fold and a cofactor binding site 
located at the interface between two monomers [87]. The human AcpS belongs to 
the type II class. It consists of two identical domains connected by a short linker 
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region, in a fold that is similar to the Sfp one, with the exception of the N- and C- 
terminal region that are unique to the human enzyme. The type I ACP domain was 
also solved in this study, but the ACP serine was mutated to an alanine to facilitate 
crystallization. The interaction between the two proteins occur on a large interface 
and it is predominantly hydrophobic [66]. This recognition is different from the one 
proposed for the B. subtilis complex, where negatively charged residues are 
proposed to mediate AcpS binding [86], although the positioning of the human 
ACP is similar to that for the B. subti/is fatty acid ACP. A comparison between 
human and E. coli ACPs revealed a considerably lower overall negative charge in 
the human ACP. It was proposed that, after magnesium and CoA binding, ACP 
completes the complex. A proton is then abstracted from the serine not by a water 
molecule, but by a glutamate residue from AcpS [66], in contrast to what was 







Figure 1.18 Interaction between B. subtilis AcpS and ACP. Conserved arginines in 
the AcpS make salt bridges with negative ACP residues (Figure adapted from [86]). 
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Figure 1.19 Human AcpS: ACP complex. Cartoon representation of the human 
AcpS in complex with type I fatty acid ACP domain and CoA (PDB code: 2cg5). 
AcpS in shown in cyan, ACP in yellow, and CoA in green. 
1.4.3.3.1 Streptomyces coelicolor AcpS 
The gram positive Streptomvices coelicolor produces the antibiotics actinorhodin 
and methylenomycin A [88], the immunosuppressive undecylprodigiosin [89], the 
non-ribosomal peptide antibiotic CDA [90-92] and also the usual range of bacterial 
fatty acids. All of these compounds require holo-ACPs for their biosynthesis. The 
gene cluster encoding for undecylprodigiosin synthesis appears to contain a 
phosphopantetheinyl transferase gene [89], but the other biosynthetic gene clusters 
do not, suggesting that S. coelicolor contains a multifunctional protein capable of 
activating a wide range of acyl proteins. S. coelicolor AcpS was identified, 
expressed and characterized by Cox and colleagues [74]. It was shown that this 
AcpS can transfer the phosphopantetheine chain to the fatty acid ACP as well as to 
the type I and II polyketide ACPs [74], a property that is quite unusual. In addition, 
it was proved that this protein can transfer modified CoAs to its ACP partner. S. 
coelicolor AcpS is therefore "promiscuous", in term of both substrate recognition 
and cofactor transfer. The S. coelicolor AcpS, in an activation reaction with apo- 
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ACP and modified CoAs, can be used for the production of acylated ACPs, which 
can be utilised for further investigation of the PKS. 
1.4.3.4 Ketosynthase a and ketosynthase ß 
The ketosynthase a (KS, ) and ketosynthase ß (KS13) form a heterodimer in solution 
[93], and show high sequence similarity (Figure 1.20). KS1; is lacking an active site 
serine, which is essential for the activity. KS, catalyzes the Claisen condensation, 
while the role of the KS1j subunit is not very clear and became the subject of 
scientific investigations. The important cysteine in the active site of the a subunit is 
mutated to a glutamine in the KSO. Despite this, KS1 is not catalytically silent. This 
glutamine seems to be involved in loading malonyl-CoA and its decarboxylation to 
acetate (Figure 1.21). 
Figure 1.20 Type II actinorhodin KSa/ KSp. Cartoon representation of the 
actinorhodin ketosynthase/chain length factor. KSa is coloured in red, KS13 in grey. 
The serine and the glutamine in both active sites are shown as sticks. 
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In addition, mutagenesis studies on the ß-ketoacyl synthase unit of an animal fatty 
acid synthase, where the cysteine was replaced with a glutamine, showed that the 
rate of malonyl decarboxylation was increased by two orders of magnitude [94]. 
Consequently, it was proposed that the ß subunit acts as a chain initiation factor that 
generates acetyl ACP, and for this reason it was also called chain initiating factor 
(CIF) [54]. In addition, KSp is supposed to be the primary determinant of the right 
carbon length, and for this reason it is also known as chain length factor (CLF) [95, 
96]. From the analysis of the actinorhodin KS-CLF crystal structure [93], it was 
proposed that a protein cleft keeps the growing chain extended. Several amino acids 
were identified that serves as gatekeepers in the polyketide tunnel. In addition, the 
first ring cyclization of the polyketide occurs within the KS-CLF tunnel, and it was 












Figure 1.21 Reaction catalyzed by the KSa and KSji complex. A) Acetyl starter unit 
is formed by decarboxylation of malonyl-CoA catalyzed by KS, i. B) The starter unit 
is transferred to the KSa, while the ACP is loaded with the malonyl extender unit. 
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1.4.3.5 Ketoreductases 
Ketoreductases (KRs) catalyze the stereospecific hydrogen transfer from NAD(P)H 
onto a keto group. In most cases, they are an integral part of bacterial aromatic 
PKSs, where they can be the first enzyme to modify the nascent polyketide chain 
prior to cyclization [97]. 
1.4.3.5.1 Actinorhodin ketoreductase 
The minimal system responsible for the synthesis of actinorhodin produces a 16 
carbon polyketide chain, and can also partially control the first cyclization, though 
aberrant products with the wrong cyclization can be observed [53,98]. The 
actinorhodin ketoreductase (KR) is the first enzyme that modifies the nascent 
polyketide, reducing the carbonyl group at C-9. The act minimal system produces 
two compounds, SEK4 with the correct first cyclization (C7-C12), but with the 
other incorrect, and SEK4b - the intermediate preceding mutactin - with the 
alternate (C10-15) cyclization [53]. The addition of the KR to the minimal system, 
in vivo and in vitro, predominantly yields mutactin, which is correctly cyclised and 
reduces the presence of incorrectly cyclised intermediates, SEK 4b and SEK4 [99, 
100] (Figure 1.22). This is good evidence that KR can help the minimal system in 
catalysing the correct cyclization C7-C12. 
Moreover, in presence of KR there is an increase in the overall polyketide 
production in comparison with the minimal system, and in KR-deficient mutants 
there is an increase in misfolded polyketide [101,102]. Both pieces of evidence 
could suggest that KR may stabilize the complex or produce more efficient 
intermediates. 
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Figure 1.22 Putative biosynthetic scheme for the early steps of actinorhodin 
biosynthesis. A mixture of SEK4 and SEK4b is produced by the minimal system, 
and the addition of the KR leads to production of mutactin (Figure adapted from 
[103]). 
Recently, the first structure of a type II ketoreductase, the actinorhodin KR from 
Streptomyces coelicolor, was solved at a resolution of 2.5 A [103]. Act KR belongs 
to the short-chain dehydrogenase/reductase evolutionary family (SDR) of 
NADP(H)-dependent enzymes [24,104-106]. The most closely related sequences 
are those of fatty acid ketoreductases, which reduce the beta-keto carbonyl of the 
beta-ketoacyl-ACP in the first reductive stage of fatty acid synthesis [107-110]. In 
the crystal structure (Figure 1.23), the enzyme is a tetramer made up of a dimer of 
dimers, and each crystallographic unit contains 2 subunits, A and B, with two 
different conformations. Both subunits are arranged in a Rossmann dinucleotide 
binding fold, each containing a7 stranded ß-sheet and 8 a-helices, and bound to the 
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Figure 1.23 Actinorhodin ketoreductase crystal structure. A) Tetrameric 
arrangement of KR, with the A subunit in magenta and the B subunit in green. B) 
Topology diagram (Figure adapted from [103]). 
The act KR was crystallized in the presence of 4M sodium formate, and formate 
molecules are found in the active site of the open subunit A, while in the closed 
subunit B they are not present. These formate molecules could indicate favourable 
binding sites for the carbonyl oxygens of the nascent polyketide. 
The active site is composed of a conserved triad of residues, which consists of 
serine, tyrosine and lysine, and it is characteristic of the whole SDR family [I 1 I], 
while the substrate binding site is located above the NADP+ and toward the C- 
terminal end of the subunit, near helices a6 and 0. In SDR enzymes, the reduction 
catalytic mechanism is proposed to occur via hydride transfer from the NADPH 
followed by proton donation from a nearby tyrosine hydroxyl group. This proton 
transfer occurs from the tyrosine of the enzyme to the carbonyl oxygen of the 
substrate. The conserved serine is thought to help stabilize the bound substrate 
through hydrogen bonds. The amino group of the lysine can provide hydrogen bond 
interaction with the nicotinamide ribosyl moiety of the cofactor and can also lower 
the pKa of the proton on the catalytic tyrosine through ionic interactions [ 108,1 1I]. 
By superimposing the two subunits, it appears clear that there is a structural 
difference in the conformation of helices a6 and a7, that, compared to subunit B, 
appear to be rotated 19° in subunit A, and resulting in a more open active site 
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conformation for the subunit A, while in the subunit B the closed position of these 
helices seems to restrict the access to the active site (Figure 1.24). 
Figure 1.24 KR open and closed forms. Superimposition between the open A 
subunit (magenta) and the closed B subunit (green) (Figure adapted from [ 103]). 
It was suggested that the active site is opened by the binding of the cofactor [1 10], 
but the fact that both subunits are bound to NADP+ in the act KR seems to 
contradict this hypothesis. It appears instead that a crystal contact between the A 
subunit and a symmetry related B' subunit leads to the opening, in particular 
helices as and ab of the B' subunit impinge upon both the cofactor binding region 
and the active site of subunit A [103]. So, protein-protein interaction seems to be 
the mechanism for the opening of the subunit A. In particular, there are features of 
the interacting part of subunit B that are reminiscent of ACP. A model is therefore 
proposed for the interaction between KR and ACP. The cofactor should bind to 
each subunit, stabilising the formation of the tetramer. In this state, the catalytic 
triad is placed in the right position and the substrate binding site is closed with 
water excluded. Then a negative charged patch on helix a2 of ACP can recognize 
the positive patch present on KR surface, inducing the conformational change that 
allows the insertion of the substrate in the active site. Inspection of this docking 
model revealed that negative glutamate ACP residues were located in a positive 
patch formed by arginines 38,65 and 93. On the contrary, for the E. coli KR FabG, 
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arginines 129 and 172 were proposed to be essential for ACP binding. Mutations of 
these two residues abrogate the fatty acid biosynthesis [25]. These two residues are 
not conserved among PKS KRs, and their closest counterparts are far away from 
the active site [103]. 
1.4.3.6 Cyclases and aromatases 
Highly reactive poly-p-keto intermediate can undergo spontaneous aldol reaction or 
directed cyclization. Cyclases (CYCs) function in a chaperone-like way, directing 
the intermediate into particular channels were aldol chemistry is suppressed. 
Unfortunately, the instability of their substrates complicates their study. So, their 
function can only be understood through inactivation experiments and analysis of 
the products. Anyway, it seems that cyclization occurs before the dehydrogenation 
carried out by aromatases [29]. Cyclases can exist as didomain with internally 
duplicated motifs [52,112], or as monodomains [113]. These domains can be fused 
with other functionalities, for example CYC/KR or CYC/MT. An example of 
cyclise is given by the tetracenomycin F2 cyclase from S. glaucesens, Tcml. The 
crystal structure revealed an arrangement similar to the one found in other 
polyketide monoxygenases, with a large cavity where the substrate should bind 
[114]. 
In addition to cyclases, aromatases help the cyclization process. These enzymes 
dehydrate cyclic alcohols to yield aromatic rings. A particular example is given by 
LanV involved in landomycin biosynthesis. The protein appears to be bifunctional, 
catalysing the ketoreduction step at position C-6 followed by the dehydration 
reaction and thus the aromatization of the ring A of angucycline [115]. The crystal 
structure of the tetracenomycin (tcm) ARO/CYC was solved recently [116]. This 
enzyme contains a highly conserved interior pocket. The size, shape and 
composition of the pocket are proposed to be important to orient and specifically 
fold the polyketide chain for C9-C14 first-ring and C7-C16 second-ring 
cyclizations. It was also proposed that the regiospecific cyclizations of the first two 
rings and subsequent aromatizations take place in the interior pocket. 
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1.4.3.7 Tailoring enzymes 
In addition to the enzymes previously described, polyketide synthesis is also 
characterized by the presence of tailoring enzymes that extend the structural 
diversity of the products. Methyltransferases usually use the S-adenosyl-L- 
methionine (SAM) cofactor to transfer its activated methyl group to nitrogen, 
carbon or oxygen atoms. The degree of amino acid similarity among these proteins 
is quite low, although they often share a common chain-fold consisting of a central 
ß-sheet with surrounding a-helices, with a SAM binding site. Oxygenases promote 
the incorporation of oxygen into a substrate. They are divided into mono or 
dioxygenases, depending on the number of oxygens transferred. Several types of 
oxygenases are known to act in the post-PKS II modification, such as the 
cytochrome P-450 monooxygenases, flavin-dependent mono- and dioxygenases, 
and anthrone oxygenases. Finally, glycotransferases can catalyse the formation and 
attachment of sugars to bacterial aromatic polyketides [29]. 
1.4.3.8 Daunorubicin/doxorubicin synthesis 
Daunorubicin belongs to the anthracycline family and it is used for the treatment of 
cancer. It was initially isolated form Streptomyces peucetius and it is most 
commonly used to treat specific types of leukemia. The hydroxylation of carbon 
C14 yields doxorubicin, a drug widely used in cancer therapy. Daunorubicin is 
more abundant as natural product, and can be produced by a wide range of 
Streptomyces strains, while doxorubicin can be produced only in special 
environmental conditions or by introduction of genetical modifications [117,118]. 
The cytochrome P450 oxydase, DoxA, catalyses the oxidation of daunorubicin to 
doxorubicin [119,120]. The anthracycline skeleton of doxorubicin is produced by a 
type II polyketide synthase. A 21-carbon decaketide chain is produced by 
condensation of a single propionyl-CoA and 9 malonyl-CoA. After the elongation 
steps are concluded, successive modifications produce a tetracyclic anthracycline 
aglycone [ 121 ]. The daunosamine amino sugar is attached to the aglycone and other 
modifications yield daunorubicin and finally doxorubicin [122]. Dps genes are 
responsible for the linear chain formation and the first cyclizations. The dnr and 
dnm gene clusters are responsible for the remaining modifications and for the 
amino sugar synthesis respectively. After the reactions catalyzed by the minimal 
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system DpsA (KS, ), DpsB (KSi) and DpsG (ACP), with the additional help of 
DpsC and DpsD, the ketoreductase DpsE is the first enzyme that catalyzes 
reduction in position C9. It was suggested that DpsC, a FabH-like ketosynthase, is 
responsible for the selective choice of propionyl as a starter unit and catalyzes the 
first condensation of malonyl-CoA with propionyl-CoA [ 123,124], and then DpsD, 
an acyl-transferase, loads the diketide onto the minimal complex [ 118,125]. After 
genetic modification experiments, it was also revealed that DpsE requires substrates 
with a chain length of more than 16 carbon atoms [126]. The catalysis of 
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Figure 1.25 Daunorubicin/doxorubicin polyketide synthase. 
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1.4.4 Type III PKSs 
Type III PKSs are found in bacteria and higher plants. They are typically 
multifunctional enzymes that catalyse the synthesis of important intermediates for 
the production of floral pigments, phytoalexins and mediators of plant fertility, and 
melanin and other napthoquinone ring based metabolites in various filamentous 
bacteria [30,31,127,128]. Examples are the chalcone and stilbene polyketide 
synthases (Figure 1.26). They are giant condensing enzymes that catalyze the 
condensation of p-coumaroyl-CoA and malonyl-CoA to a common tetraketide 
intermediate, followed by different cyclization reactions that produce naringenin 





















Figure 1.26 Reactions catalyzed by type III chalcone and stilbene polyketide 
synthases. 
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These PKSs utilize CoA thioesters directly, without using the phosphopantetheine 
arm of ACP, moreover, they catalyze all the decarboxylation, condensation, 
cyclization and aromatization reactions in a single active site. The Medicago sative 
chalcone synthase crystal structure was solved in 1999 [127]. The protein is related 
to the E. coli KASIII and the thiolase super family. In the active site, the conserved 
residues Cys164, Phe215, His303 and Asn336 were identified. It was proposed that 
the thiolate of the cysteine acts as a nucleophile to load the acyl intermediate, the 
asparagine and histidine carry out the decarboxylation of malonyl-CoA, and the 



























Figure 1.27 Proposed mechanism for the chalcone synthase. R is the coumaroyl 
moiety in the first reaction cycle, coumaroyl-acetyl in the second, and coumaroyl- 
diacetyl in the third. Figure adapted from [3]. 
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1.5 Objectives and aims 
The aim of the work carried out during the PhD was to increase the understanding 
of type II polyketide synthesis. The main areas of the project have included: 
1. analysis of the crystal structure of the Streptomyces coelicolor acyl carrier 
protein synthase (AcpS), and its comparison with other type I and II AcpSs; 
2. investigation of the substrate promiscuity of the AcpS, in particular 
analysing the crystal structure of the enzyme in complex with acetyl-CoA, 
and the substrate binding sites of other type I and II AcpSs; 
3. proposals about the S. coelicolor AcpS: ACP recognition and interaction, 
and about the phosphopantetheinylation mechanism; 
4. generation and analysis of the crystal structures of HI IOA and DI I IA AcpS 
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2.1 Expression vectors 
A plasmid vector is an extra chromosomal DNA element that can replicate 
independently of the chromosomal DNA. It is commonly present in prokaryotes 
and usually it is a circular double stranded DNA. A gene that encodes the protein of 
interest, can be cloned in a well determined position without altering the 
functionality of the rest of the plasmid. The majority of expression vectors are 
produced by natural plasmids, and they usually have the following features for a 
correct replication and protein expression: 
- an origin of replication (ori) for replication of the plasmid in the host; 
- one or more selection markers, such as antibiotic resistance genes, in order to 
select the bacteria that contain the plasmid; 
-a Multiple Cloning Site (MCS), characterized by unique cleavage sites, in 
order to clone the gene in a defined position; 
-a promoter, usually from a bacteriophage, capable of being recognized by a 
specific RNA polymerase, and controlled by a specific system for a controlled 
protein expression; 
-a repressor gene sequence, that can bind to the operator site before the 
promotor, preventing the RNA polymerase from binding and starting the gene 
transcription. A classical example is the lacl repressor, which binds to the OIac 
operator. The repression can be switched off by the inducer isopropyl-ß-D- 
thiogalactoside (IPTG); 
-a Ribosome Binding Site (RBS), situated before the first ATG codon; 
- an optional gene (tag) that allows the expression of an amino acid sequence 
(His6-tag) or a polypeptide (GFP), on the N- or C- terminus of the protein, in 
order to help the subsequent purification. 
2.1.1 pET vectors 
The pET vectors (Novagen) are among the most common systems for the cloning 
and the expression of proteins in E. coli. Target genes are cloned under the control 
40 
Chapter 2 Methods 
of the strong bacteriophage T7 promoter and the expression is induced by a T7 
RNA polymerase provided by the host cell. In particular, these plasmids carry a fl 
origin of replication; the T7 promoter and terminator; a lacl gene coding for the lac 
repressor protein; a lac operator that can block transcription; a Multiple Cloning 
Site; the ampicillin or kanamycin resistance gene. In addition, with the exception of 
pET-3d, they carry a His6-tag and a thrombin site coding region. Vector maps are 
presented in Appendix 2. 
2.2 E. coli BL21 star (DE3) 
The Escherichia coli BL21 star (DE3) strain is a very common host for the 
expression of proteins that are cloned into pET vectors. These bacteria contain the 
A. DE3 lysogen phage, which carries the gene for the T7 RNA polymerase, the latter 
controlled by the IacUV5 promoter. IPTG inhibits the lacl repressor and is required 
to induce the expression of the T7 RNA polymerase (Figure 2.1). Furthermore, the 
Ion protease and the outer membrane protease OmpT are missing, therefore 
reducing the possible protein degradation. A mutated me gene (rnel3l) also 
















Figure 2.1 Expression of a target protein cloned into a pET vector. The lacl 
repressor precludes the expression of the T7 polymerase. Following the IPTG 
induction, the lacI repressor is inhibited by IPTG, the T7 RNA polymerase is 
expressed and so the target protein, controlled by the T7 promoter. (Figure adapted 
from Novagen manual). 
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2.3 PCR 
The Polymerase chain reaction (PCR) is an in vitro enzymatic replication used to 
amplify a DNA template. The reaction is characterized by several thermal cycles of 
alternately heating and cooling, and the following reagents are necessary: 
- the DNA template containing the target region to be amplified; 
- two primers, single strand DNA fragments complementary to both sides (5' 
and 3') of the target DNA region. The optimal length for a primer is around 18- 
22 bp, with a GC content of 40-60% to avoid the formation of secondary 
structure, and they should end with aC or better G base, as this guarantees a 
strong binding at the 3' end; 
- the DNA polymerase, like the Taq polymerase, is the extending enzyme 
working at a high temperature; 
- dNTPs, the building blocks; 
- buffer solution to ensure the right chemical environment for the polymerase; 
- divalent cations, like magnesium or manganese ions, to stabilize dsDNA. 
A PCR reaction involves 3 steps: denaturation, annealing and extension. The 
temperature and time employed for each cycle depends on the length of the 
template (usually 1 kb/minute), the particular polymerase used, the concentration of 
cations and dNTPs, and the melting temperature (Tm, the temperature at which one 
half of the DNA template dissociates to become single stranded) of the primers. 
During the denaturation step, usually at 95°C, the two strands of the DNA template 
are separated. Primers binds to each single strand DNA during the annealing step, 
at a temperature that is around 2-3°C below the T. of primers. Finally, at the 
optimal temperature for the particular polymerase used (usually between 70-80°C), 
the new DNA strand complementary to the template is synthesized during the 
extension step in the 5'-3' direction. These 3 cycles are usually repeated 20-40 
times. 
2.4 Stratagene site-directed mutagenesis 
Site-directed mutagenesis is a powerful and very precise technique that makes 
possible the analysis of the function of a particular amino acid residue. The 
technique allows the introduction of almost any mutation at any site. Several 
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protocols are available, but they require a single strand DNA as template. In 
contrast, the Stratagene QuickChange II site-directed mutagenesis allows site 
specific mutations in any dsDNA template. A dsDNA containing the target gene 
and the two primers, which enclose the mutated sequence, are used in a PCR 
reaction. The PCR is performed with the PfuUltra high-fidelity (HF) DNA 
polymerase. The extension of the primers produces a mutated plasmid carrying the 
desired mutation. The product is then treated with the DpnI endonuclease (target: 
5'-Gm6ATC-3'), which is specific for methylated and hemimethylated DNA, and 
cleaves the parental DNA. DNA isolated from E. coli is methylated by the Dam 
methylase and therefore subject to Dpnl cleavage. The mutated plasmid is 
transformed in XL1-Blue supercompetent cells for an optimal replication of the 
vector. 
2.5 Chromatography techniques 
The first chromatography technique was invented in 1903 by the Russian botanist 
Tswett, who noticed the formation of coloured bands on a liquid absorption column 
while separating different plant pigments. The most important separation and 
purification techniques are based on chromatographic processes, where the target 
mixture, the mobile phase, is suspended as a gas (gas chromatography) or a liquid 
(liquid chromatography) and introduced into columns provided with solid particles, 
the stationary phase. The process of purification is based on the interaction between 
the two phases, delaying the elution of the analyte in a way that is strictly 
dependent on the property of the analyte itself. If the initial mixture is pictured like 
a narrow band, the different interactions with the stationary phase determine a 
different and characteristic migration speed for the target analyte, transforming the 
narrow band in a series of different bands composed of pure solutes. 
Chromatography separations can be compared to organic extractions, although they 
are characterized more by absorption processes rather than partition phenomena 
that are common for small molecules. The retention process for each analyte is due 
to the equilibrium that the analyte establishes with the mobile and the stationary 
phase. This equilibrium is described by the equilibrium constant or partition 
coefficient Kam, defined as the molar concentration of analyte in the stationary phase 
divided by the molar concentration of the analyte in the mobile phase. 
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Various chromatographic parameters must be considered during a purification, such 
as: 
- the dead volume Vo, or the volume of mobile phase between the sample 
injection and the peak maximum of the solute that is not retained; 
- the retention volume VR;, the volume of mobile phase at the analyte peak 
maximum; 
- the base width W; for each peak; 
- the capacity factor k; = 
VRI - V0 
V O 
The separation between each solute depends on both the width and the distance of 
the peaks. The separation of large bands requires more time, so smaller peaks are 
preferred. This preference is described by the efficiency or number of theoretical 
plates N= 16 
VR' 
. This value is obtained 
from the parameters that characterize 
W; 
each band, creating a relation between the band width and the time of retention (VR; 
= tR; ). A column can be seen as a number of theoretical plates, or imaginary layers 
where the separation occurs. 
All these parameters describe the properties of each band. The following 
parameters are used to describe the properties that relate two or more peaks: 
- the selectivity factor a12 = 
k2 
(always greater than 1); 
- the resolution R=1 
VRZ - VR' 
2 
(W2 -W, ) 
Resolution offers a quantitative measure of the separation grade between two 
peaks. For R=1.5, the overlapping region is about 0.1%. If the efficiency is a 
measure of the peak enlargement and is determined by the property of the column 
(type of matrix and packing) used and by the rate of the mobile phase, the 
resolution is determined by the properties of both phases, and by the temperature 
and length of the stationary phase. Another important parameter is the height 
equivalent to a theoretical plate HETL = L/N, where L is the length of the column. 
The best chromatographies are obtained with low HETL values. 
Finally, the best model used to describe the creation of a band is given by the van 
Deemter equation. The band width reflects the distribution of the molecule that has 
been eluted in the system. The model describes the variation of HETL in relation to 
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the linear average rate of the mobile phase v: H=A+B+ Cv (Figure 2.2). A, B 
V 
and C are constants associated to physical properties of the mobile and stationary 
phases. The equation describes the enlargement of the chromatographic bands. 
Contributions are given by the longitudinal diffusion (B), by the Eddy diffusion 
(A), related to the packing of the column, and the resistance to the mass transfer 
(C), to which contribute both the mobile phase rate and the distribution of the 
dimension of the pores in the stationary phase. 
The different chromatographic techniques are classified on the base of the 
properties of the two phases and of the nature the interaction between solute and 
stationary phase. 
A typical Van Deemter plot 





Mobile phase velocity 
Figure 2.2 The Van Deemter equation predicts the minimal plate height and the 
optimal rate for a chromatographic separation (Figure adapted from [132]). 
2.5.1 Affinity Chromatography 
Affinity chromatography separates macromolecules through the use of a specific 
reversible interaction, such as that between a receptor and its ligand, antigen and 
antibody, or enzyme and substrate. The ligand is attached to a matrix and usually it 
is separated from it by a spacer. This technique is very useful as the first step of a 
protein purification, and allows a great capacity and good resolution. Starting from 
a huge volume, the protein will result in being concentrated and relatively pure. In 
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order to elute the protein, the interaction is weakened by a competitor or non- 
specific ligand, by changing the pH, the polarity or the ionic strength. 
Proteins that have affinity for metallic ions can be separated by Immobilized Metal 
Ion Affinity Chromatography (IMAC). Some amino acids, like histidine or 
cysteine, can interact with ions at basic pH. The matrix is usually a polysaccharide, 
such as agarose, which prevents aspecific interactions. Chelating groups capable of 
binding ions are attached to the matrix and the ions used are Nie+, Zn 2+, C02+ , Fe 
3+, 
Cu 2+ and Cat+, which carry partially empty d orbitals that can be occupied by 
electrons present in some amino acids (Figure 2.3). For example, the imidazole ring 
of histidine has a free electron pair at a neutral pH (pKa histidine = 6.6). In this 
case, a high concentration of imidazole is used for the protein elution. Biological 
interaction can also be used to get rid of an unwanted protein. For example, it is 
possible to remove thrombin using a benzamidine column. The benzamidine, a 
competitive inhibitor of serine proteases, is covalently linked to a long spacer arm 












Figure 2.3 The structure of the IMAC resin used. The spacer carries nickel ions, 
which interact with two histidines (Figure adapted from the Amersham purification 
handbook). 
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2.5.2 Ion exchange chromatography 
In ion exchange chromatography (IEC) macromolecules are separated according to 
their charge. The separation relies on a charge-charge interaction between the 
analyte and the charged matrix. IEC can be divided into: cation exchange 
chromatography, in which positive charges are exchanged with a negatively charged 
matrix, and anion exchange chromatography, where negative charges are binding to 
a positive matrix. In the first case sulphate derivatives (S-) or carboxylate derived 
ions resins (CM-) are used, while quaternary amine (Q-) or diethylaminoethane 
(DEAE-) cellulose resins are utilized in the second. Elution is achieved by 
increasing the ion strength. Ions from the mobile phase will interact with the matrix 
or with the protein, thus preventing an interaction with the stationary phase. 
Alternatively, elution can be achieved by altering the pH. This alters the charge of 
the amino acid lateral chains and therefore causes a change in the whole charge of 
the protein. 
2.5.3 Size exclusion chromatography 
Size exclusion chromatography (commonly known as gel filtration), allows the 
separation of different macromolecules according to their hydrodynamic volume. 
The difference from the other chromatographic methods relies on the fact that no 
chemical or biological interaction occurs. The stationary phase is a matrix 
composed of porous spherical particles that are chemically and physically inert. 
The particles can be made of silica or by organic polymers, and the pores have 
different sizes. These pores can either be channels through the bead, or depressions 
on the surface. The elution is isocratic, so the starting conditions do not change. Big 
molecules are eluted before smaller ones. The separation depends on their ability to 
enter the pores of the stationary phase. The molecules with a volume which is 
bigger than the pores will move faster than the ones that are smaller than the pores. 
It is possible to define an elution volume Ve = Vo + k., V;, where VO or void volume, 
is the volume of the mobile phase surrounding the beads; V; is the volume inside 
the beads, also called stationary phase volume Vs; and kav is the distribution 
coefficient of the solute between the mobile and stationary phases: 
ka = 
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A completely retained molecule will have kam 1, and the volume of elution will 
coincide the entire value of the column: Ve = Vo + V; (permeation limit). On the 
contrary, a molecule that is not retained will have ke =0 and Ve = Vo (exclusion 
limit). It is possible to separate molecules that have elution volumes included 
between the two limits. In this range, there is a linear relation between the 
logarithm of the molecular weights and the elution volume. This relation allows to 
determine the molecular weight of an unknown sample starting from its elution 
volume and a calibration curve obtained with standard molecules. Finally, size- 
exclusion chromatography can also be used as a quick and simple method for buffer 
exchanging or desalting. 
2.6 Electrophoresis 
Electrophoresis, the migration of ions under the influence an electric field, is a 
common technique used to separate and identify single components from mixture 
of macromolecules, such as DNA, RNA, protein. This method allows to verify the 
presence of a target molecule, its degradation and purity level. Particles that are 
dispersed on a fluid carry an electrical surface charge. A molecule with a charge q 
under the electric field E is under the influence of the electric force F. = qE, that 
drives the molecule towards the pole with opposite charge. The movement of the 
charged particles is also under the influence of a frictional force of opposite 
direction, Fa =6 it r1v, that opposes the movement. r is the molecule 
hydrodynamic radius, rl is the viscosity of the medium and v the velocity of the 
charge particles, that depends on both the viscosity and the shape and dimension of 
the molecule itself. When the two forces are the same, the molecule will move with 
a constant velocity v= (E q) / (6 it r il). If E and rl are constant, v depends on the 
ratio between the charge and the hydrodynamic radius (v oc q/r). It is possible to 
define the electrophoretic mobility for a charged particle: 
µ=v/E=q/(6nrrl) 
This property is used to separate different macromolecules that have a characteristic 
charge and mass ratio, and therefore migrate with a distinctive velocity under an 
electric field. 
Gel electrophoresis is widely used with protein and nucleic acid. Porous gels are 
commonly made by polyacrylamide (polyacrylamide gel electrophoresis (PAGE) 
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gel) for protein or agarose for DNA. SDS-PAGE gels run in denaturing conditions. 
Sodium dodecyl sulphate (SDS) is an anionic detergent that denatures secondary 
and non disulfide linked tertiary structures. SDS binds with a constant ratio of 1.4 g 
of SDS for g of protein (about a molecule of SDS every 2 amino acids), conferring 
a negative charge to each protein in proportion to its mass. The charge of the lateral 
chain can therefore be ignored. All proteins will be transformed into elongated 
objects that present the same charge and mass ratio, but with a mobility that 
depends only on the molecule dimension. The biggest proteins will be delayed by 
the porous gel more than the smallest. 
2.7 ITC 
Isothermal Titration Calorimetry (ITC) is a biophysical technique that is used to 
study the thermodynamic parameters of interaction among small molecules. The 
ITC experiment gives a quantitative measure of the binding affinity (lca), binding 
stoichiometry (n) and variation in enthalphy (AH) of the interaction between two 
molecules in solution. A VP-ITC unit was used for the experiment. It consists 
mainly of a spinning syringe for injecting and mixing the reagents and two 
chambers, a reference and a sample cell. Prior to addition of ligand, a constant 
power is applied to the reference cell. This directs a feedback circuit that activates a 
heater located on the sample cell. This feedback power is used to maintain the 
temperature equilibrium. The syringe containing the ligand is titrated into the cell 
containing the receptor. The temperature difference between the cells is recorded. 
For exothermic reactions, a negative change in the differential power (DP) occurs, 
since the heat evolved in the reaction can be used instead of the feedback power. 
The contrary happens for endothermic reactions. Since the DP has units of power 
(µCal/sec), it is possible to measure the OH by integrating each peak over time. The 
relation between released or adsorbed heat and the amount of binding that occurs is 
directly proportional. When the saturation occurs, the heat signal diminishes until 
the background heat of dilution can be observed. 
For a ligand X binding to a single set of n identical sites on a macromolecule M 
(MXn. 1 +X= MX), it is possible to define a single-site binding constant K: 
K_ 
[filled sites] 
[empty sites] " [L] 
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and the Gibbs free energy changes 
AG°=-RTInK=AW-T4S° 
R is the gas constant and T is the absolute temperature, and AH'' and AS° the 
changes in enthalpy and entropy for a single site binding in standard conditions. K, 
AH° and n are determined by non linear least square fit of calorimetric titration data, 
and 4G° and AS° can be then quantified. The critical parameter that determines the 
shape of a binding isotherm is the unitless constant c: 
c=KM,, n 
M,,,, is the total concentration of macromolecule and n the stoichiometry parameter. 
Very tight bindings lead to very high c values, and the isotherm has a rectangular 
shape. Its height corresponds exactly to OH° and there is a sharp drop that identifies 
n. The shape of this curve remains constant when K varies but c remains above 
5000. If c is reduced by decreasing Mt,,, the drop around n broadens and the 
intercept at the Y axis is lower than the real AH°. At a very low initial M, 0 , 
concentration the isotherm becomes similar to an horizontal line indicating a very 




, -. inn 
Figure 2.4 The ITC constant c. Values of C between 5 and 500 are ideal for 
measuring K with an ITC experiment (Figure adapted from the Microcal manual). 
For the best results, ideally the concentration of ligand should be 8 times more than 
the protein concentration. The buffer in which the ligand is dissolved must be the 
same of that of protein. It is necessary to avoid heat effects caused by buffers 
mixing and control experiments must be carried out in order to determine the heat 
of dilution of ligand. 
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2.8 Protein crystallography 
2.8.1 Protein crystallization 
In order to solve a structure with the X-ray diffraction technique it is imperative to 
crystallize the protein as first step. The crystallization process is influenced by a lot 
of variables and is characterized by the nucleation process, the crystal growth, and 
the cessation of growth. The formation of a crystal depends on many physical and 
chemical parameters, specific of the reagents used, and on experimental variables 
that can determine its reproducibility, such as: the volumes used (0.5-2 Al); the 
process of mixing a protein solution and the precipitant; the temperature 
fluctuations; and the presence of additives. The protein must be very pure and 
characterized by a high level of homogeneity. The aqueous solvent is also essential 
for the conservation of the three-dimensional structure inside the crystal. 
Macromolecule crystals include a volume of solvent between 20% and 70% of the 
total volume of the crystal. The conventional methods of crystallization for small 
molecules, such as the total evaporation of the organic solvent or the drastic 
variation of temperature, will cause the crystal structure to collapse. The 
crystallization process must also be relatively slow. In this way, it is possible to 
obtain crystals with bigger dimensions and a higher level of regularity in the 
arrangement and orientation of the molecule inside them (low mosaicity). 
For crystal growth, macromolecules must be in a supersaturation condition, a state 
of thermodynamic instability that returns to equilibrium as precipitate or as 
crystalline form. Supersaturation can be achieved by slow evaporation of the 
solvent or by changing the experimental variables. During crystal growth, it is 
possible to define three different steps, which happen at a different values of 
protein and precipitate concentration: 
1. the nucleation phase: the spontaneous formation of the first nuclei is a 
statistical phenomenon whose probability increases the higher the level of 
supersaturation is. As the number of the nucleation centers increase, the 
level of supersaturation decreases. In addition, during the formation of the 
first aggregates, the formation of ordered nuclei can compete with the 
irreversible formation of amorphous aggregates, a process that can decrease 
the degree of supersaturation; 
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2. the growth phase, during which the crystal grows around the first protein 
nuclei. This phase needs a lower energy and a supersaturation lower than 
the nucleation phase; 
3. the cessation of the growth. Several causes can determine the cessation of 
growth, such as the decrease in concentration of the crystalline solute to the 
point where the solid and the solution phases reach the equilibrium, growth 
defects, poisoning of the faces and ageing of the molecules. 
The process of crystal formation depends on both the chemical properties of the 
protein and on its interaction with the solvent. The most common parameters that 
affect the protein solubility are: 
- the temperature; 
- the net charge: pH and pKa of the buffer; 
- the ionic strength: the salt concentration; 
- the dielectric constant; 
- the property of the precipitant. 
These parameters can affect the solubility of the protein, but they can also affect the 
nucleation and growth phases. In solution, the stability of a macromolecule is 
controlled by balancing its interactions with the solvent and its intramolecular ones, 
which are responsible for its tertiary structure. Changing the pH of the solution will 
change the charge of some amino acid residues and therefore the net charge of the 
protein. At values near the pKa, the solubility of charged residues can vary very 
quickly, affecting the overall charge and therefore the protein solubility. On the 
contrary, protein solubility is relatively stable to pH changes at pH values far from 
the pKas. The ionic strength depends on the salt concentration and on the charge of 
each ion, and it affects the protein-buffer, protein-salt and salt-buffer interactions. 
Normally, when the salt concentration increases the protein solubility first increases 
(the salt ions interact with the protein charges), and then decreases. The protein 
solubility is also affected by the nature of the salt. The ability of salt to influence 
the solubility is summarized by the Hofmeister series. The relationship between 
solubility and temperature is an intrinsic property of a protein and cannot be 
predicted. Generally, the crystallization process is slower at lower temperatures. 
Finally, the polarity of the solvent is another parameter to consider. The polarity 
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can be reduced by adding a variable amount of an organic solvent, whilst avoiding 
high concentrations that can denature the protein in solution. 
2.8.2 Vapour diffusion technique 
Isothermal vapour diffusion is one of the most commonly used techniques for 
achieving the supersaturation condition that is necessary for the formation of 
crystals. A drop of protein solution, mixed with the precipitant solution, is 
equilibrated with a reservoir containing the same precipitant at a higher 
concentration. The two solutions are placed in a closed and isothermal system. The 
equilibration occurs via diffusion of the volatile species, like water or organic 
solvents, until the vapour pression of the drop and that of the reservoir are the same. 
If the process occurs with the evaporation of the water in the drop, the volume of 
the drop decreases while the protein concentrates till the supersaturation value. The 
solubility of the protein depends on many parameters, and a phase diagram can 






Figure 2.5 The solubility curve. The curve delimits the supersaturation and 
undersaturation zones. 
The solubility curve defines the zones of undersaturation and supersaturation. 
Below the solubility curve the solution is not saturated, the system is 
thermodynamically stable and the protein cannot crystallize. On the contrary, in the 
supersaturation zone the concentration is higher than that present at the equilibrium. 
In this region is possible to distinguish the precipitation, nucleation and metastable 
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zones. The first one occurs at very high protein concentrations, and the insoluble 
molecules precipitate as an amorphous state. Nucleation requires a low 
supersaturation, while in the metastable region the critical supersaturation is not yet 
achieved, and spontaneous nucleation occurs only if induced by vibration or by the 
presence of additives. Usually, when the concentration of the precipitant in the 
reservoir is higher than that in the drop, the protein starts to concentrate from the 
not saturated A state (Figure 2.6), characterized by the concentration Cip, to the 
supersaturated B state, at the Cff concentration. If the nucleation zone is reached, 
the first crystals begin to appear (A -> B in fig. 2.6 B), and the supersaturation is 




------- --- fn , 
A 
Solubility curve 








Ci Cf [precipitant] 
Figure 2.6 The nucleation zone. Solubility curve of a protein in function of the 
concentration of precipitant and of the protein concentration with the isothermic 
vapour diffusion. The crystal formation occurs when the nucleation zone is reached. 
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This condition can be achieved with either the hanging drop or the sitting drop 
methods (Figure 2.7). In the first case, the protein solution mixed with the 
precipitant agent is placed on a coverslip that is then turned over and placed above 
a well containing the reservoir at a higher concentration. With the second methods, 
the drop is placed on a bridge that is placed inside the well which is hermetically 
closed. In both cases the system is isolated with some grease or oil. 
precipi drop =[ precipi reservoir 
2 
H, O H, O 
Figure 2.7 The hanging drop and sitting drop technique with vapour diffusion. The 
concentration of precipitant in the drop is lower than in the reservoir. 
2.8.3 X-rays diffraction 
2.8.3.1 The choice of X-rays 
X-ray crystallography gives the possibility to determine the structure of a biological 
macromolecule, such as protein, DNA and RNA. An object must diffract the light 
to be seen, and the wavelength of the light must be smaller than the object. 
Individual bonded atoms 1.5 A apart cannot be seen with the visible light, whose 
wavelength lies in the range of 400-700 nm. On the other hand, x-rays are an 
electromagnetic radiation of about 1 A, and thus are suitable for diffraction of 
individual atoms. Unfortunately, lenses for an X-ray microscope do not exist. X- 
rays cannot be focused, and also most of the X-rays pass through the molecule 
without being diffracted. The problem can be solved by measuring the intensities 
and directions of the diffracted X-rays, and with the help of a computer that 
simulates a microscope lens. Protein crystals are ordered arrays containing a certain 
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number of identical molecules with identical orientation that the diffracted beams 
can add up, producing a strong unique detectable diffraction pattern. 
There are two common sources of X-rays: rotating anodes and synchrotrons. In the 
first source a metal anode, typically copper, is bombarded with electrons of high 
potential (> 10 KeV) from a cathode, usually a tungsten filament. The anode rotates 
to allow cooling and a high current. These high energy electrons collide with the 
atoms in the anode, causing the displacement of electrons in lower orbitals. 
Electrons from higher orbitals drop into these empty orbitals, thus emitting their 
excess energy as X-ray photons. The emission spectrum of copper is characterized 
by two peaks, Cu-Ka (A, = 1.54 A) and Cu-Kß (A, = 1.39 A), with wavelengths 
similar to those of individual bonded atoms. The other source of X-rays is the 
synchrotron, a particle accelerator ring where electrons are generated and forced to 
circulate at about the speed of light by powerful magnets. Because of the electrons 
curved path, a synchrotron radiation energy is emitted, some of it as X-rays. 
Undulators can also be used to bend the beam further, in order to magnify the 
intensity of the radiation. In comparison with the rotating anodes, synchrotrons 
allow a greater energy and the possibility of tuning wavelength selecting a 
wavelength from a comparatively large spectrum. 
2.8.3.2 X-ray diffraction 
Diffraction can be seen like a reflection (and for this reasons each spot is called 
reflection) from sets of equivalent parallel planes of atoms in a crystal, called Bragg 
or lattice planes. When X-rays interact with an ordered array like a protein crystal, 
the diffracted rays can interfere either constructively or destructively. Waves with 
the same phase will add up giving an amplitude that is the sum of the amplitudes of 
the individual scattered rays. On the contrary, out of phase rays interfere 
destructively resulting in an amplitude that is the difference between the individual 
rays. 
Bragg's law shows that two waves diffract in phase from the planes (Figure 2.8) 
only if 0, the incident and reflection angle, meets the condition: 
2dsin0=nk 
where d is the interplanar distance, X the wavelength, and n an integral number. R2 
travels the same distance as RI, plus the added distance 21. Using trigonometry, 21 
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is equal to 2d sin 0 (sine 0= BC/AB). If this distance is equal to an integral number 
of wavelengths, n X, the two wavelengths will interfere constructively resulting in a 
diffracted beam. 
B 
Figure 2.8 Condition that produces diffracted ray according to the Bragg's law. 
In addition, if d has a value of 1, atoms on the planes will diffract in phase, while 
objects between the planes diffract out of phase. The angle of diffraction is also 
inversely related to the interplanar distance d, so for large unit cells (the smallest 
and simplest volume element that can reproduce the entire crystal by simple 
translation) the angle of diffraction will be small, producing more reflections that 
collide with a convenient angle from the incident beam than for a small unit cell. 
The Bragg's law is also valid in reciprocal space. If a sphere of radius 1/X and with 
a point located at the origin of the reciprocal lattice is drawn, all lattice points that 
make contact with the surface of this Ewald's sphere can satisfy Bragg's law and 
result in reflections (Figure 2.9). Rotating the crystal by a phi-axis during a 
diffraction experiment allows the collection of almost all the reflections. In other 
words, rotation of the reciprocal lattice allows sets of lattice points to make contact 
with the Ewald's sphere. The theoretical maximum number of reflections that is 
possible to measure is equal to the number of lattice points contained in a sphere of 
radius 2/ X and centre at the origin of the reciprocal lattice, called the limiting 
sphere. 
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L. eeoo p. rm 
Figure 2.9 Ewald's sphere of reflection. Each lattice point making contact with the 
Ewald's sphere gives a diffraction spot. The sphere has radius I/A and one of its 
point is located at the origin of the reciprocal lattice (0,0,0). 
2.8.3.3 Data collection, processing and reduction 
The diffracted X-ray beams are measured by a detector that is placed in the path of 
the beam. Originally an X-ray sensitive film was used, while now an image plate 
device or a CCD detector is preferred. An image plate consists of a layer of 
phosphor crystals that cover the plate. The plate is scanned between exposures by a 
laser and the emissions from the excited phosphor layer are recorded. The 
emissions are proportional to the intensity of the x-rays that collide with the image 
plate at each diffraction spot. Solid-state electronic charge-coupled device (CCD) 
detectors are more recent, and eliminate the scans between each exposure, 
decreasing the time needed for the experiment. CCDs count the photons that are 
emitted from the phosphor layer. 
The first diffraction images, usually taken 90" apart, are very useful to determine 
the best strategy necessary to obtain the best data from both a quantitatively and 
qualitatively point of view. These images can be autoindexed to determine the 
lattice type and the unit cell dimensions. Afterwards, it is possible to decide the 
optimal data collection strategy. Several programs utilize the cell dimensions and 
the spacegroup to determine the starting orientation of the crystal and the number of 
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frames to be acquired for the best completeness in the minimum time. The 
incoming diffraction images are then processed to generate a data tile in which the 
intensity and position (hkl indices) of each reflection are recorded. Finally, all the 
data contained in the data file are scaled and merged. This compensates for 
fluctuations in the intensity of the beam and permits the combination of partial 
reflections, giving a final file containing the average intensity for each unique hk1 
position. 
In addition, after scaling many of important statistical indicators regarding the 
quality of data become available. The ratio between signal and noise, or 1/01, can 
indicate the highest resolution where the crystal diffraction is reliable and 
comparable to background noise or measurement errors. Usually, data are 
considered no longer reliable when this ratio drops below 2 in the highest resolution 
shell. The agreement between multiple measurements of the same reflections in a 
data-set is defined as Rmcrgc: 
likl i Rmergc -1 
i 
hkl 
where li is the ith intensity measurement of the reflection hkl, and 1 is the average 
intensity from multiple observations. R,,, ergc values around 10% over the whole 
data-set and around 40% in the highest resolution shell are accepted. Redundancy 
describes the average number of observations acquired for each reflection, so the 
higher redundancy is, the better the data are. Finally, it is also important to consider 
the completeness of the dataset, which is the percentage of the calculated maximum 
number of reflections that has been collected. An incomplete dataset will result in 
zeros in the Fourier summation (chapter 2.8.3.4) that can introduce noise. 
2.8.3.4 The Fourier transform 
As a consequence of the X-ray diffraction experiment, a series of diffraction images 
are collected from the crystal. The aim of a crystallographic experiment is to 
calculate a map of the distribution of electrons in the molecule, the electron density 
map. The relationship between this electron density and the diffraction pattern can 
be described with the Fourier transform. If the electron density is seen like a 
mathematical function, the diffraction pattern is the Fourier transform of this 
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function. The structure factor FhkI describes a diffracted ray that produces a 
reflection to the detector. The atomic structure factor fhki describes the contribution 
of a single atom j for the reflection hkl: 
fhkl = fe e2a 
i(hxj+ky, +lzj ) 
f is the scattering factor of atom j, a mathematical function that describes the 
scattering of X-rays by an atom. This scattering function can be determined 
assuming that the electron density of each atom is a discrete and a simple sphere. 
For a unit cell containing n atoms, the structure factor FhkI, describing all the 
diffractive contribution of all atoms for the reflection hkl, can be defined as a 
Fourier series in which each term is the contribution of one atom, treated as a 
simple sphere of electron density: 
n 27ri(hx+kyj+lzj) Fhk1-j: fje 
j=1 
Alternatively, the structure factor Fhkl can be described in terms of sum of electron 
density contributions at different positions xyz within the unit cell: 
i(hx+ky+lz) Fhk1- f P(x, y, z)e 2n dV 
V 
where V is the total volume of the unit cell. The Fourier transform is a reversible 
function. So, the Fourier transform of the diffraction pattern results in the 
description of the electron density of all atoms within the unit cell. This Fourier 
transform relates the real-space electron density map to the reciprocal space 
structure factors: 
P(X, Y, Z) =v j]Z Fhkle -2ni(hx+ky+lz) 
hk1 
In order to build the electron density p(x, y, z), it is necessary to construct a fourier 
series from the structure factors. 
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2.8.3.5 The phase problem 
The previous equation can be rearranged in this way: 
p(X, y, Z)= Vj: 
2: 2jlFh4lJe-2ni(hr+ky+/s-ak, ) 
FhkI is in fact a periodic function, and can be described with an amplitude IFhk1l ,a 
frequency, and a phase a. The frequency is that of the X-ray source, the amplitude 
is proportional to the square root of the intensity Ihkl, but the phase is not directly 
measurable from the reflection intensity measure. That is the origin of the phase 
problem. Currently three main methods are available to overcome the phase 
problem. The heavy atom method (or multiple isomorphous replacement, MIR) 
relies on the introduction of heavy atoms, such as silver, gold etc, into the protein 
crystal. These heavy atoms, through their greater scattering factors, will dominate 
the diffraction. Using a Patterson function it is possible to determine their relative 
position. The Patterson function is a Fourier series calculated using only intensities 
and no phases: 




where u, v, w are coordinates in the Patterson map. Once the positions of the heavy 
atoms are determined, their contribution to the phase angles of each reflection can 
be calculated. The structure factor for an isomorphous derivate (FPH) is equal to the 
sum of the structure factors of the native protein (Fp) and the heavy atoms (FH). 
The multiple wavelength anomalous diffraction (MAD) relies on the anomalous 
scattering of some heavy atoms, like iron or selenium, at a specific wavelength. It is 
possible to introduce these atoms in the same way as in the MIR, or to heterogously 
express the protein in the presence of selenium methionine, using E. coli strains 
auxotrophic for this amino acid. It is possible to locate these atoms following the 
same MIR principle: anomalously diffracting atoms behave in a different way from 
the other atoms in the protein, absorbing X-rays at specific wavelengths. The phase 
can be calculated following the same MIR idea. In addition, MAD has the 
advantage that anomalous atoms scatter differently at different wavelengths, so 
only a single crystal is needed to collect the native and the derivate set of data. 
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Finally, the molecular replacement method (MR) relies on the availability of a 
structure with sufficient structural similarity to the unknown protein. Other direct 
techniques for determining the phase are also available. They rely on computational 
manipulation of the diffracted data without any additional information. These direct 
methods are extensively used in the crystallography of small molecules, and can be 
used also for macromolecules, but they must diffract at atomic resolution and this 
approach is in continuous development. 
2.8.3.6 Molecular replacement 
This method for phase determination relies on initial phases generated from a 
model with sufficient sequence and, more importantly, structural similarity: 
, cl 
new -2 ni 
(hx+ky+IZ-CE hkl ) 
P (X, YZ) =V 
hk1 
IFhkl le 
where the structure factor amplitudes are those of the new protein, and the phases 
those of the model. The search model is chosen based on a number of factors, 
including sequence and suspected structural similarity, that is essential for 
molecular replacement. When the unknown protein and the search model share a 
sequence identity of more than 30%, the probability they share also a similar 
structure is very high. In addition, if there is a sequence dissimilarity, then the 
difference in the structure is more restricted. This method calculates the correlation 
of the search model Patterson vectors to those of the unknown molecule, assuming 
that two molecules with a similar structure display similar Patterson functions. The 
model must be placed in the correct position within the unit cell. To perform this, a 
six dimensional search, comprising the translational xyz values and the rotational 
apy values, is carried out. The rotation corresponds to the rotational function, and is 
performed before the translational search because the Patterson map is independent 
of the position of an object within the unit cell as long as its orientation is 
maintained. The rotation is obtained by rotating one of the two Patterson maps, 
aiming to the maximum overlap. In addition, the Patterson map is determined 
mainly by strong reflections, so weak high resolution data are not used in this 
process. The next step is to locate the correct position, that is, translations in x, y, z 
62 
Chapter 2 Methods 
in the unit cell for the molecule. This step is carried out in real space. For each 
attempt, the structure factors are calculated and compared to the experimental ones. 
The R-factor: 





and the correlation coefficient C: 
I F(obs) 12 
hkl 




F(obs) I2 -I F(obs) I2 x 
., 
(IF(calc)l2 
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describe the difference between the calculated structure factors amplitude F(calc) 
and those observed F(obs). The best position solutions are chosen on the basis of 
the correlation coefficient and R-factor values, and also on the difference between 
the best correlation coefficient and the following one. Correct solutions can be 
identified because they will not cause clashes between a molecule and its symmetry 
related ones. The molecular replacement usually finishes with a rigid body 
refinement in order to improve the amplitude structure factor fits and the phase 
estimate. 
2.8.3.7 Refinement and model validation 
Structure factors calculated from the model are employed to calculate the electron 
density map. The electron density is usually displayed as both Fo-Fc difference 
map (structure factors observed minus those calculated) and 2Fo-Fc maps, with the 
former highlighting the difference between the calculated and observed data, and 
the latter giving more weight to the observed amplitudes. The aim of the refinement 
is for the model to describe the experimental data completely, that is, Fo to be equal 
to Fc. The Fo-Fc difference map is very useful to assess the progress of refinement, 
producing positive or negative peaks where Fo differs from Fc. The 2Fc-Fo map 
gives information about the shape of the structure and it is often in the form of a 
continuous molecular surface. This map is very useful for the construction of the 
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new model. After the first map is created, the model building can start. This is a 
process where the model is fit into the observed data. In addition to manual model 
building, a computational refinement is carried out, aiming to reduce as much as 
possible the R factor, implying an increase in the agreement between the model and 
the real structure. In order to achieve this, atom positions are changed to obtain the 
best density map fit and the temperature B factor. Software like Refmac [133] 
applies the principle of maximum likelihood, which is based on the fact that the 
probability of observing a particular set of observation should be very high. When 
changes are applied to the model, in the attempt to bring it closer to the actual 
model, there is an increment in the probability of observing the real structure. The 
principal problem with refinement is the fact that the number of observations is not 
very much superior to the number of parameters, causing a small over- 
determination of the structure. Because of this, it is necessary to either reduce the 
number of parameters or effectively increase the number of observations. 
Therefore, to increase the structure determination, new observations in the form of 
geometrical restraints, which keep bond lengths, bond angles and atomic contacts in 
the ranges typically seen in very high resolution structures, are added. Finally, the 
refinement of a structure is followed by different markers, like the R-factor, that is 
however subjected to bias by the refinement process. So, the unbiased Rfree was 
introduced. It is calculated in the same way as the R-factor, but it refers to a set of 
reflections that are not part of the refinement process. These reflections are 
normally between 2-10% of the total reflections, picked randomly to minimize any 
sort of errors. Besides to the monitoring of these errors, the density map inspection 
is always a very useful tool to obtain a better model. The atomic model must agree 
with the electron density map. The analysis of the Ramachandran plot is also useful 
for checking the geometry and stereochemistry of the model. 
2.8.3.8 Density modification 
The first calculated map may have an insufficient quality or may be highly biased. 
Cycles of density modifications, like solvent flattening, non crystallographic 
symmetry (NCS) averaging and histogram matches can be used to obtain better 
phases and therefore electron maps. Solvent flattening smooths the map eliminating 
small spikes and random fluctuations in density, and defines the boundaries 
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between solvent and protein. For example, the unit cell can be divided into a grid of 
regularly spaced points. At each points, the value of p (x, y, z) in the Fo map is 
evaluated. If p is negative, it is reassigned a value of zero, while if it is positive it is 
assigned a value equal to the average value of p within a certain distance. 
Therefore, the map is divided into a region of relatively high and low density: the 
protein and the solvent regions. 
The strength of the signal can also be increased by averaging the signals from 
identical molecules but having a different orientation in the unit cell. These 
molecules may be related by symmetry elements that are not aligned with 
symmetry elements that apply across the entire unit cell (crystallographic symmetry 
elements). By knowing the location and type of non crystallographic symmetry 
elements, it is possible to add the signal of these set of elements together, 
improving the signal to noise ratio. This modification technique can be successful 
with two-, three- and five-fold rotation axes. 
A density histogram is a probability distribution of values of the electron density 
sampled at regular intervals throughout the three-dimensional map, and density 
histograms of protein structures have a characteristic form. In histogram matching, 
the electron density distribution of the map is compared to that of a standard map at 
similar resolution, and then it is modified trying to match the standard map in order 
to reduce possible errors. When all possible improvements have been done to the 
electron density map, the map can be back-transformed to give more accurate 
phases than those obtained imply from the atoms of the model alone. 
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Chapter 3 
Materials and Protocols 
3.1 Media 
3.1.1 Luria-Bertani (LB) liquid medium 
A pouch provided by MP Biomedical (10 g tryptone, 5g yeast extract, 10 g NaCI) 
was dissolved in 1L of ultrapure water and then autoclaved at 121°C for 15 
minutes. The appropriate antibiotic (carbenicillin (50 µg/mL) or kanamycin (50 
gg/mL), Apollo Scientific) was then added prior to inoculation. 
3.1.2 LB plates 
100 mL LB with the addition of agar (1% w/v), provided by the Department of 
Cellular and Molecular Medicine, were boiled until the melting point was reached, 
then let to cool down to approximately 40°C. The appropriate antibiotic 
(carbenicillin (50 gg/mL) or kanamycin (50 gg/mL)) was then added and about 20- 
25 mL of medium were poured in a Petri dish (Sterilin), in a sterile environment. 
The agar was left to solidify again at room temperature and then the plate was 
stored at 4°C. 
3.2 Vectors 
- pET-11 c-ACP (kindly donated by Dr Matt Crump and Dr John Crosby, 
Department of Chemistry) carries the ACP gene and the ampecillin resistance; 
- pET-15b-AcpS (kindly donated by Dr Matt Crump and Dr John Crosby, 
Department of Chemistry), carries the AcpS gene with the addition of a N- 
terminal hexa-histidine tag coding region and the ampicillin resistance gene. 
AcpS H11OA and D111A mutants were also cloned into this vector; 
3.3 Host strain 
- E. coli BL21 Star (DE3) One Shot (Invitrogen) competent cells. Genotype: F- 
ompT hsdSB (rB-mB) gal dem mel31 (DE3)). 
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3.4 Molecular biology 
3.4.1 Agarose gel electrophoresis 
lg of agarose (Invitrogen) was dissolved in 100 mL TAE buffer (40 mM Tris 
acetate, 1 mM EDTA) and heated at 800W for 1-2 minutes with a microwave, until 
the solution was clear. The solution was left to cool down to about 40°C before 
adding ethidium bromide (Invitrogen) to a final concentration of 0.5 µg/mL. The 
solution was then poured into the plate and left to set with the comb in place. 5X 
sample running buffer (Bioline) was added to the DNA samples to give a final 
concentration of 1X. 5µL Hyperladder I markers (Bioline) were used as a molecular 
marker. The gel was run in TAE buffer at 100 V for 90 minutes, and then 
visualized under UV light. 
3.4.2 DNA miniprep 
10 mL E. coli liquid culture, with the appropriate antibiotic, was grown overnight at 
37°C. The bacterial pellet was collected by centrifugation and plasmids were 
extracted using the QlAprep Spin Miniprep Kit (Qiagen) according to the protocol 
provided by the manufacturer. The DNA was stored at -80°C until required. 
3.4.3 Restriction enzyme digest 
- ACP restriction sites: NdeI and BamHI; 
- AcpS, HI 1OA and D111A mutants restriction sites: NdeI and BamHI; 
The digest solution (2.5 pL of DNA, 9.2 µL of deionized water, 0.8 µL of BSA, 
1.5 µL of buffer and 1 µL for each appropriate restriction enzyme) was left at 37°C 
for 75 minutes. The result was checked by running an agarose gel. Restriction 
enzymes were bought from Roche. 
3.4.4 Site-directed mutagenesis for AcpS mutants 
AcpS-pET15b was first sequenced (10 µL at a concentration of 100 ng/µL, service 
provided by Cogenics Lark Inc. ). Then, primers were designed to introduce the 
single mutation H11OA or D111A and synthetized by MWG. The primers are 
described in Table 3.1. The site-directed mutagenesis was performed using the 
QuickChange II Site-Directed Mutagenesis Kit (Stratagene), following the 
suggested protocol. Various concentrations of 25,50,100 and 200 ng of DNA 
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template were tested, with 125 ng of each primer. 100 ng of DNA template gave the 
best results. PfuUltra HF DNA polymerase was used. In the PCR mixture, 1 pL of 
DMSO (for a final concentration of 20 µM) was added to avoid the formation of 
CG hairpins; this step turned out to be essential for the success of the experiment. 
As suggested, 16 cycles were chosen for the single amino acid substitution. After 
DpnI digestion, the DNA was transformed into XL1-Blue Supercompetent Cells. 
The higher number of colonies was obtained using 3 µL (for D111A) and 2µL (for 
Hi 1 OA) of DNA. After extraction using the miniprep, the products of the 
mutagenesis were firstly subjected to restriction enzyme digest, and then the 
restriction products were checked in an agarose gel to see if they were of the 
appropriate size. Finally, they were sent to Cogenics Lark Inc. for sequencing. 
Primer Sequence (5' to 3') 
D111A forward 
TGG CAC GTG TCG CTG AGC CAC GCC GCG GGG ATC GCG 
TCG GC 
D111A reverse 
GC CGA CGC GAT CCC CGC GCC GTG GCT CAG CGA CAC GTG 
CCA 
Hii OA forward CAC GTG TCG CTG AGC GCC GAC GCG GGG ATC GCG TC 
H11OA reverse GA CGC GAT CCC CGC GTC GCC GCT CAG CGA CAC GTG 
Table 3.1 Primers used for PCR in AcpS site-directed mutagenesis. The bases in 
bold and underlined correspond to the mutation sites from aspartate (CAC) or 
histidine (GAC) coding region to alanine (GGC) coding region. 
3.4.5 Heat-shock transformation of plasmid DNA into competent E. coli 
1 µL of DNA was transferred into 25 mL of supercompetent cells (Novagen). The 
solution was left in ice for 5 minutes, transferred into a water bath at 42°C for 
exactly 30 seconds, and put back in ice for 2 minutes. 125 µL of SOC medium were 
added and the culture was placed in the incubator at 3°C, 220 rpm, for 1 hour. 20 
and 40 µL were then spread into Petri dishes, containing agar medium and the 
appropriate antibiotic, and were left overnight at 37°C. To test whether the 
transformation had been successful, 4 single colonies from each Petri dish were 
chosen and spread again in a new plate. 2 colonies from each plate were finally 
chosen and their DNA extracted. 
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3.4.6 Glycerol stock 
1 colony was transferred into 10 ml LB medium with the appropriate antibiotic and 
left in an incubator at 37°C, 225 rpm, overnight. Then, 700 µL from each of the 10 
mL culture were gently mixed with 50% glycerol in PBS (300 AL). Each tube was 
then frozen in liquid nitrogen and stored at -80°C. 
3.5 Protein expression 
A single colony from an agar plate (obtained from the glycerol stock) was 
transferred, using a sterile toothpick, into 100 mL of LB medium, with the 
appropriate antibiotic, in a 250 ml flask to set up an overnight culture (ONC) at 
37°C under stirring (220 rpm). 500 mL or 1L LB broth with the appropriate 
antibiotic was placed in a 2.5 L conical flask. 40 mL of the ONC were added, and 
the culture incubated at 37°C, 220 rpm. When the optical density of the culture 
reached about 0.6 (measured using spectroscopy at 600 nm with lmL culture and 
using LB broth as a blank), IPTG was added to result in a final concentration of 1 
mM. The culture was then incubated at 30°C (32°C for ACP) for 4-5 hours. 
3.6 Protein purification 
3.6.1 Buffers 
All buffers were filtered (0.22 µm Minisart filters, Sartorius) prior to use. Buffers 
for gel filtration chromatography were also degassed under reduced pressure. All 
pH meter measurements were undertaken using a S20 Seven Easy pH meter 
(Mettler Toledo). Chemicals were bought from Sigma-Aldrich, BDH or Fisher 
Scientific, unless otherwise stated. 
3.6.2 Cell harvest and bacterial lysis 
Cells were harvested by centrifugation at 5000g, 4°C for 20 minutes. The 
supernatant was decanted off and the cell pellet was resuspended in a small volume 
of PBS, then centrifuged at 18000g, 4°C for other 20 minutes. The resulting pellet 
was then frozen at -80°C until required. The pellet was resuspended in about 30 mL 
of appropriate resuspending buffer (described in Table 3.2), with the addition of 0.1 
mg/mL lysozyme and a tablet of protease inhibitors (Complete EDTA-free, Roche). 
The solution was then sonicated (VibraCell sonicator, Sonics) on ice, using the 
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macrotip at 70% amplitude, for 25 seconds. After a pause of 25 seconds, the 
sonication was repeated for seven/eight times, or until the solution was less viscous. 
The resulting solution was then centrifuged at 18000g for 20 minutes at 4°C. The 
pellet was discarded and the supernatant containing the soluble protein retained for 
the purification steps. 
Protein Resuspending buffer 
ACP 50 mM Tris-HCI pH 8,2 mM DTT 
AcpS 50 mM Tris-HC1 pH 8 
Table 3.2 Lysis buffers used for each different protein. 
3.6.3 Affinity chromatography 
The affinity chromatography steps were performed using an FPLC machine (Akta 
Prime, GE Healthcare) and a HisTrap HP 5 mL column (Amersham). The flow rate 
was 1 mL/min. The Ni2+ affinity column was firstly equilibrated with the 
appropriate equilibrating buffer. The clarified supernatant (chapter 3.6.2) was 
filtered with 0.22 µm filters and then loaded into the column, that wash washed 
with a minimum of 3 column volumes of equilibrating buffer. The protein was 
eluted with a gradient of 70% elution buffer B in 50 mL. To check if other proteins 
were still bound to the resin, the gradient was then taken to 100% elution buffer B 
in 3 column volumes and maintained for another column volume. The resulting 
fractions were pooled and concentrated for further purification steps. Equilibration 
and elution buffers are described in Table 3.3. 
Protein Equilibrating buffer Elution buffer B 
AcpS 50 mM Tris-HC1 pH 8,5 mM imidazole, 50 mM 
Tris-HC1 pH 8,1 M imidazole, 
10 mM MgCI2,500 mM NaCI 10 mM MgCI2,500 mM NaC1 
Table 3.3 Equilibration and elution buffers used with the Ni2+ affinity column. 
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3.6.4 Ion exchange chromatography 
The ion exchange purification was performed using a Q-Sepharose HiLoad 16/60 
column (Amersham) and a flow rate of 2 mL/min. The Q-Sepharose anion- 
exchange column was firstly equilibrated with the appropriate buffer, then the 
protein solution was loaded and eluted with the gradient of salt (0-100% ion 
exchange buffer B over 15 column volumes). 2 mL fractions were collected. The 
fractions containing protein were identified using SDS-PAGE gel and concentrated 
for the following purification steps. The buffers used are summarized in Table 3.4. 
Protein Ion exchange buffer A Ion exchange buffer B 
50 mM Tris-HC1 pH 8,5 mM ß- 50 mM Tris-HC1 pH 8,5 mM ß- ACP 
mercaptoethanol, 10 mM MgC12 mercaptoethanol, 10 mM MgC12, IM NaCl 
Table 3.4 Ion exchange buffers used with the ion exchange chromatography. 
3.6.5 Size exclusion chromatography (gel filtration) 
The previous fractions containing protein were pooled and concentrated to 500 µL 
or 1 mL. The column was initially washed with the appropriate equilibrating buffer 
with a flow rate of 0.5 mL/min. The protein solution was then loaded and fractions 
collected every 1 mL. Fractions were monitored using the online UV monitor 
measuring absorbance at 280 nm, by running samples on SDS-PAGE gels. The 
different buffers used are described in Table 3.5. 
Protein Equilibrating buffer Column used (Amersham) 
ACP 
50 mM Tris-HC1 pH 8,10 mM MgC12, 
HiLoad 16/60 Superdez 75 
300 mM NaC1,5 mM DTT 
50 mM Tris-HCI pH 8,10 mM MgC12, HiLoad 16/60 Superdex 75 / AcpS 
300 mM NaC1 Superdex 75 10/300 GL 
Table 3.5 Gel filtration buffers used for gel filtration purification. 
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3.6.6 Thrombin cleavage of wild type his-AcpS and purification of untagged 
AcpS 
The concentration of protein was measured by UV absorbance and Bradford assay. 
10 units of thrombin (Sigma) were added per mg of protein and the resulting 
solution was left at either 18°C or 37°C for a recorded amount of time, in order to 
set up a time course experiment to ascertain the best temperature and time for 
complete cleavage. A solution containing wild type AcpS and thrombin was made 
and left at 18°C overnight. An affinity chromatography column (HisTrap HP 5 mL 
(Amersham)) was placed directly at the top of a benzamidine column (HiTrap 
Benzamidine FF, 1 mL (Amersham)) in the Akta prime (GE Healthcare). This 
system was equilibrated with equilibrating buffer (50 mM Tris pH 8,0.5 M NaCl, 
10 mM MgC12), then the solution was injected into the nickel column. Both 
columns were washed again using the same buffer. The untagged protein should be 
eluted immediately. 
3.6.7 Dialysis 
3,500 Da dialysis membranes (Medicell International Ltd) were washed in 
deionised water, then in dialysis buffer (Table 3.6). After sealing one end with a 
clip, the pooled protein fractions were inserted. The other end was then sealed and 
the membrane transferred into 1L of the dialysis buffer at 4°C, for 1 h, under gentle 
agitation. The membrane was then placed in 1L of fresh buffer, which was left at 
4°C overnight. The next morning the buffer was replaced with 1L of fresh dialysis 
buffer and left for a couple of hours at the same temperature. 
Protein Dialysis buffer 
AcpS 50 mM Tris-HCI pH 8,10% v/v glycerol, 10 mM MgCl2 
Table 3.6 Dialysis buffer used. 
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3.6.8 Desalting 
The HiTrap Desalting 5 mL (Amersham) column was initially equilibrated with the 
appropriate desalting buffer (Table 3.7) at a flow rate of 1 mL/min. Then, up to 1.5 
mL of protein solution was loaded and 0.3 mL fractions were collected. 
Protein Desalting buffer 
ACP 50 mM Tris-HCI pH 8.5,10 mM MgC12,10 mM DTT, 
AcpS 50 mM Tris-HC1 pH 8,10% v/v glycerol 10 mM MgC12 
Table 3.7 Desalting buffers used for each different protein. 
3.6.9 Activation and purification of holo-ACP 
For the phosphopantetheinylation of apo-ACP, 100 µL aliquots of reaction buffer 
(50 mM Tris, 10 mM MgC12i 5 mM DTT, pH 8.8) containing the reaction mix (100 
µM ACP, 1 pM AcpS, 1 mM CoA) were left for 1 hour at 30°C in a water bath. 
Then samples were centrifuged and loaded into a gel filtration column (Superdex75 
HiLoad 16/60 (Amersham) or Superdex75 10/300 GL (Amersham)), which was 
previously equilibrated with gel filtration buffer (50 mM Tris, 200 mM NaCI, 10 
mM MgC129 5 mM DTT, pH 8.8). 
3.7 Biochemical characterization 
3.7.1 SDS-PAGE gels 
SDS-PAGE gels were used to check the presence of protein after its expression and 
throughout the purification. Polyacrylamide gels are made using the following 
reagents (for 12 gels): 
- for stacking gel (4% polyacrylamide): 15 mL deionised water, 3.75 mL 30% 
acrylamide (Severn biotech), 6.25 mL stacking gel buffer (30.3 g Tris, 10% 
SDS, pH 6.8). Then: 15µL Temed (Bio-Rad), 250 µL 10% APMS; 
- for resolving gel (15% polyacrylamide): 17.5 mL deionised water, 35 mL 30% 
acrylamide, 17.5 mL resolving gel buffer (184.8 g Tris, 10% SDS, pH 6.8). 
Then: 45µL Temed, 700 µL 10% APMS. 10% or 8% stacking gels were made 
varying the volume of polyacrylamide added. 
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The protein samples were mixed with an equal amount of sample application buffer 
(30 mL glycerol, 50 mL 10% SDS, 10 mL 0.5 M EDTA, 5 mL ß-mercaptoethanol, 
0.1% Bromophenol blu, 0.6 g Tris, pH 7, for a final volume of 100 mL). This 
mixture was then heated to 100°C for about 10 minutes. 15 pL of this mix was 
usually loaded into each well, along with 5 µL low molecular weight marker 
(Sigma). Running buffer (25 mM Tris-HCI, 0.192 M glycine, 10% SDS) was used 
to make the gel run at 180-200V for about 1 hour, or until the visible blue dye 
reached the bottom of the gel. The gel was then removed and placed in Coomassie 
blue stain (500 mL stain solution contains 125 mL ethanol, 50 mL acetic acid, 1.25 
g Coomassie brilliant blue and deionised water) on a rocker for about 10 minutes. 
After removing the stain solution, the gel was transferred into a destain solution 
(20% ethanol, 5% acetic acid) until clear bands were visible. 
3.7.2 Protein concentration 
The protein concentration was calculated using the Lambert-Beer equation: 
A=ccl 
where A is the absorbance at 280 nm (measured in a Perkin-elmer lambda 25 
Uv/vis spectrophotometer), c the extinction coefficient for the protein (calculated 
using the software ProtParam [134]), c the concentration of protein in mg/mL and I 
the pathlength (1 cm). Protein was concentrated to the suitable value using a 
concentrator of the appropriate cut-off (3,10 or 30 kDa Vivaspin 20, Sartorius), 
and then was frozen in liquid nitrogen and stored at -80°C until required. 
3.7.3 Bradford assay 
Bradford assay was used to determine protein concentration, especially when no 
tryptophan residues were found. Dilutions of BSA (1,0.5,0.25,0.05 mg/mL) were 
used as standards. 20 µL of protein solution were diluted with 180 µL of Bradford 
reagent (Sigma-Aldrich), for a total volume of 200 µL. Each dilution was repeated 
at least twice. A Microtitre 96-well plate (Sterilin) was used and the absorbance at 
595 nm measured with a Versa Max microplate reader (Molecular Devices). 
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3.7.4 Mass spectroscopy 
Phosphopantetheinylation of apo-ACP was checked by NMR by the proteomic 
service at the Department of Biochemistry, Bristol. 10 pL protein samples were 
checked in a MALDI-MS Voyager-DE STR Mass Spectrometer (Applied 
Biosystems) to give a mass fingerprint. The purity of the cofactors used in the 
crystallization of AcpS was kindly checked by Chris Arthur, Department of 
Chemistry, using a positive ion mode on a QStar XL mass spectrometer (Applied 
Biosystems). Samples were delivered using a Nanomate nano-electrospray source 
(Advion) at a voltage of 1.3 kV and a gas pressure of 0.3 Psi. 
3.8 X-ray crystallography 
3.8.1 Crystallization trials 
The hanging drop technique was used. The cofactor, when needed (generally at a 
final concentration of 5 mM), was added to the protein solution (usually 5 or 10 
mg/mL). The mixture was left at 4°C or 18°C for 30 minutes, then centrifuged at the 
same temperature for 30 minutes at the maximum speed. For 24 well plates (24 
well VDX plates with sealant, Hampton Research), 0.5-2 µL drop of protein 
solution at the suitable concentration were mixed with the same volume of 
crystallization reagent on the coverslip, and placed in vapour equilibration with 400 
pL of liquid reservoir. The corresponding well was sealed and left at 18°C in the 
crystallization room or at 4°C in the fridge. Alternatively, the Phoenix robot (Art 
Robbins Instruments) was also used to test a very small volume of protein. Up to 
0.2 µL drops (0.1 pL + 0.1 µL) were obtained using 50 µL of precipitant solution 
and 96 well plates (MRC 96 well plates, Molecular Dimension LTD). If a protein 
complex was required, proteins were incubated together for 30 minutes at a ratio of 
1: 1. The crystallization kits used were: Crystal Screens 1 and 2, PEG/Ion Screen 
(Hampton Research); Clear Strategy Screen I and II; Structure Screen I and 11 96 
HT; PACT premiere 96 HT; JCSG plus 96 HT (MDL); Jena Screens 1-9. The 
formulations of the screens are shown in Appendix 3. 
3.8.2 Cryoprotectant and loop mounting 
All crystals were flash-frozen in liquid nitrogen before testing them on synchrotron 
source. Crystals were mounted on a nylon loop of the suitable dimension (Hampton 
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research), transferred for 5-10 seconds into a stabilising solution containing the 
cryoprotectant (generally the reservoir plus 10-30% glycerol or 10-30% PEG400), 
then flash-frozen in liquid nitrogen. 
3.8.3 Data collection and processing 
Data were collected at the synchrotron SRS, Daresbury (beamline 14.1 / Quantum 4 
ADSC detector and 10.1 / MAR 225 CCD detector), DLS, Diamond (beamline 102 
and 103 / ADSC Q315 CCD detectors) and ESRF, Grenoble (beamline BM14 / 
MAR 345 image plate detector). The diffraction patterns were displayed, indexed, 
integrated and scaled using HKL2000 [135]. 
3.8.4 Molecular replacement 
In preparation of subsequent datasets of the same crystal form, the same set of R- 
free reflections was used. The molecular replacement was performed using Phaser 
[136,137]. The search models used to solve the different structures are summarized 
in Table 3.8. 
Protein Search model PDB 
Apo-AcpS (2jca) B. subtilis apo-AcpS polyserine model 1 fit 
AcpS in complex with CoA (2jbz) S. coelicolor apo-AcpS 2jca 
AcpS in complex with Acetyl-CoA S. coelicolor holo-AcpS 2jbz 
AcpS H11OA S. coelicolor holo-AcpS 2jbz 
AcpS DI 1IA S. coelicolor holo-AcpS 2jbz 
Table 3.8 Search models used for the molecular replacement. 
3.8.5 3-fold averaging and density modification for apo-AcpS 
After Phaser [136,137], an electron density map was obtained, but it was difficult 
to build into. Structure factors and phases were calculated using SFall [138], and 
appropriate weights for the Fourier coefficients were then calculated using SigmaA 
[139]. Attempts to automate model building with ARP/wARP [140], with the 
option `automated model building starting from existing model', using the model 
obtained after Phaser, failed. So, DM [141] was used to 3-fold average to the 
76 
Chapter 3 Materials and Protocols 
electron density map and to generate new experimental phases. DM was run with 
the solvent, histogram, averaging and ncycle auto options. ARP/wARP [140] was 
then used to automatically trace the chain, utilizing the `automated model building 
starting from experimental phases' option with 10 (50 in total) building cycles. 
Further rounds of model building in Coot [142] and refinement with Refmac5 [133] 
(provided with the CCP4 suites of programs [143]) resulted in the final model. 
3.8.6 Refinement and model building 
Refinement of the structures was done using Refmac5 [133], while the manual 
model building was made using Coot [142]. After a first cycle of rigid body 
refinement, restrained refinements were run. The software was used with the 
default options, except that a Babinet scaling was used and the overall weight for 
B-factor restrains were set at 1 (overall wt), 3 (sigmas bonded), 5 (non bond), 6 
(planar) and 10 (H atom). This was to allow greater deviation along sidechians 
where the terminal portion can be more variable than parts close to the main chain. 
The improvement of the quality of the model was followed by the Rrree and R-factor 
values. The geometric quality of each structure was analyzed by Procheck [144], 
Molprobity [145] and using the interactive tools in Coot. In this thesis, two type of 
electron density map were routinely used: FWT with phases PHWT, an equivalent 
to the 2Fo-Fc where the exact weight is determined using SigmaA as Refmac 
output, and the difference electron density map DELFWT with phases DELPHWT, 
equivalent of Fo-Fc. 
3.8.7 Generation of AcpS-ACP complex model 
The NMR structures of S. coelicolor apo- and holo-ACP, kindly provided by Dr 
Matt Crump, Department of Chemistry, were used to study the possible interaction 
with AcpS. The structure closest to the geometric mean was chosen from the 
ensemble of NMR solutions. B. subtilis AcpS-ACP complex (PDB: 1f80) was used 
as starting model. A trimer of S. coelicolor apo- or holo-AcpS was superimposed to 
the B. subtilis AcpS using the SSM superpose tool in Coot [142], while apo- or 
holo-ACP was superimposed on B. subtilis ACP (D subunit) and the complex was 
visualized in Coot. 
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3.9 ITC 
Kd for wild type and mutants AcpS and cofactors binding was determined by ITC. 
The protein and cofactor were first dialysed in ITC buffer (50 mM Tris-HC1 pH 8). 
A protein concentration of 8-10 µM and a cofactor concentration of 120 µM were 
used. The ITC was carried out using a VP-ITC microcalorimeter (MicroCal). A 
single experiment consisted of an initial injection of 7.5 µL of cofactor solution into 
the cell containing the protein solution, followed by other 18 injections of 15 µL. 
The reaction was carried out at 25°C and each injection lasted for 30 seconds (15 
for the first one) followed by 240 seconds of pause. For the determination of the 
weaker CoA binding site of the D111A AcpS, an initial concentration of 1.5 mM of 
CoA was used. 15 injections of 2.5 pL of cofactor over 5 seconds were followed by 
other 15 injections of 15 µL over 30 seconds. For each cofactor or protein, the 
experiment was repeated at least 3 times. A blank that covered the concentration 
range of the appropriate cofactor was run as a negative control in the absence of 
protein and was subtracted from experimental data. Alternatively, OH determined at 
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Chapter 4 
The Acyl carrier protein Synthase (AcpS) 
Streptomyces coelicolor Acyl carrier protein Synthase (AcpS) catalyzes the transfer 
of the phosphopantetheine chain from coenzyme A (CoA) to a conserved serine of 
the Acyl carrier Protein (ACP). This chain has a core role during both fatty acid and 
polyketide synthesis. It holds and delivers the growing chain to the different 
enzymes involved in the syntheses. S. coelicolor AcpS is capable of activating both 
fatty acid and polyketide ACP [74]. This chapter presents the structure solutions of 
the apo-AcpS and of the protein in complex with CoA. The comparison of this type 
I S. coelicolor AcpS with the type I fatty acid B. subtilis and S. pneumoniae AcpS, 
and with the type II human AcpS, are presented in order to highlight the common 
aspects and the differences that characterize this promiscuous enzyme. 
4.1 Sequence analysis 
pET-16b-AcpS DNA was kindly donated by Dr Matt Crump and Dr John Crosby, 
Department of Chemistry. The sequence of the protein is shown in Figure 4.1. The 
protein was cloned with a polyhistidine tag at the N-terminal position, with the 
additional presence of a thrombin recognition site for cleavage of the tag. The 
software ProtParam [134] was used to determine the molecular weight of 14.7 kDa, 
the pI of 6.75 and the extinction coefficient of 1.120 M" cm's. No cysteines were 
present, so no reducing agents were used during the purification protocol. Finally, 
the presence of three tryptophanes and three phenylalanines guaranteed the UV 
absorbance at 280 nm. The poly-histidine tag was not removed during AcpS 
purification. 
MGSSHHHHHHSSG LVPRGS H MSIIGVGIDVAEVERFGAALERTPALAG 
RLFLESELLLPGGERRGVASLAARFAAKEALAKALGAPAGLLWTDAEV 
WVEAGGRPRLRVTGTVAARAAELGVASWHVSLSHDAGIASAVVIAEG 
Figure 4.1 The sequence of the S. coelicolor his6-AcpS. The polyhistidine tag and 
the sequence preceding the AcpS gene are underlined. The LVPRGS thrombin 
cleavage site is shown in bold. 
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4.2 Expression of wild type AcpS 
Before the expression, pETl5b-AcpS DNA was transformed into E. coli BL21 
(DE3) (chapter 3.4.5). The success of the transformation was checked by extracting 
plasmid from transformants (chapter 3.4.2), subjecting the DNA to endonuclease 
restriction digest (chapter 3.4.3) and checking the size of the fractions on an 
agarose gel. 
AcpS was expressed by induction with I mM IPTG at 37°C, and the expression 
continued for 4-5 hours at 30°C (chapter 3.5). AcpS was expressed very well in 
both 0.5 L and 1L culture. Some protein can be seen in the insoluble fraction, but 
the amount of soluble protein obtained after sonication (Figure 4.2) was still very 
satisfactory for purification purposes. 
4 AcpS 
Figure 4.2 AcpS expression. P: pellet after sonication; Sri: supernatant after 
sonication. 
4.3 Purification of wild type AcpS 
The supernatant after sonication was loaded into the affinity column (chapter 3.6.3). 
AcpS was eluted from the column as a single and well defined peak, at a 
concentration of imidazole of about 120 mM (Figure 4.3 A). The SDS-PAGE gel 
(Figure 4.3 B) also showed that the fractions after the affinity chromatography were 
very pure. To increase protein purity, as well as for analytical purposes, aliquots 
from this peak were collected, concentrated to I mL and loaded into the Superdex 
75 gel filtration column (chapter 3.6.5). 
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As shown in the chromatogram and in the SDS-PAGE gel (Figure 4.4), AcpS was 
eluted again as a very well-defined single peak. Aliquots from this peak were 
dialysed or desalted in the desalting buffer (chapter 3.6.7-3.6.8) and then stored at - 
80°C. The protein concentration was determined by UV absorbance and Bradford 
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Figure 4.3 AcpS affinity chromatography. A) Chromatogram from the HisTrap 
column. AcpS is eluted as a well defined single peak. UV absorbance is shown in 
blue, the gradient of the elution buffer in red. B) SDS-PAGE gel showing AcpS 
fractions pooled from the peak of the chromatogram. MW: molecular weights; W: 
aliquots after column washes with equilibrating buffer; F: AcpS fractions. 
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Figure 4.4 AcpS gel filtration chromatography. A) Chromatogram from the gel 
filtration column. AcpS is eluted as a single peak. UV absorbance is shown in blue. 
B) SDS-PAGE gel showing AcpS fractions pooled from the peak of the 
chromatogram eluted between 58 and 69 mL (1 mL fractions). MW: molecular 
weights; F: AcpS fractions. 
4.4 AcpS crystallization, data collection, processing and refinement 
4.4.1 Apo-AcpS data collection and processing 
The apo-AcpS was purified and crystallized by Dr Chris Arthur, Department of 
Chemistry, using the hanging drop vapour diffusion method. A crystal obtained at 
18°C, using 10 mg/mL protein concentration, 0.2 M NH; SO49 0.1 M NaCacodylate 
pH 6.5,30% PEG 8000 as precipitant (Figure 4.5), was donated and tested at the 
beamline 14.1 at the Synchrotron Radiation Source (SRS), Daresbury. The crystal, 
about 1.2x0.1 x0.1 mm, was transferred into 0.2 M ammonium sulphate, 0.1 M 
NaCacodylate pH 6.5,30% PEG 8000,10% glycerol prior to flash freezing in 
liquid nitrogen. A nice protein-like diffraction pattern was obtained (Figure 4.5). 
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This crystal belonged to the trigonal space group P3i21 with a=b=75.9 A and 
c=108.3 A, and diffracted to a resolution of approximately 2 A. The data processing 
was done using the HKL2000 [135]. 
A) B) 
Figure 4.5 Apo-AcpS crystal and related diffraction pattern. A) Crystals obtained 
in 0.2 M ammonium sulphate, 0.1 M NaCacodylate pH 6.5,30% PEG 8K. B) 
Example of diffraction image. 
4.4.2 Molecular replacement and refinement 
Calculation of possible solvent content suggested that there were 3 molecules per 
asymmetric unit. The structure was solved by molecular replacement using Phaser 
[ 136,137] and the B. subtilis FAS AcpS protein (PDB: 1 f7t [86]) as search model 
(chapter 3.8.4). ARP/wARP [140] was not able to build the structure automatically 
into the initial electron density map using the existing Phaser model (chapter 3.8.5). 
So, 3-fold averaging was used to obtain better phases. After 3-fold averaging with 
DM [141] (chapter 3.8.5), the electron density map was much improved (Figure 
4.6). The NCS averaging correlation between related density regions was enhanced 
of about 30% (from 57% to 87% and from 54% to 87% for the correlation between 
monomers A and B and monomers A and C respectively). ARP/wARP was then 
run using the structure factors and phases obtained with DM (chapter 3.8.5), and 
automatically built 337 out of 429 residues (including the histidine tags) into this 
averaged map. Further rounds of model building in Coot [ 142] and refinement with 
Refmac5 [133] resulted in the final model. The apo-AcpS model was deposited in 
the PDB as 2jca, and contains 123 residues per each molecule, 3 sulphate ions, I 
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calcium, I glycerol and 199 water molecules. The histidine tag resulted very 
disordered, and it was not possible to build any model for it. 3 protein subunits (I 
complete trimer) are found in the asymmetric unit. The electron density was weak 
and not well defined for residues 65-68 in the B subunit, and for residues 22-24 in 
the C subunit, due to the high mobility of these loops. The refinement led to a 
structure model with R-factor and Rfree values of 0.18 and 0.22 respectively. Data 
processing and refinement statistics are shown in Table 4.1 
1, 
B) 
Figure 4.6 Map improvement after 3-fold averaging. A) 2Fo-Fc density map 
(FWT, PHWT) after molecular replacement solution contoured at 
l (T with the final 
model shown as bonds. B) 2Fo-Fc electron density (FDM, 
PHIDM) obtained using 
the structure factors and phases from DM contoured at 
Icy, with the final model 
shown as bonds. 
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Apo ACPS [2jca] 
Wavelength (A) 1.488 
Resolution (A) 50-1.98 (2.05-1.98) 
Space group P 3121 
a=b=75.9 A, c=108.3 A 
Completeness (%) 99.3 (95.7) 
N unique reflections 25759 
Redundancy 6.4 (3) 
hoI 22.2 (2.0) 
R merge 0.08 (0.38) 
Mosaicity (°) 0.37 
Rfr,, 0.22 
R-factor 0.18 
RMS bond (A) 0.018 
RMS angle (°) 1.690 
Table 4.1 Data processing and refinement statistics for the apo-AcpS. Data 
corresponding to the highest resolution shell are shown between brackets. 
4.4.3 Geometry and B-factor analysis 
MolProbity [145,146] was used to check the geometry and the conformation of the 
model. The Ramachandran plot is presented in Figure 4.7.98.1 % of the residues 
are in the most favoured region, while Asp 111 of subunits A and B, and A1a67 and 
Leu70 of subunit C, are in the allowed region. 3 outliers were identified: Thr23, 
Pro24 and A1a25 of subunit C. These residues belong to a mobile area, with a very 
high B factor, and their model building was quite difficult to complete. Metl, 
Leu49 and Leu 108 of subunit A, Ser2, Arg43 and Leu 108 of subunit B, and Leu70 
and Val 101 of subunit C were recognized to have unusual rotamers. In most of the 
cases, this is probably due to the fact that the electron density of the side chains is 
not very well defined. An analysis of the average B-factor of the main chains was 
also performed with Baverage [143] (Figure 4.8). The average B-factor is 32 A2,36 
A2 and 42 A2 for monomer A, B and C. This analysis shows that the average B- 
factor of the areas that will be identified as mobile (chapter 4.6.3) is higher than the 
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one of the neighbouring regions. The difference of the B factor values between each 
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Figure 4.7 Ramachandran plot related to the apo-AcpS. This analysis was 
performed by MolProbity. A) general case; B) glycine; C) proline; D) pre-proline. 
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Average B factor for the main chain 
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Figure 4.8 Apo-AcpS B-factor analysis. Average B-factor values for the main 
chain of the three subunits of the apo-AcpS. The B-factor values reflect the 
mobility of the mobile loops. 
4.5 AcpS in complex with CoA 
4.5.1 Holo-AcpS crystallization and data collection 
AcpS at the concentration of 10 mg/mL was crystallized in the presence of 5 mM 
CoA at 18°C (chapter 3.8.1). Very nice and quite big crystals were obtained when 
the Peg/Ion and the Clear Strategy Screen I and II at pH 6.5 were used. The most 
regular and big crystals were obtained at 18°C in the conditions shown in Table 4.2. 
Salt Buffer PEG 
0.2 M lithium sulphate 0.1 M NaCacodylate pH 6.5 25% PEG 2K MME 
0.2 M lithium sulphate 0.1 M NaCacodylate pH 6.5 15% PEG 4K 
0.2 M potassium thiocyanate 0.1 M NaCacodylate pH 6.5 15% PEG 4K 
0.2 M potassium thiocyanate 0.1 M NaCacodylate pH 6.5 10% PEG 8K+ 10% PEG IK 
0.2 M potassium bromide 0.1 M, NaCacodylate pH 6.5 25% PEG 2K MME 
0.2 M potassium bromide 0.1 M NaCacodylate pH 6.5 15%PEG 4K 
0.2 M potassium bromide 0.1 M NaCacodylate pH 6.5 10% PEG 8K+ 10% PEG IK 
0.2 M Lithium Nitrate none 20% w/v Polyethylene Glycol 3350 
0.2 M Ammonium Sulfate none 20% w/v Polyethylene Glycol 3350 
Table 4.2 Holo-AcpS crystallization conditions. 
88 
Chapter 4 The Acyl carrier protein Synthase 
Optimization plates were prepared varying the salt (0.1,0.2 and 0.3 M) and/or the 
PEG concentration (variations in steps of 1% for PEG 4K , 
between 13-18% w/v, 
and in steps of 2% for PEG 2K MME, between 19-27% w/v). Very nice triangular 
crystals were obtained in many different conditions, with an average size of about 
0.74.6x0.3 mm (Figure 4.9). Cryosolutions consisting of the appropriate reservoir 
with the presence of 10 or 20% v/v glycerol were then prepared and the crystals 
were tested at beamline 10.1, Daresbury synchrotron. The best diffraction pattern 
was obtained using crystals from 0.2 M potassium thiocyanate, 15% PEG 4K, 0.1 
M NaCacodylate pH 6.5. The best crystal, in a cryosolution containing 0.2 M 
potassium thiocyanate, 15% PEG 4K, 0.1 M NaCacodylate pH 6.5,10% v/v 
glycerol, diffracted to approximately 1.6 A. Data were collected at beamline 10.1 at 
the SRS synchrotron, Daresbury. Crystals belonged to the cubic P213 space group 
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Figure 4.9 Holo-AcpS crystals and example of diffraction image. A) Crystals 
obtained in 0.2 M potassium thiocyanate, 15% PEG 4K, 0.1 M NaCacodylate pH 
6.5. B) An example of diffraction image of the best crystal. 
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4.5.2 Molecular replacement and refinement 
One protein subunit was found per asymmetric unit, with the trimer axis therefore 
lying on a crystallographic 3-fold axis. The apo-AcpS structure was used as search 
model for molecular replacement. Structure refinement was performed using Coot 
[142] and Refmac5 [133]. The holo-AcpS model was deposited in the PDB as 2jbz. 
It contains residues 0-123 of an AcpS monomer, a molecule of CoA, one 
magnesium ion, one potassium ion and 183 water molecules. Each molecule is 
organized in a trimeric oligomerization state. Whereas in the apo structure the 
entire his-tag was disordered, in the holo structure it was possible to model the 
histidine (residue 0) preceding the portion containing the His6-tag, with further 
density likely to be the N-terminal portion which was difficult to model. The 
refinement led to a structure model with R-factor and Rfree values of 0.19 and 0.21 
respectively. Data processing and refinement statistics are summarized in Table 4.3. 
Holo-ACPS [2jbz] 
Wavelength (X) 1.478 




N unique reflections 16798 
Completeness (%) 90.7 (69.3) 
Redundancy 6.1 (1.8) 
UQI 18.9 (2.2) 
R merge 0.08 (0.33) 
Mosaicity (°) 0.5 
Rye 0.21 
R-factor 0.19 
RMS bond (A) 0.011 
RMS angle (°) 1.417 
Table 4.3 Data processing and refinement statistics for AcpS in complex with CoA. 
Data related to the highest resolution shell are reported between brackets. 
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4.5.3 Geometry and B-factor analysis 
The geometry and the conformation were checked using MolProbity [ 145,146]. 
The Ramachandran plot is presented in Figure 4.10.99.2 % of the residues are in 
the most favoured region, while Ser2 is in the allowed region. Leu59 and Arg83 
were recognized to have unusual rotamers (0.2% and 0.1% respectively). An 
analysis of the average B-factor of the main chains was also performed with 
Baverage [143] (Figure 4.11). The average B-factor is 23 A2. From this analysis, it 
is also evident that the average B-factor of the areas that will be identified as 
mobile (chapter 4.6.3) is higher than the one of the neighbouring regions. 
( .. 
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Figure 4.10 Ramachandran plot related to holo-AcpS. All residues are in the 
favoured regions with the exception of Ser2, that are located in the allowed region. 
A) general case; B) glycine; C) proline; D) pre-proline. 
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Figure 4.11 Holo-AcpS B-factor analysis. Average B-factor values for the main 
chain of AcpS in complex with CoA. The B-factor values reflect the mobility of the 
mobile loops. 
4.6 Structural analysis of the Acyl carrier protein Synthase 
In the following section, the structure of the holo-AcpS is introduced first, then the 
structure of the apo-AcpS is described and compared to the holo-AcpS. 
4.6.1 AcpS fold and oligomerization 
Holo-AcpS is a trimer, with the three fold axis of the trimer coinciding with a 
crystallographic 3-fold axis so that there is one subunit in the asymmetric unit. 
Each subunit is made up from 4a helices and 5ß strands (Figure 4.12). The core of 
the subunit is helix a3, which runs between residues 45 and 63, and packs against a 
3-stranded antiparallel 1 sheet on one side, with the other a helices decorating the 
other side of the subunit. This ß sheet has topology 01, ß4 and ß5. To form the 
biological unit, a trimer with one active site at each interface between 2 subunits, 
the 3-stranded antiparallel ß sheets come together around a 3-fold axis to make a 9- 
stranded 0 barrel with parallel interactions between the ß sheets. 
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Figure 4.12 Structure of S. coelicolor AcpS. Diagram of the holo-AcpS biological 
trimer with the protein shown in cartoon representation, CoA as sticks and coloured 
according to atom type and magnesium shown as a grey sphere. 
4.6.2 Active site 
The active site and CoA binding site lie at the interface between 2 monomers 
(Figure 4.14). The adenine ring interacts with one monomer, while the 
phosphopantetheine arm binds to the adjacent monomer. The electron density of the 
cofactor is shown in Figure 4.13. 
4.6.2.1 CoA binding site 
In the following description the numbering describes the active site at the interface 
between A and B, but there are 3 equivalent active sites in the whole biological 
trimer, one at each subunit interface. The adenine ring binds in a pocket that is 
formed by the end of helix a3 on monomer B, and the ML3 of the adjacent A 
molecule. The ribose is present in the 3' endo-conformation. The 3'-phosphate is 
held in place by interactions with residues HisAl 10, SerA48 and ArgA52 and 
through hydrogen bonds provided by waters. The a-phosphate is within hydrogen 
bonding distance with magnesium, AspB9, LysB6l and the main chain of 
HisA110, while the ß-phosphate with AspB9 and 3 water molecules. 
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The phosphopantetheine arm lies in a hydrophobic cavity on B between the central 
helix a3 and the small helix a5. At the entrance of the cavity, GIuB57 makes a 
hydrogen bond to a backbone nitrogen at the phosphopantetheine side chain, (PNK), 
and side chain carbonyl oxygens (P05 and P09) make water mediated hydrogen 
bonds with ProB66 and AlaB67 in ML2. The hydrophobic cavity is composed of 
the aliphatic part of the LysB56 side chain and by residues LeuB59, LeuB63, 
LeuB69, TrpB71, AlaB74, VaIB92. 
Coenzy 
Figure 4.13 Electron density map (FWT, PHWT) at 1.2 a of CoA and the 
magnesium coordination sphere. CoA in shown as sticks and coloured according to 
atom type and magnesium is shown as a grey sphere. The magnesium ion is 
coordinated to the a- and ß-phosphate of CoA, to 3 water molecules (in red) and to 
an oxygen of the side chain of Asp9. 
4.6.2.2 Magnesium binding site 
Magnesium is essential for activity. This ion was present in the crystallization 
buffer and is clearly visible in the electron density in the presence of CoA. S. 
coelicolor holo-AcpS is the first type I AcpS structure where the essential 
magnesium ion is present in the active site. Its coordination sphere is composed of 
the oxygens of the alpha and beta-phosphates of CoA, the oxygen from the side 
chain of AspB9 and 3 waters molecules (Z12, Z16 and Z183) (Figure 4.13). One 
coordinating water (Z12) interacts with the oxygens of the beta-phosphate of CoA, 
AspB9, two water molecules (Z 16 and Z 183), and water Z 175 from monomer A. 
The second water (Z 16) is held in place by hydrogen bonds with the oxygens of the 
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alpha phosphate of CoA and of the backbone of Va1B 10, the side chain oxygen 
from SerA109, and 2 water molecules (Z12 and Z183). The third water (Z183) is 
within hydrogen bonding distance with the oxygen of the alpha phosphate, the side 
chain oxygen of AspA 111, the other 2 coordinating waters, and water Z 172 from 
monomer A. 
4.6.3 Comparison between apo- and holo-AcpS 
In the apo crystals, a complete trimer with 3 subunits is found in the asymmetric 
unit. The Ca atoms of the three subunits can be superimposed with a root mean 
square difference (RMSD) of 0.55 (A on B), 0.72 (A on C) and 1.05 A (B on Q. 
Three main flexible loops (ML1-3) are found between residues 37-44,65-70 and 
79-82 (Figure 4.14). There is also a small displacement in the final portion of helix 
al, especially between residues 21-26 (MH1). The average B factor of these mobile 
portions is higher than in the other region. The Ca superimposition is improved to 
0.29 (A on B), 0.39 (A on C) and 0.46A (B on C) when these areas are omitted. The 
magnesium is not visible in the electron density in the absence of CoA, even if it is 
present in the crystallization buffer at the concentration of 10 mM. A sulphate ion, 
present in the mother liquor for the crystallisation, was found at the position where 
the 3'-phosphate of CoA is located in the holo-AcpS. 
By superimposing a trimer of holo-AcpS generated using crystallographic 
symmetry on a trimer of apo-AcpS, some conformational changes can be identified. 
The RMSD after Ca superimposition of the A monomers, is 0.94 A. The areas 
identified as mobile loops in the apo-protein are ordered in the holo model and are 
displaced compared to the apo. Residues in ML1 which are displaced by about 2A 
between the holo- and apo-structures, including ArgA44, are in the binding pocket 
for the 3'-phosphate. ML2 from the B subunit lines the phosphopantetheine binding 
pocket and ML3 stacks against the adenine base of the CoA. The loop that contains 
AspA111, which interacts with a magnesium coordinating water, is also displaced 
up to 6 A. Moreover, by superimposing the 2 trimers, with a rigid superimposition 
of monomers A, it is possible to notice that helix al is displaced by 4-5 A in chains 
B and C, clearly indicating a change in the trimer arrangement in the active holo- 
protein compared to the apo-protein, which results in an "opening up" at the top of 
the trimers, as displayed in Figure 4.15. 
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Mt 
Figure 4.14 CoA lies at the interface between 2 monomers. Cartoon representation 
of holo-AcpS monomers A and B, coloured in magenta and cyan. CoA is shown as 
sticks and coloured according to atom type. Magnesium is shown as a grey sphere. 
Helix al and mobile loops in the apo-AcpS are colored in red. The equivalent 
positions in the holo protein are colored in pale magenta and cyan. 
Figure 4.15 Superimposition between S. coelicolor holo- (in magenta and cyan) 
and apo-AcpS (in pale colors), picturing that the holo-protein seems to assume a 
more open conformation. Monomers A and B are shown as ribbon representation. 
Mobile loops are coloured in red. CoA is shown as sticks and coloured according to 
atom type. Magnesium is shown as a grey sphere. 
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4.7 Multiple sequence alignment of analogue type I phosphopantetheinyl 
transferases 
The result of a multiple sequence alignment, carried out firstly with protein BLAST 
[147] and then with ClustalW [148], with analogue type I phosphopantetheinyl 
transferases is shown in Figure 4.16. 
1 15 22 29 
S. coelicolor AcpS I II - 
B. subtilis AcpS I , "GIGLDI7 }IN. "ELDQY'Y 
S. pneuminiae AcpS MkMIVGHGIDIEELA-, 1E-AViRflE l, A}"IRVLIALEMERFT 
S. avermitilis AcpS M? IIGVGIDVAEIDRFRASLERTPGLADR-LFLERE-LLL 
K. radiotolerans AcpS MIIGVGIDVVDVARFKRQVERTPLLLER-LFGD(: -E-RNL 
S. erythraea AcpS MIVGIGTDLVGVVRFGESLERTPALAER-VFI'PAE-RRT 
L. xyli AcpS MIA T VDVVDLARFGRSLAR'IPALRDR-LFTEAE-R(L 
D. hafniense AcpS MJf-- VDIVEIQRFAKACERTPKLRER-LFTEREIEKL 
T. denticola AcpS Mli! l : )IVEV: RLEKWLN-DKKLLER-FFNKEELE'i V 
D. desulfuricans AcpS ml; i D)LTEL('RIRAALERC)PERFPPRILHD'FT, AAM 
B. halodurans AcpS Pý IiI'!! ' 
" ý 
0D 
ßl al a2 
57 61 
S. coel F EEýk_ VA- LAAkF Aid, FR' A, , --PA_ LLW I DAPVWVE"; A- I-. 
B. sub EL--, EKRKNEFLAGRFAAh: EAE. i IGRQLSFQDIEIRKDQNGK 
S. pneu LKGRRQIEYLAGRWSAKEAFSKAMGTGIS-KLGFQDLEVLNNERGA 
S. averm PNGERRGIASLAARFAAKEAVAKALGA--PGGLYWTDAEVWVEDSGR 
K. radio P------ AESLAARFAAKEAVAK'L17A--PVfLVWRDVVVEREDGHR 
S. ery F lAF. VTSLAARFAAKEAAAKAI V--P: ' 'RFTDCEVVQADDGR 
L. xyli F------VHLAARFAAKEALIKA: --. E VRWHDLEIVSDEERN 
D. haf 
. 
i! K---AVASWAARFAGKEAVLKAI -LRGLSWHDIEILSNDLGE 
T. dent L, KRDGAAPSLAVRFAAKEAFGKALLIG-LAGIELKDIAVANDKTGR 
D. desul PR---LSVAWLAARFAAKEAAAKAL('7, -FTGrVAFRDTFV'i'KFT, fl, -K 
B. halo FL: RRkRLEIA FFAAFEAFVFRV I AI: F 
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Figure 4.16 Multiple sequence alignment of type I AcpSs. Numbering and location 
of secondary structure elements refer to those of S. coelicolor AcpS ("*" means 
identical residue, ". " a conserved substitution, ": " a semi-conserved one). 
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The various sequences are very similar to the S. coelicolor AcpS. 14 residues are 
completely conserved. The residues that were proposed to be important for ACP 
binding and for the catalysis [86] are Asp9, arginines 15,22 and 29, Glu57, Lys6l 
and Hisl05, and are very well conserved among the others type I AcpSs. While 
His 110 is highly conserved, Asp l11 is only partially conserved, and can be 
substituted by the similar glutamate residue or by a threonine, glycine or serine. 
4.8 Comparison between B. subtilis and S coelicolor holo-AcpSs 
The structure of the FAS Bacillus subtilis type I holo-AcpS [86] was superimposed 
on the S. coelicolor holo-AcpS, giving a RMSD of 1.35 A between the Ca atoms of 
the 2 structures. Both structures are trimeric with similar folds, and there is a single 
subunit in the crystallographic asymmetric unit. The major difference between the 
folds is that there is an extra helix (helix a4) in the S. coelicolor structure (Figure 
4.17). In the part of the B. subtilis sequence which corresponds to the helix a4 in S. 
coelicolor AcpS, a PCR error resulting in the mutation of a glutamine to proline in 
the crystallized protein was noted, which would preclude the formation of the extra 








Figure 4.17 Ca superimposition between S. coelicolor (in magenta and cyan) and 
B. subtilis holo-AcpSs (in grey), shown as ribbons. Mobile loops are coloured in 
red. The proline introduced by PCR error in B. subtilis AcpS and CoAs are shown 
as sticks. S. coelicolor CoA is coloured in yellow, the B. subiilis one in grey. 
Magnesium is shown as a grey sphere, calcium as a green one. 
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The remaining differences are in regions surrounding the active site, interacting 
with the coenzyme CoA (Figure 4.18). The region that was identified as mobile and 
involved in binding the 3' phosphate, MLl which is the loop at the end of helix 3, 
is replaced by a longer helix a3 in B. subtilis FAS AcpS, which joins on a longer 
central helix a3. ML3, which interacts with the adenine base, is in a similar 
conformation in both S. coelicolor and B. subtilis AcpS. ML2, which interacts with 
the phosphopantetheine chain, is in a different conformation. Comparing the 
location of the coenzymes in both structures, it is evident that they overlay almost 
perfectly from the tip of the adenine base up to and including the (x-phosphate, and 
they diverge from the ß-phosphate. However in the B. subtilis AcpS, a calcium ion 
is observed in the binding site of the magnesium required for catalytic activity due 
to the crystallization conditions [86]. Its coordination sphere includes Asp8, an 
oxygen from the alpha phosphate of CoA and 3 water molecules, and this is similar 
to the coordination observed for Mg 2+ in the S. coelicolor AcpS. The final ligand for 
the calcium observed in the B. subtilis FAS AcpS is the side chain of Glu58, 
whereas the final ligand for the Mg`+ in S. coelicolor AcpS is an oxygen from the 
ß-phosphate. In the S. coelicolor structure, the equivalent G1u57 side chain is in a 
different rotamer and creates a hydrogen bond with the phosphopantetheine chain. 
A) B) 
Figure 4.18 Surface representations for CoA binding pockets. A) S. coelicolor 
pocket shown in surface representation, with CoA shown as sticks and magnesium 
as a grey sphere. Monomers A and B are coloured in magenta and cyan. B) B. 
subtilis pocket shown in surface representation, with CoA shown as sticks and 
calcium as a green sphere. 
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It seems possible that the calcium observed in the B. subtilis structure, which is 
bigger than magnesium, affects the conformation of the alpha and beta phosphates 
and therefore the orientation of the subsequent phosphopantetheine chain in the B. 
subtil is AcpS structure. This is consistent with the observation that calcium allows 
catalysis in the B. subtilis enzyme, but at a much reduced rate. Whereas in the S. 
coelicolor structure the phosphopantetheine chain is buried in a hydrophobic 
pocket, and it is very well defined, in the B. subtilis structure it extends over the 
surface of the same monomer. The stretch defined earlier as ML2, which is mobile 
in the apo structure and forms the side of the pocket for the phosphopantetheine 
chain is in a different conformation in the B. subtilis holo structure, and the authors 
suggest it needs to move in order to accommodate the ACP. In the current holo 
structure, a similar conformational change occurs on CoA binding rather than ACP 
binding. 
Finally, in the B. subtilis complex between AcpS and ACP [86], three AcpS 
arginines were proposed to be important for ACP binding: Argl4, Arg2l and 
Arg24. These three arginines are conserved in the S. coelicolor AcpS. As it will be 
discussed in Chapter 6 more in detail, Arg15, Arg22 and Arg29 can make salt 
bridges with negative residues located on the ACP. 
4.9 Comparison between S. pneumoniae AcpS in complex with 3', 5'-ADP and 
S. coelicolor holo-AcpS 
The RMSD after Ca superimposition of the Streptococcus pneumonia [87] and S. 
coelicolor AcpSs is 1.72 A. Both active proteins are trimers, with the active site 
located at the interface between two monomers. Helix a4 is substituted by a loop in 
the S. pneumoniae structure, due to a deletion in the sequence. ML1 is substituted 
by a helix, followed by a loop. The adenine rings in both proteins are located in the 
same position. The other major differences are located in the area identified as 
mobile in the S. coelicolor AcpS. In particular, while the region including ML1 is in 
the same conformation for the B. subtilis AcpS, the equivalent region in the S. 
pneumoniae structure is in a different conformation. ML3, which stacks against the 
adenine base of CoA, and its equivalent region in the S. pneumoniae protein, can be 
quite easily superimposed. The region equivalent to S. coelicolor ML2, which form 
one side of the pocket, is in a complete different conformation. In particular, S. 
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coelicolor ML2 seems to be very open, while the equivalent region in the S. 
pneumoniae structure, which is not determined in the presence of it 
phosphopantetheine arm, is very closed, in a conformation similar to that one 
assumed by the equivalent loop in the B. . subtilis protein (Figure 4.19). This 
observation may be useful to explain the broader cofactor selection of S. coelicolor 
AcpS. This will be explored in more detail in chapter 5. 
44 
Figure 4.19 Comparison between ML2 of different proteins. S. coelicolor ML2 and 
CoA are shown in cyan and yellow respectively, B. subtilis ML2 equivalent region 
and CoA in grey, and S. pneumoniae ML2 equivalent loop and 3', 5'-ADP in 
orange. The ribbon representation of S. coelicolor holo-AcpS monomers A and B is 
shown in magenta and cyan, of B. subtilis AcpS in grey and of S. pneumonia AcpS 
in orange. 
With regard to the arginine residues that were proposed to be important for ACP 
binding [86], only S. coelicolor Arg22 and Arg29, are conserved in the S. 
pneumoniae AcpS, while Argl5 is not conserved. The interaction between S. 
coelicolor Arg15 and ACP Asp4l, discussed in Chapter 6, will be proposed to be 
important for the catalysis. A different conformation of S. pneumoniae Arg46 could 
take the place of Arg 15, 
Finally, as it will be discussed in depth in Chapter 6 and 7, S. coelicolor His 1 10 and 
Asp 111 are proposed to deprotonate (in)directly the active serine on ACP. In the S. 
pneumoniae AcpS, His 110 is conserved but is in a different conformation and a bit 
closer to the active site, but interacting with the 3' phosphate rather than the a- 
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phosphate of CoA. Analogue to B. subtilis AcpS, a threonine is found where the 
Asp III is located. 
4.10 Comparison between S. coelicolor and human holo-AcpS 
Human AcpS [66] belongs to type 11 phosphopantetheinyl transfcrase family, a 
group that is represented by the Sfp protein from B. subtilis [78]. While S. 
coelicolor AcpS is 123 residues, the human one is longer - 315 amino acids. In 
addition, all type II enzymes show a trimeric arrangement, while the human AcpS 
is characterized by a2 domain architecture, linked by a linker region. Each type 11 
domain is similar to a single type I subunit from the trimer, thus the single proteins 
can be superimposed. Human AcpS has a longer N- and C-terminal in comparison 
to the S. coelicolor protein. The Ca superimposition between the holo-AcpS and the 
human one shows that the active site and the cofactor binding regions are very 




Figure 4.20 Superimposition between the human and S. coelicolor AcpS active 
sites. The ribbon representation of S. coelicolor AcpS monomer A and B is shown 
in magenta and cyan, the ribbon representation of human AcpS in purple. S. 
coelicolor CoA is coloured in yellow, the human one in purple. Magnesium ion is 
shown as a grey sphere for the S. coelicolor model, as a purple one for the human 
AcpS. Side chains for S. coelicolor AcpS are shown as sticks and coloured in 
magenta and cyan, for the human AcpS in purple. 
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CoA and magnesium are located at the interface between the 2 domains, with the 
ribose in the same 3'-endo conformation. MLI is substituted by an a-helix, while 
ML3 is in a similar conformation. The adenine rings of CoAs are bound in a similar 
way, but the phosphopantetheine chains are bound in two different conformations. 
The two sulphur atoms are 6A apart. In addition, the cleft for the base seems to be 
wider in the human AcpS, and the human phosphopantetheine arm is located in a 
hydrophobic outer shell, provided by Ile l 40, Met 142, Tyr 184 and Trp l 87 [66], that 
is smaller than the S. coelicolor cavity. The region equivalent to ML2 is in a 
different conformation. S. coelicolor ML2 is more open, while the human one is in 
a intermediate conformation between the B. subtilis and the S. coelicolor loops 
(Figure 4.21). In the human model, the magnesium ion is coordinated to the two 
phosphates of CoA, a water molecule, an aspartate, equivalent to Asp9, and a 
glutamate residue, equivalent to G1u57. 
Figure 4.21 Comparison between different ML2 equivalent regions. S. coelicolor 
ML2 and CoA are shown in magenta and yellow respectively, B. subtilis ML2 
equivalent region and CoA in grey, and the human ML2 equivalent loop and CoA 
in purple. The ribbon representation of S. coelicolor AcpS monomer A and B is 
shown in magenta an cyan, of B. subtilis AcpS in grey and of human AcpS in 
purple. 
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With regard to the interaction with the ACP (discussed in Chapter 6), even though 
S. coelicolor helix al is substituted by a loop in the human AcpS, Arg22 and Arg29 
are conserved. Similarly to the S. pneumoniae structure, Arg15 is not conserved in 
the human AcpS, but human Arg65 can take its place. For the human AcpS it was 
proposed that a residue of the protein, Glul9l, can directly deprotonate the serine 
in the ACP [66]. In the S. coelicolor model, the equivalent to G1u191 is G1u57, 
which interacts to the phosphopantetheine chain. In addition, S. coelicolor His 110 
is conserved, while Asp 111 is replaced by a glutamine. This proposed mechanism 
is in great contrast to what proposed for type I phosphopantetheinyl transferase, 
where an activating water is believed to initiate the reaction deprotonating the ACP 
serine [86]. The presence of an activating residue for this type II enzyme shows 
strong parallels with the mechanism that will be proposed for the S. coelicolor 
AcpS (Chapter 6 and 7), and can be the starting point for finding an explanation to 
its promiscuity. 
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Chapter 5 
Investigating the cofactor promiscuity of AcpS 
In this chapter, the crystal structure of the S. coelicolor AcpS in complex with the 
acetyl-CoA is presented. A comparison with the holo-AcpS is shown, and 
hypotheses about the cofactor promiscuity in the active site are discussed. ITC was 
also used to determine the affinity constants for CoA and acetyl-CoA binding. 
5.1 AcpS in complex with acetyl-, propionyl- and malonyl-CoA 
S. coelicolor AcpS is considered to be a promiscuous enzyme, capable of working 
with modified versions of CoA [74]. Indeed, it is used by colleagues in the 
Department of Chemistry for routinely preparing a range of holo- and acyl- forms 
of ACP. As can be seen from Figure 5.1, CoA is surrounded by a very well defined 
hydrophobic cavity, which allows even more room for extended version of the 
cofactor. 
Phosphopantethei 
chain of CoA 
I 
Figure 5.1 AcpS hydrophobic cavity. Charged surface representation of the 
hydrophobic cavity that surrounds the phosphopantetheine chain. The neutral 
regions are coloured in green, while the positive and negative areas are shown in 
blue and red respectively. CoA is shown as sticks and coloured according to atom 
type. 
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Whilst it has been shown that this S. coelicolor AcpS can transfer an aceto-acetyl-, 
hexanoyl- and benzoyl-CoAs [74], from the crystal structure of the holo-AcpS, 
there seems not to be enough space for very long or aromatic activating groups. To 
experimentally explore the promiscuity in terms of substrate transfer, we tried to 
solve the structure of the AcpS in complex with modified CoA of a reasonable 
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Figure 5.2 Cofactor promiscuity of S. coelicolor AcpS. Structure of the acetyl (A), 
propionyl (B), malonyl (C), acetoacetyl (D), hexanoyl (E) and benzoyl (F) groups 
that are covalently attached to the phosphopantetheine arm of CoA and were 
proved to be transferred to the ACP. 
5.2 Determination of the structure of the AcpS in complex with acetyl-CoA 
5.2.1 Acetyl-CoA AcpS crystallization 
The conditions that gave the best diffracting holo-AcpS crystals (table 5.1) were 
screened to crystallize the protein in complex with acetyl-CoA (chapter 3.8.1). 
Salt Buffer PEG 
0.2 M lithium sulphate 0.1 M NaCacodylate pH 6.5 25% PEG 2K MME 
0.1 M potassium thiocyanate 0.1 M NaCacodylate pH 6.5 15% PEG 4K 
Table 5.1 Crystallization conditions for AcpS in complex with acetyl-CoA. 
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Optimization trays were prepared for both conditions. Salt concentrations of 0.1 M, 
0.2 M and 0.3 M were tested, and the PEG concentration was varied in 2% (for 
PEG 2K, between 19-27% w/v) or I% steps (for PEG 4K, between 12-18% w/v). 
Regular and triangular crystals, measuring about 0.7x0.6x0.3 mm, were obtained at 
18°C after a couple of days (Figure 5.3), using a protein concentration of 10 mg/mL 
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Figure 5.3 Acetyl-CoA AcpS crystals. A) Typical acetyl-CoA AcpS crystals 
obtained in 0.2 M lithium sulphate, 25% PEG 2K MME, 0.1 M sodium cacodylate 
pH 6.5. B) An example of a diffraction image. One of the CCDs of the detector was 
not working during data collection, and this region was excluded during integration. 
5.2.2 Data collection and processing 
Several crystals were tested at beamline 10.1 at the Synchrotron Radiation Source 
(SRS), Daresbury, and 102 and 103 at the Diamond Light Source (DLS). The best 
diffracting crystal was obtained in 0.2 M lithium sulphate, 25% PEG 2K MME, 0.1 
M sodium cacodylate pH 6.5, with the presence of acetyl-CoA at the concentration 
of 5 mM. The reservoir plus 15% v/v glycerol was used as cryoprotectant. Data 
were collected at the 102 station. This crystal diffracted to an approximately 
resolution of 1.5 A and belonged to the cubic P213 space group with a=b=c=72.8 A. 
The data processing was carried out using the HKL2000 [135] and CCP4 suites of 
programmes [ 143]. 
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5.2.3 Molecular replacement and refinement 
Similarly to the holo-AcpS, one molecule per asymmetric unit was found. The 
structure was solved by molecular replacement using Phaser [136,137] and the 
holo-AcpS as search model. In addition, in order to verify that the right cofactor 
was present, Phaser was run initially without the presence of acetyl-CoA, in order 
to have an unbiased map. The model contains 123 residues, I magnesium ion, I 
molecule of acetyl-CoA with 0.75 occupancy, I of CoA with 0.25 occupancy, I 
glycerol, 1 sulphate ion and 237 water molecules. Inspection of the electron density 
in the acetyl-CoA region, initially refined with a full occupancy cofactor, and the 
fact that the acetyl-CoA stock contained a contamination of the standard cofactor, 
suggested the additional presence of CoA (Figure 5.4). As it will be demonstrated 
by ITC, CoA has also a higher affinity than the acetyl-CoA. In this model, the 
difference map was used to set the correct occupancy for both cofactors, by trying 
to minimize the positive and negative density. Finally, the occupancy was set to 
0.25 for CoA and 0.75 for acetyl-CoA. 
A 
( 
Figure 5.4 Suggested presence of CoA in the acetyl-CoA AcpS active site. A) 
Unbiased difference map (DELFWT, DELPHWT) after refining the model without 
cofactor (acetyl-CoA from the final model is shown for comparison). The electron 
density maps (FWT, PHWT) and difference maps (DELFWT, DELPHWT) after 
refinement with acetyl-CoA (B) or CoA (C) are then shown. D) Maps related to the 
final model, with acetyl-CoA and CoA in the active site. The electron density map 
is contoured at 1.2ß, the difference map at 36. Cofactors are shown as bonds. 
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In addition, the electron density for the small loop containing AspI ll was not very 
clear: an apo-like and a holo-like form of this loop could be identified. The 
refinement led to a structure model with R-factor an Rfree values of 0.20 and 0.23 
respectively. Statistics for data processing and refinement are shown in Table 5.2. 
Acetyl-CoA AcpS 
Wavelength (A) 0.953 




N unique reflection 18659 
Completeness (%) 100 (100) 
Redundancy 9.4 (9.1) 
Val 32 (2.5) 
R. merge 0.057 (0.381) 
Mosaicity (°) 0.18 
Rye 0.23 
R-factor 0.20 
RMS bond (A) 0.012 
RMS angle (°) 1.533 
Table 5.2 Statistic data for AcpS in complex with acetyl-CoA. Data related to the 
highest resolution shell are reported between brackets. 
5.2.4 Geometry and B-factor analysis 
The geometry and the conformation were checked using MolProbity [145,1461. 
The Ramachandran plot is presented in Figure 5.5.97.8 % of the residues are in the 
most favoured region, while A1a65 and Asp 111 are in the allowed region. No 
residues were recognized as having unusual rotamers. An analysis of the average 13- 
factor of the main chains was also performed with Baverage [143]. The average 13- 
factor is 17 A2, while the average temperature factor for the mobile areas, except 
for ML2, is higher: 22 A2 (MHl), 30 A2 (ML1) 16 A2 (ML2) and 24 A2 (ML3). 
However, the average B-factor for ML2 is higher than the neighbouring regions. 
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The loop containing the Asp lll has also a higher average B-factor: 25 A2. The 
temperature factor analysis and the comparison with the wild type AcpS are shown 
in Figure 5.6. The average B-factor of the AcpS in complex with acetyl-CoA is 
lower than the wild type one, but its pattern is very similar, with the mobile loops 
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Figure 5.5 Ramachandran plot related to the acetyl-CoA AcpS. All residues are in 
the favoured regions with the exception of A1a65 and Aspl 11, that are located in 
the allowed region. A) general case; B) glycine; C) proline; D) pre-proline. 
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Figure 5.6 Acetyl-CoA AcpS B-factor analysis. Average B-factor values for the 
main chain of AcpS in complex with acetyl-CoA. The B-factor values reflect the 
mobility of the mobile loops, and the pattern is similar to that of the holo-AcpS. 
5.3 Analysis of the crystal structure of AcpS in complex with acetyl-CoA 
The model for the acetyl-CoA AcpS is very similar to the holo-AcpS. The RMSD 
after Ca superimposition between the AcpS in complex with CoA and the one with 
acetyl-CoA is 0.20 A. In addition to the presence of CoA, the electron density for 
the small loop containing the Aspl 11 is not clear: both an apo-like and a holo-like 
forms of this loop can be seen, but no explanation for this disorder was found. The 
density for the acetyl-CoA is very clear, especially for the extra acetyl group. All 
mobile loops have the same conformations in comparison to the protein in complex 
with CoA. The magnesium ion is 1.9 A away from the cation of the holo structure, 
and similarly to the loop containing the Asp l 11, no particular interaction or 
conformational changes were noticed to cause this displacement. The magnesium 
coordination sphere is different in comparison to the holo-AcpS, but no explanation 
for the displacement was found. Whilst in the holo structure it was coordinated to 
both phosphates of CoA (with a distance of 2A and 1.9 A respectively), to the 
carboxyl group of Asp9 (2.1 A) and 3 water molecules (within 2.2 A of distance), 
the magnesium in the acetyl-CoA structure is 3.3 A and 3.2 A far from the a- and 
ß-phosphates, 2.6 A from the main chain oxygen of Val 10,3.2 A from the carboxyl 
group of Asp111, and 3.4 A from Asp9. In addition, the ion is coordinated to 
waters Z230 (the equivalent to Z12,2.9 A far away) and Z232 (equivalent to Z183, 
1 10 19 28 37 46 55 64 73 82 91 100 109 118 
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3.1 A distant), but there does not seem to be any equivalent to water Z16 (Figure 
5.7). Water Z232 is quite far from its equivalent water Z183. Other two waters, 
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Figure 5.7 Comparison between the holo-AcpS and acetyl-CoA AcpS active sites. 
Amino acidic residues are shown as sticks, water molecules and magnesium ions as 
spheres. CoA, residues and waters belonging to the holo-AcpS are coloured in 
yellow, while acetyl-CoA, waters and residues belonging to the acetyl-CoA 
structure are shown in pink. The magnesium in the holo-AcpS is coloured in grey, 
the ion in the acetyl-CoA in pink. 
The a-phosphate is within hydrogen bonding distance with the carbonyl group of 
Asp9, the side chain of Lys6l, the hydroxyl group of the Serl09, a water molecule 
and the main chain oxygen of His110, while the ß-phosphate with Asp9 and 3 water 
molecules. The oxygen of P09 is held in place through hydrogen bonds provided 
by waters Z209 and Z107, and all the other interactions present in the CoA bound 
protein are conserved. Whilst the His 110 retains its interactions, Asp 1 11, which 
only interacts with magnesium via a water in the holo structure, makes a direct 
interaction with the magnesium ion in the acetyl-CoA AcpS. The two cofactors are 
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disposed in the same position until the PC5 atom, and then the other atoms are 
displaced up to 2.4 A. The acetyl-CoA seems to adopt a more contracted 
conformation between PC3 and PSI atoms rather than to cause evident 
conformational changes on ML2 (Figure 5.8). The sulphur atom of CoA and the 
carboxyl group of the acetyl-CoA are just 0.65 A apart. All the residues that form 
the hydrophobic cavity that contains the phosphopantetheine arm are disposed in 
the same way and with the same conformations. Superimposing both trimers using 
a Ca rigid superimposition of monomers A, ML2 in the acetyl-CoA protein results 
to be displaced of about 0.65 A in comparison to the ML2 of the protein in complex 
with CoA. It was supposed that ML2 can move to accommodate extended CoAs. 
The addition of just 3 atoms (a carbonyl and methyl group) does not seem to cause 
any dramatic conformational changes. 
Figure 5.8 Conformation of ML2 after CoA and acetyl-CoA binding. Cartoon 
representation of holo-AcpS, shown in magenta and cyan, and AcpS in complex 
with acetyl-CoA, pictured in pale colours. CoA (in yellow) and acetyl-CoA (pink) 
are shown as sticks. 
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5.4 Crystallization of AcpS in complex with malonyl- and propionyl-CoA 
Crystallization trials, using the same crystallization conditions for the acetyl-CoA 
AcpS (Table 5.1), were set after incubating AcpS with solutions of frozen or fresh 
propionyl- (5 or 10 mM final concentration) and malonyl-CoA (5 mM). Crystals 
appeared after 1-2 days at 18 °C (Figure 5.9). These crystals had very similar 
dimension and triangular shape of the other holo-AcpS proteins. Several datasets 
were collected for each complex at beamline 10.1 at the Synchrotron Radiation 
Source (SRS), Daresbury, and 102 and 103 at the Diamond Light source (DLS). 
All crystals belonged to the cubic P213 space group, with similar unit cell 
dimensions to the other holo-AcpS proteins. Table 5.3 shows the data collection 
statistics for several datasets. To check the presence of the appropriate cofactor, the 
structures were solved by molecular replacement using the holo-AcpS as search 
model with or without the presence of the cofactor CoA. Unfortunately, all the 
structures solved resulted in holo forms of the protein. Inspection of the difference 
map did not reveal any evidence of a longer density corresponding to propionyl- or 
malonyl-CoA. Consequently, the cofactors were analyzed by mass spectroscopy in 








Figure 5.9 Crystals of AcpS in the presence of malonyl- (A) and propionyl-CoA 
(B). A) Crystals obtained in 0.2 M lithium sulphate, 0.1 M NaCacodylate pH 6.5, 
25% PEG 2K MME. B) Crystals obtained in 0.1 M potassium thiocyanate, 0.1 M 
NaCacodylate pH 6.5,15% PEG 4K. 
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Cofactor propionyl-CoA 
(10 mM, frozen) 
malonyl-CoA 
(5 mM, frozen) 
malonyl-CoA 
(5 mM, fresh) 
Wavelength (A) 0.92 0.953 0.92 
Resolution (A) 50-1.8 (1.86-1.8) 50-1.7 (1.76-1.7) 50-2.3 (2.38-2.3) 






N unique reflection 12206 14515 5702 
Completeness (%) 100 (100) 100 (100) 100 (100) 
Redundancy 10.8 (10.6) 9.7 (9.4) 8.6 (9) 
Vol 23.1 (2.5) 20.6 (2.2) 31.3 (2.1) 
R merge 0.11 (0.78) 0.10 (0.74) 0.07 (0.7) 
Mosaicity (°) 0.65 0.85 0.79 
Table 5.3 Data collection statistics for AcpS incubated with propionyl- or malonyl- 
CoA. Data corresponding to the highest resolution shell are in brackets. 
5.5 Mass spectroscopy analysis of cofactors 
All cofactors incubated with the AcpS were analyzed by mass spectroscopy (kindly 
carried out by Chris Arthur, Department of Chemistry) to check their state in 
solution (chapter 3.7.5). CoA, acetyl-CoA and malonyl-CoA were bought from 
Sigma-Aldrich, while propionyl-CoA was a kind gift of the Department of 
Chemistry. Initially the crystallization trials and the mass spectroscopy analysis 
were carried out on samples that were stored at -20°C and were 1 month old. This 
analysis confirmed the presence of CoA, acetyl- and propionyl-CoA, but also 
showed that a degradation process was present. In particular, while in all the 
previous cofactors peaks corresponding to CoA contaminations were present, no 
peak related to malonyl-CoA was found. The malonyl-CoA stock seemed to be all 
degradated to CoA and acetyl-CoA. So, new crystallization trials and mass analysis 
were carried out with fresh new cofactors immediately after resuspension in water 
and prior the incubation with the protein. All spectra are quite salty and different 
deprotonation states for each cofactor are present (Figure 5.10). 
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Figure 5.10 Mass spectra of CoA (A), acetyl- (B), propionyl- (C) and malonyl- 
CoA (D). All spectra are quite salty. The presence of all cofactors is confirmed. All 
errors are within ± 0.9 kDa. 
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CoA is in the form of a sodium salt hydrate, with a purity of 96% and a calculated 
mass of 767.53 Da. From its mass spectrum, it is possible to notice that several 
peaks are present, from 758.15 to 762.15 Da, reflecting different deprotonation 
states of CoA. Acetyl-CoA is sold as a sodium salt, 95% pure, with a calculated 
mass of 809.57 Da. It is enzymatically prepared by reacting CoA with acetyl 
phosphate and phosphotransacetylase, and the product is then purified by ion 
exchange chromatography. The mass spectrum shows the presence of CoA as a 
contamination, with other peaks corresponding to acetyl-CoA, and 3 or 4 sodium 
ions are present. For malonyl-CoA, it is in the form of a lithium salt, with a purity 
of 90% and a calculated mass of 853.58 Da. The mass spectrum confirms the 
presence of this cofactor with a lithium ion bound, but also shows that the 
degradation process is still present even if the stock was fresh. Finally, the spectrum 
related to propionyl-CoA, characterized by a weight of 823.6 Da, shows its 
presence with a sodium ion bound. 
5.5.1 Instability of cofactors 
As proved by mass spectroscopy analysis, a considerable degree of degradation 
affects especially the propionyl- and malonyl-CoA in solution, and contaminations 
of CoA are present in the other stocks. Datasets collected from crystals obtained 
after incubation with frozen malonyl-CoA did not result in any structure with the 
modified cofactor bound. This result did not change when fresh cofactor was used. 
Several hypotheses can explain the fact that just CoA is bound to the protein. There 
can be a sort of self hydrolization of the cofactor catalyzed by the AcpS, but this 
seems unlikely since acetyl-CoA is observed in the crystal structure and it was 
proved that these modified CoAs can be transferred to the ACP [74]. These 
cofactors could not be as stable as indicated by the manufacturer. In particular, 
malonyl-CoA seems to be stable just for a few days. The crystals obtained after 
incubation with fresh malonyl-CoA were frozen within a week after their 
appearance. To avoid degradation, it would be very useful to freeze them as soon as 
they appear. In addition, CoA, that is present as a contamination, could have an 
affinity that is much tighter than malonyl- and propionyl-CoAs, similarly to what 
happens in the acetyl-CoA structure. Even though incubation with 10 mM of 
propionyl-CoA was not successful, it would be interesting to set new trays with 
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higher malonyl- or propionyl-CoA concentration. Moreover, purification of these 
compounds by HPLC could also be a good way to get rid of the contaminants. 
Finally, it would be useful to try to soak the longer cofactors into apo-AcpS 
crystals, and investigate whether the conformation of the apo-protein will change 
after cofactor binding. 
5.6 Determination of Kd for CoA and acetyl-CoA by ITC 
ITC was used to determine the binding constant for AcpS and CoA or acetyl-CoA 
(chapter 3.9). In the acetyl-CoA structure, CoA seems also to be present as 
contamination, and the occupancy for the two cofactors were set to 0.75 (acetyl- 
CoA) and 0.25 (CoA), suggesting a weaker binding for the acetyl-CoA, that is in 
higher excess in the stock used. ITC brilliantly confirmed what was predicted by 
the structures. Preliminary experiments indicated that an initial CoA concentration 
of 120 µM should be used to obtain an accurate Kd, avoiding saturation that occurs 
at a higher cofactor concentration. K and the stoichiometry for the two cofactors 
are reported in Table 5.4. 
CoA Acetyl-CoA 
Kd (nM) 380 ± 20 2400 ± 100 
n 1.2±0.1 0.94±0.07 
AH (caUmol) -4000 ± 400 -1600: t 200 
Table 5.4 Binding affinity for the holo-AcpS and the acetyl-CoA AcpS. Kd, 
stoichiometry and difference in enthalpy are shown for CoA and acetyl-CoA 
binding to the wild type AcpS. 
As expected, it was found that a molecule of CoA/acetyl-CoA binds to a monomer 
of AcpS (3: 3 ratio). The value for n is affected by about a 10% error that could be 
due to pipetting error or to experimental errors in the determination of the protein 
or cofactor concentration. K for CoA is about 6.4 times tighter than for the acetyl- 
CoA. The weaker binding for the longer cofactor is also evident from the shape of 
the ITC graphs. Whilst the curve related to CoA has almost a rectangular shape and 
reflects a high value of the ITC constant c, the one relating to the acetyl-CoA starts 
to resemble to a horizontal line with a lower c value (Figure 5.11). Finally, the 
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change in entropy for CoA binding is greater than for the acetyl-CoA. A blank 
without the presence of the protein was also run to determine the background heat 
of dilution of the cofactor. A straight line, indicating no binding as expected, can be 
seen in Figure 5.12. 
Time (min) 









































Figure 5.11 ITC data showing CoA and acetyl-CoA binding to wild type AcpS. 
The affinity for the acetyl-CoA (B) is lower than that for CoA (A). 
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Figure 5.12 Blanks for CoA (A) and acetyl-CoA binding (B). 
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5.7 Cofactor promiscuity of S. coelicolor AcpS 
Russell et al. [16] proved that the S. coelicolor AcpS can transfer several acyl- 
phosphopantetheine chains from acyl-CoA to the apo-ACP. In addition to the 
natural CoA, this protein can promote the phosphopantetheinylation of ACP by 
accepting acetyl-, malonyl-, methylmalonyl-, propionyl-, n-butyryl-, isobutyryl-, 
acetoacetyl-, hexanoyl- and benzoyl-CoAs [16]. Therefore, type I S. coelicolor 
AcpS is consider to be promiscuous in terms of substrate binding, a property that is 
quite unusual for type I AcpS and it is more characteristic of type II enzymes. As 
demonstrated, it can transfer chains that are much longer than CoA, and also with 
the presence of an aromatic benzoyl group. 
5.7.1 The hydrophobic cavity surrounding the phosphopantetheine chain 
The phosphopantetheine arm in the bolo-AcpS lies in a hydrophobic cavity on a 
subunit between the central helix a3 and the small helix a5. At the entrance of the 
cavity (chapter 4.6.2.1), several hydrogen bonds between protein residues or some 
water molecules, and polar atoms of the phosphopantetheine chain, are made. The 
terminal end of the arm is located into a hydrophobic cavity that is sealed by the 
apolar side chains of residues that form ML2. The cavity that surrounds the 
phosphopantetheine chain of CoA in the holo-AcpS is very well defined, and there 
seems to be more room for extra atoms. Water molecules are excluded from the 
cavity. Figure 5.13 shows the cavities surrounding the phosphopantetheine arms of 
CoA and acetyl-CoA. Both cavities are very similar, probably due to the fact that 
the binding of acetyl-CoA, just 3 atoms bigger than CoA, adopts a contracted 
conformation without causing dramatic conformational changes to the protein. On 
the contrary, the cavity of the fatty acid B. subtilis AcpS (Figure 4.18 B) allows 
even less room than the S. coelicolor one. 
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Figure 5.13 Charged surface representation of the hydrophobic cavity and ML2 
surrounding CoA (A) and acetyl-CoA (B). The neutral regions are coloured in 
green. The positive and negative areas are shown in blue and red respectively. CoA 
and acetyl-CoA are shown as sticks and are coloured in yellow and pink 
respectively. ML2 is shown as ribbon. 
5.7.2 Role of mobile loop ML2 
By comparison with the B. subtilis, S. pneumoniae and human AcpSs, the 
equivalent areas of ML2 are located in different positions (Figure 4.19 and 4.21). 
ML2 in the S. coelicolor AcpS is in a more open conformation, while in the S. 
pneumoniae AcpS, in complex just with 3', 5'-ADP, ML2 is in a much closed 
position. The equivalent ML2 region in the human AcpS assumes a sort of 
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the relatively high mobility of ML2 could be very important to accommodate the 
phosphopantetheine chain of different acyl-CoAs by enlarging the cavity, making 
this enzyme promiscuous in term of substrate variety. No dramatic conformational 
changes on ML2 were observed in the structure of AcpS in complex with acetyl- 
CoA (Figure 5.8), probably due to the fact that this cofactor is just slightly longer 
than CoA and it should assume a contracted conformation, occupying 
approximately the same area that is covered by CoA. 
5.7.3 Modelling modified CoAs into the cavity 
Using the S. coelicolor AcpS as model, it is possible to notice that it is difficult to 
fit the acetoacetyl- or malonyl-CoAs, or the aromatic benzoyl-CoA, in the cavity, 
but it must be taken into consideration that these models were created using the 
holo-AcpS with the standard CoA and a conformation of ML2 that is characteristic 
of it. In addition, from these pdb models it is not possible to determine if these 
cofactors can assume contracted conformations as it happens for the acetyl-CoA. 
Figure 5.14 shows the surface representation of the hydrophobic cavity with several 






Figure 5.14 Modelling extended CoAs inside the hydrophobic cavity. A) malonyl 
group; B) acetoacetyl group; C) haxanoyl group; D) benzoyl group. AcpS subunit B 
is coloured in cyan, negative regions in red. 
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The phosphopantetheine chains of these modified CoAs were superimposed to the 
tail of CoA in the holo-AcpS structure, and it was tried to find the best possible 
conformations that allow the least steric clash between the phosphopantetheine 
chains and the protein. The cavity is well defined and seems to allow space for 
cofactors longer than CoA or acetyl-CoA. However, in this model the pocket is too 
small for even the smaller substrate analogues, malonyl- or benzoyl-CoAs, 
suggesting that this loop should assume a more open conformation in vivo to allow 
the binding of longer CoAs. 
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Chapter 6 
Insight into AcpS mechanism and its interaction with ACP 
In this chapter, a model for the interaction between the S. coelico/or AcpS and the 
S. coelicolor ACP, and for the pantetheinylation reaction mechanism, are presented. 
The proposed models are not based on a crystal structure of the complex between 
AcpS and ACP, but on the analysis and the comparison of several pdb structures. 
So, in order to clarify the role of these two proteins and to obtain a clearer picture 
of the reaction mechanism, efforts were also made to try to purify and crystallize 
this complex in vitro. 
6.1 Interaction between AcpS and ACP 
6.1.1 Proposed ACP recognition and interaction 
After ACP binding, phosphopantetheine transfer occurs. For the type I fatty acid B. 
subtilis AcpS-ACP complex (PDB code=1 f80), it was proposed that the contacts 
between the two proteins are predominantly hydrophilic with a determinant 
interaction between aspartate and glutamate residues on ACP helix 0 and arginine 
residues on AcpS helix al (Figure 6.1) [86]. This interaction places the ACP at the 
bottom of the active site orienting the activating ACP serine correctly. On the 
contrary, for the type II proteins, although the positioning of ACP near the active 
site is the same, hydrophobic interactions seem to contribute more strongly to the 







Figure 6.1 B. subtilis AcpS-ACP interaction. AcpS arginine residues can interact 
with aspartate and glutamate residues on the ACP (Figure adapted from [86]). 
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AcpS arginines and ACP negatively charged residues are well conserved among 
different homologous proteins (Figures 6.2 and 6.3). S. coelicolor Arg l5 is 
conserved among all the other type I AcpSs, with the only exception of S. 
pneumoniae AcpS, while Arg22 and Arg29 are conserved in 9 and 10 proteins 
respectively. In the B. halodurans AcpS, both arginines are substituted by positive 
lysine residues, and in the T. denticola AcpS another lysine is very close to the 
position of the conserved Arg22. With regard to negative residues on ACP, Asp4I 
and G1u47 are completely conserved, while Glu53 is present in 11 different ACPs. 
Where G1u53 is not conserved, other glutamates or aspartates are in close 
proximity. Asp32 and Asp37 are also quite well conserved among different ACPs. 
S. coelicolor act ACP 
S. coelicolor FAS ACP 
B. subtilis ACP 
Streptomyces R1128 PKS ACP 
Streptomyces sp. C5 PKS ACP 
S. peucetius daunorubicin ACP 
S. argillaceus mtmS ACP 
S. roseofulvus ACP 
S. glaucescens Tcm ACP 
Streptomyces R1128 FAS ACP 
S. nogalater Snoa3 PKS ACP 
S. avermitilis MA-4680 ACP 
S. arenae ACP 
S. antibioticus PKS ACP 
Actinomadura hibisca PKS ACP 

















Figure 6.2 Multiple sequence alignment of polyketide and fatty acid ACPs. The 
conserved aspartate and glutamate residues are in bold and red. 
S. coelicolor AcpS 
B. subtilis AcpS 
S. pneumoniae AcpS 
K. radiotolerans AcpS 
L. xyli AcpS 
D. hafniense AcpS 
B. halodurans AcpS 
S. erythraea AcpS 
S. avermitilis AcpS 
T. denticola AcpS 
D. desulfuricans AcpS 













Figure 6.3 Multiple sequence alignment of polyketide and fatty acid AcpSs. The 
conserved arginines are in bold and blue. 
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The structure of the B. subtilis AcpS and ACP complex reveals a trimeric 
arrangement with a central core of AcpS molecules binding ACP on the outside 
with a stoichiometry of 1: 1 [86]. Since this is the only AcpS: ACP complex 
structure available for type I AcpSs, it was utilized as a model for analysing the 
interaction with ACP and the reaction mechanism. 
To investigate the S. coelicolor ACP binding to the AcpS, an AcpS: ACP complex 
model was made by superimposing the S. coelicolor holo-AcpS trimer to the B. 
subtilis AcpS, and a S. coelicolor apo-ACP NMR structure, kindly donated by Dr 
Matt Crump, on B. subtilis ACP, as described in chapter 3.8.7. In this model, AcpS 
helix al is very close to ACP helix a2. CoA is located at the interface between one 
monomer of AcpS and a molecule of ACP, and no clashes between the cofactor and 
ACP were observed. The active ACP serine is quite distant from the active site and 
from the ß-phosphate of CoA (Figure 6.7). 
The mechanism of interaction seems to be the same and the positive-negative 
recognition motif seems to be preserved. Several negatively charged residues 
protrude from the ACP. In particular, AcpS Arg15 can interact with Asp4l, AcpS 
Arg22 is close to G1u47, and AcpS Arg29 can interact with G1u53. These 
interactions are shown in Figure 6.4. 
6.1.2 Identification of a common structural motif for ACP binding 
A set of arginine residues were also observed and proposed as a potential ACP 
binding site in the S. coelicolor ketoreductase [103], one of the enzymes S. 
coelicolor ACP interacts with during the synthesis of polyketides. The known 
complex of B. subtilis AcpS-ACP and S. coelicolor models were superimposed on 
the S. coelicolor ketoreductase, by overlapping the ACP modelled into that putative 
binding site. Three arginines from the proposed ACP binding site in ketoreductase 
are disposed in the same spatial orientation as that of the arginines from the 
proposed ACP binding site in AcpS and they can interact with ACP. Small 
adjustments allowed Arg38, Arg65 and Arg93 from the ketoreductase to 
superimpose very well with Arg15, Arg22 and Arg29 of AcpS (Figure 6.5). 
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G1u53 
Figure 6.4 Model of S. coelicolor ACP interacting with AcpS. Cartoon 
representation of AcpS helix al and ACP helix a2. AcpS is coloured in cyan, ACP 
in yellow. The side chains of the residues involved in the interaction are shown as 
sticks. 
Ahloll 
Figure 6.5 Proposed ACP binding site for KR. Cartoon representation of the 
proposed ACP binding site in ketoreductase (coloured in green). The side chains of 
the arginines from the AcpS are shown in cyan. These three AcpS arginines overlap 
very well with three KR arginines. 
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6.1.3 Analysis of mutational ACP data 
The pdb model for the S. coelicolor ACP and AcpS interaction and binding was 
very useful to analyze mutational data on the ACP that were carried out by Dr Chris 
Arthur in the Department of Chemistry. Several C17S ACP double mutants were 
expressed and purified: C17S D41A, C17S D41E, C17S E47A and C17S E53A. 
The mutated residues, conserved among other fatty acid or polyketide ACPs, were 
supposed to be involved in the interaction with the AcpS, as proposed for the B. 
subtilis complex (Figure 6.4). Table 6.1 summarizes the results of the tryptophan 
fluorescence experiments and ESMS analysis of percentage of conversion to holo- 
ACP of these mutants. The affinity for apo-AcpS is within the same order of 
magnitude for each different ACP mutant, suggesting that, even though the selected 
ACP residues are important for the interaction with the AcpS and are necessary to 
tune the precise location of ACP in the AcpS active site to allow catalysis, other 
hydrophobic interactions are also involved and participate to lock the ACP in the 
right position. For example, from the model it is possible to notice that ACP Leu43 
can extend into a pocket formed by AcpS Leu20, Leu26, Leu30, Phel6, Phe53 and 
Trp71. 
ACP I{d M % of conversion 
Apo-ACP 1.11 ± 0.05 100% 
Holo-ACP 2.07 ± 0.07 / 
D41A 7.02±0.21 0% 
D41E 1.42±0.06 15% 
E47A 1.81 ± 0.22 100% 
E53A 2.07 ± 0.11 75 % 
Table 6.1 Affinity for apo-AcpS and percentage of conversion to holo-ACP of 
C 17S ACP mutants. 
6.1.3.1 ACP E47A and E53A mutants 
Mutants E47A and E53A both have similar affinity for complex formation as the 
product of the reaction, holo-ACP, which is about 2-fold reduced compared to the 
substrate, apo-ACP. Therefore, there is not much difference in affinity between the 
apo and the holo-protein. These mutations do not destroy the interaction between 
AcpS and ACP, suggesting that other interactions are involved. However, the 
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change in activity related to E53A ACP could be indicative of a role of G1u53 in 
the precise positioning of the loop where the ACP serine is located. While the 
mutation of G1u47 to an alanine does not affect the percentage of conversion to 
holo-ACP, the mutation of G1u53 to an alanine reduces its efficiency by 25%. 
G1u53, located at the top of the helix, is probably more important than G1u47 to 
lock the position of the ACP with respect to the AcpS and placing the loop 
containing the active serine close enough to the AcpS active site. 
6.1.3.2 ACP D41A and D41E mutants 
The mutagenesis of the conserved Asp41 into an alanine results in the only 
significant change to binding affinity, which is reduced seven fold compared to apo 
enzyme. In addition, this enzyme is completely inactive in phosphopantetheine 
transfer. The more conservative substitution of aspartate with glutamate, residue 
that has similar chemical properties but is just slightly longer, reduces the affinity 
for complex formation just slightly. The percentage of conversion to holo-ACP is 
reduced by approximately seven fold for this mutant. This suggests that ACP 
Asp41 can have a specific role in promoting catalysis, and not only a role in 
binding to the AcpS. The pKa of both aspartate and glutamate are extremely similar. 
By inserting the extra carbon atom, the position of ACP and therefore of the serine 
attachment site could be probably altered. So, even if Asp41 is not involved in any 
chemical reaction, it seems to be important for locating the region containing the 
activating ACP serine in the right position. Its substitution with a glutamate could 
change the orientation of ACP Ser42 within the active site. 
6.2 Proposed reaction mechanism 
6.2.1 Initiation of ACP binding 
In the holo-AcpS, helix al and MH1 are displaced in comparison with the apo- 
protein. The movement of these portions can be a possible signal to ACP that CoA 
is bound and AcpS is ready to react (Figure 6.6). 
129 
Chapter 6 Insight into AcpS mechanism and its interaction with AC'P 
Conformational change on Helix al helix a1 and MH1 






Figure 6.6 Initiation of ACP binding. The ribbon representations of holo-AcpS 
monomers A and B, that are coloured in magenta and cyan, and of apo-ACP, 
coloured in yellow, are shown. CoA is shown as sticks and is coloured in yellow, 
magnesium as a grey sphere. The conformational change of AcpS helix al and 
MHI that occurs after CoA binding is shown by the arrow. The equivalent helix al 
and MH I regions in the apo-AcpS are coloured in pale cyan. AcpS Arginines and 
negatively charged residues on ACP that are proposed to be important for AcpS- 
ACP interaction are shown as sticks. 
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6.2.2 S. coelicolor AcpS: ACP interaction and serine positioning 
The previous model for the S. coelicolor ACP-AcpS interaction (chapter 3.8.7) was 
used to investigate the reaction mechanism. In the B. subtilis complex between 
AcpS and ACP, the interaction between aspartate and glutamate residues on helix 
a3 of ACP and arginine residues on helix al of AcpS is considered important for 
the formation of the protein complex [86]. As discussed in chapter 6.1.1, this 
positive-negative recognition motif is preserved for the S. coelicolor AcpS-ACP 
complex. Arg15 can interact with Asp4l, Arg22 is close to Glu47, and Arg29 can 
interact with Glu53. This model is supported by analysis of the binding of ACP 
mutants to AcpS. Removing the individual interactions seems not to be sufficient to 
abrogate binding between the ACP and the AcpS. 
The mutational studies suggest that ACP Asp4l could have an important role 
during the interaction with AcpS, losing 100% of activity on mutation to an alanine 
and showing 7-fold reduction in activity on mutation to a glutamate. Inspection of 
both the B. subtilis structures and the S. coelicolor AcpS-ACP model suggests that 
some conformational change needs to take place in the ACP to allow the modified 
residue, Ser42 in S. coelicolor ACP, to access the CoA (Figure 6.7). So, after these 
mutational data and investigations of crystal structures, for the S. coelicolor 
complex it is suggested that the interaction between Asp4l in ACP and Arg15 in 
AcpS could be important for locking ACP and more importantly the Ser42 into the 
right position. Asp4l is in fact located in a region on helix a2 of ACP that can 
undergo a conformational change, permitting the formation of the salt bond 
between Arg15 and Asp4l and bringing the Ser42 near the active site (Figure 6.8). 
Substitution of the aspartate with a glutamate, residue with similar pKa but with a 
different length, could affect the precise positioning of Ser42 and so account for a7 
fold reduction in activity. 
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Figure 6.7 AcpS: ACP active site. The figure shows the beginning of the reaction: 
the interaction between AcpS Arg15 and ACP Asp4l could be important to lock 
ACP and the loop containing the serine into the active site and in the right position. 
The charged surface and the ribbon representation of AcpS monomers A and B are 
shown. The neutral regions are coloured in magenta (momomer A) and cyan 
(monomer B), while the positive and negative areas are shown in blue and red 
respectively. The ribbon representation of apo-ACP is coloured in yellow. The side 
chains of residues proposed to be involved in catalysis are shown as sticks. Water 
molecules are coloured in red, magnesium in grey. 
For the B. subtilis AcpS, a water molecule was proposed to deprotonate the ACP 
serine [86], while for the Sfp protein it was suggested that the hydroxyl group of 
the active serine could take the place of a water molecule and be deprotonated by a 
base [78]. With small adjustments to the loop on which Asp4l and Ser42 are 
located, it is possible to place the S. coelicolor Ser42 in a position where it could 
attack the ß-phosphate from either side (Figure 6.8), for example replacing water 
Z183, which coordinates with Mgt+, and is also within hydrogen bonding distance 
from Asp 111, or water Z 172 which is potentially within hydrogen bonding distance 
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from His 110 (conserved in AcpS). Figure 6.9 shows the loop containing the serine 
as observed in the docked apo NMR structure, and after modeling a possible 
conformational change which places the serine in a position where it can attack the 
n-phosphate. 
iII i 
Figure 6.8 Positioning of Ser42 in the AcpS active site. The charged surface and 
the ribbon representation of AcpS monomers A and B are shown. The neutral 
regions are coloured in magenta (momomer A) and cyan (monomer B), while the 
positive and negative areas are shown in blue and red respectively. The ribbon 
representation of ACP is coloured in sand. The side chains of residues proposed to 
be involved in catalysis are shown as sticks. Water molecules are coloured in red, 
magnesium in grey 
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Figure 6.9 Displacement of the loop containing the serine. The charged surface and 
the ribbon representation of AcpS monomers A and B are shown. The neutral 
regions are coloured in magenta (momomer A) and cyan (monomer B), while the 
positive and negative areas are shown in blue and red respectively. The ribbon 
representation of apo-ACP is coloured in yellow, while ACP modelled in a position 
to attack the ß-phosphate in the active site in sand. The side chains of residues 
proposed to be involved during catalysis are shown as sticks. Water molecules are 
coloured in red, magnesium in grey. 
6.2.3 FAS B. subtilis AcpS proposed mechanism 
For the B. subtilis type I fatty acid reaction [86], it was proposed that, after CoA 
and ACP binding, the phosphopantetheinylation of the ACP occurs. The c-amino 
group of Asp8 is deprotonated, while Lys62 is protonated. The hydrogen on Asp8 
can be transferred to Lys62, as they are spatially adjacent. A water molecule in the 
AcpS active site can be activated by the removal of a proton, reaction that can be 
carried out by another water molecule or by ACP Asp35, which is spatially 
adjacent. This "activating water" can then deprotonate the hydroxyl group of the 
ACP serine, that can be placed near this water molecule. ACP Sei-36 will carry out 
the nucleophilic attack on the ß-phosphate of CoA (Figure 6.10). 
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Figure 6.10 Reaction mechanism proposed for the B. subtilis fatty acid complex 
(Figure adapted from [86]). B: base; AMP: adenine monophosphate. Pant: 
phosphopantetheine chain. 
Finally, after the transfer of the phosphopantetheine chain to Sei-42, the 3', 5'-ADP 
product can be stabilize by magnesium, Lys62 and the main chain amide of His 105, 
and then after proton transfer from the solvent or Lys62 it can be released in 
solution. However, as described in chapter 4.8, this model is based on a crystal 
structure where a calcium and not magnesium is present in the active site, and CoA 
is in a different conformation in comparison to the S. coelicolor structure. The 
calcium can affect the conformation of the alpha and beta phosphates, the 
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coordination of residue involved in the active site in catalysis, and the orientation of 
the subsequent phosphopantetheine chain in the B. subtilis AcpS structure. 
6.2.4 The role of Asp111 and His110 in serine deprotonation 
The mechanism for the nucleophilic attack of the serine to the ß-phosphate of CoA 
and for the release of the 3', 5'-ADP, proposed for the B. subtilis AcpS (Figure 6.10 
B-D), are supported by observations in the S. coelicolor AcpS structure. As 
discussed in chapter 4.7, B. subtilis AcpS Asp8, His 105 and Lys62, and ACP 
Asp35, are conserved among other type I AcpSs and ACPs, and the equivalent S. 
coelicolor residues, Asp9, His 110, Lys6l, are located in appropriate positions in the 
active site to perform the roles proposed. 
An alternative mechanism can be proposed for the deprotonation of the active 
serine (Figure 6.10 A). In the B. subtilis AcpS, it was proposed that a water 
molecule can deprotonate the serine in the ACP [86]. In the S. coelicolor holo- 
AcpS structure, water W 183, the equivalent of B. subtilis "activating water", is 3.3 
A distant from the ß-phosphate and 3.2 A from the carboxylic group of Asp 111, 
while water W172 is 4.5 A distant from the phosphate and 3.8 A from the 
imidazole ring of His110. An alternative conformation of Asplll is also 1.6 A 
distant from water Z183. Other atomic distances are shown in Figure 6.11. As 
proposed for the Sfp protein [78], these water molecules can be replaced by the 
hydroxyl group of the ACP serine. After a small conformational change, the 
aspartate or the histidine residues can deprotonate the hydroxyl group of Ser42 
(Figure 6.11). 
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Figure 6.11 Possible catalytic role for AcpS Asplll and His110. The charged 
surface and the ribbon representation of AcpS monomers A and B are shown. The 
neutral regions are coloured in magenta (momomer A) and cyan (monomer B), 
while the positive and negative areas are shown in blue and red respectively. The 
ribbon representation of apo-ACP is coloured in yellow, while ACP modelled in a 
position to attack the (3-phosphate in the active site in sand. The side chains of 
residues proposed to be involved during catalysis are shown as sticks. Water 
molecules are coloured in red, magnesium in grey. 
6.2.4.1 Asp I11 
At the pH where the phosphopantetheinylation occurs, the carboxyl group of the 
aspartate side chain is deprotonated, and its highly electronegative oxygens can 
remove a proton from the hydroxyl group of the serine. Asp 111 could act in a 
similar way to the B. subtilis ACP Asp35 [86], but allowing less specific binding to 
promote a broader specificity for ACP recognition. Aspl 11 is not so well conserved 
among the other AcpS and it is replaced by a threonine in the B. subtilis AcpS. 
Normally, it is expected that catalytic residues are conserved among all the 
members of the same family. However, S. coelicolor AcpS is more promiscuous in 





Chapter 6 Insight into AcpS mechanism and its interaction with ACP 
site is made up from two proteins, which requires very precise positioning. For the 
S. coelicolor AcpS, a preformed active site might be partially responsible for the 
promiscuity. Asp 11 1 could be in situ as base to assist the reaction (Figure 6.12 A 
and C), without the need of an additional base contributed by the ACP which would 
requires precise positioning not only of the serine to be modified, but also of the 
accompanying base. 
6.2.4.2 His110 
Another amino acid in the active site that provoked interest was His 110, which is 
highly conserved among type I AcpS. Histidine is involved as an acid or base 
catalyst in many enzyme mechanisms. It can remove a proton from serine, 
threonine or cysteine residues activating them as nucleophiles. Therefore, this 
residue could be a possible candidate to deprotonate the hydroxyl group of the ACP 
serine (Figure 6.12 B). His l 10 could also deprotonate an activating water, as 
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Figure 6.12 ACP serine deprotonation. AcpS Asp 111 or His 110 may deprotonate 
directly (A and B) or indirectly (via an activating mediator water, C and D) the 
active serine on ACP. 
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6.2.5 Conclusions 
A model for the interaction with the ACP and for the reaction mechanism was 
proposed, based on the AcpS structures presented in this thesis and on a model of 
the S. coelicolor AcpS: ACP complex. 
6.2.5.1 Interaction with ACP 
Three conserved arginines on helix al of the AcpS can interact with aspartate and 
glutamate residues on helix a2 of ACP. Mutations of the ACP negatively charged 
residues gave further evidence for their role in AcpS binding. However, the affinity 
for apo-AcpS is within the same order of magnitude for each different ACP 
mutants. Even though the selected ACP residues are important for the interaction 
with the AcpS and are necessary for the precise positioning of ACP in the AcpS 
active site to allow catalysis, other hydrophobic interactions are probably involved 
and participate to lock the ACP in the right position. Mutation of the ACP Asp41 
resulted to destroy the activity of the enzyme, suggesting that this residue may have 
a specific role in promoting catalysis, and not only a role in binding to the AcpS. 
6.2.5.2 Proposed reaction mechanism 
After inspection of the active site and after analysis of the ACP mutational data, it 
is proposed that ACP Asp4l could play an important role in locking the loop 
containing the Ser42 near the active site in an active conformation. Whether for the 
B. subtilis protein an activating water was proposed to deprotonate the hydroxyl 
group of the serine [86], in the S. coelicolor model the serine can be placed at 
hydrogen bonding distance to AcpS Asp 111 and His 110, which are located on 
either sides of CoA. Both residues could deprotonate the serine directly or an 
activating water as proposed. If an activating water is involved, the coordinated 
magnesium will have a catalytic role, in addition to its role in binding CoA. The 
proposed reaction mechanism is summarized in Figure 6.13. 
To investigate further their role, in order to understand if these residues are 
involved in CoA binding or they have a possible catalytic role, the AcpS mutant 
H 110A and D 111 A were cloned, crystallized and biochemically characterized 
(Chapter 7). 
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Figure 6.13 Proposed reaction mechanism. The interaction between ACP Asp41 
and AcpS Arg15 could lock the loop containing the active serine in the right 
conformation allowing catalysis to occur. AcpS His 110 or Asplll could 
deprotonate (in)directly the serine, and after nucleophilic attack on the 0-phosphate 
of CoA the phosphopantetheine chain is transferred to the ACP. 
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6.3 Purification trials of the AcpS-ACP complex 
The model proposed for the interaction between ACP and AcpS and for the reaction 
mechanism was based only on the analysis of PDB structures. In order to 
understand better the reaction mechanism and to confirm the hypothesis made 
based on a model, the natural following step was to try to purify and crystallize this 
complex in vitro. So, ACP was firstly expressed and purified, and then purification 
and crystallization trials of the AcpS-ACP complex were carried out. 
6.3.1 ACP expression 
The S. coelicolor actinorhodin C 17S ACP DNA cloned in the pET 11 c vector was 
kindly donated by Dr Matt Crump and Dr John Crosby (Department of Chemistry). 
As can be seen from the sequence of the protein shown in Figure 6.14, the protein 
is not tagged. Protparam [134] calculated a molecular weight of about 9200 Da, a 
pI of 3.98 and a extinction coefficient of 0.323. No tryptophanes are present, and 
the UV absorbance is determined by the presence of 2 phenylalanines and 2 
tyrosines. 
Prior to expression, the pET-i lc-ACP DNA was transformed in fresh E. coli 
BL21(DE3) (chapter 3.4.5). The success of the transformation was checked by 
extracting plasmid from transformants (chapter 3.4.2), subjecting the DNA to 
endonuclease restriction digest (chapter 3.4.3) and checking the size of the fractions 
on an agarose gel. ACP was then expressed by induction with 1 mM IPTG at 37°C, 
and the expression continued for 4-5 hours at 32°C. 
MATLLTTDDLRRALVESAGETDGTDLSGDFLDLRFEDIGYDSLALMETAARLESRY 
GVSIPDDVAGRVDTPRELLDLINGALAEAA 
Figure 6.14 Amino acid sequence of the actinorhodin C17S ACP. 
6.3.2 ACP purification 
The protein was not tagged, and after sonication, the supernatant was loaded into 
the anion exchange column (chapter 3.6.4). The chromatogram (Figure 6.15 A) 
presents a lot of peaks, and the small but quite defined one at about 360 mM NaCI 
corresponds to ACP. As shown on the gel (Figure 6.15 B), the level of ACP purity 
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in these fractions was not very high, so a further gel filtration step (chapter 3.6.5) 
was used to get rid of the contaminants. This step was very effective due to the 
small size of ACP in comparison with the other proteins present in solution. ACP 
was eluted as a well-defined single peak during gel filtration (Figure 6.16 A), and 
the SDS-PAGE gel loaded with the correspondent fractions (Figure 6.16 B) shows 
that it is very pure. Finally, the resulting apo-ACP was desalted (chapter 3.6.8) and 
stored at -80°C until required. From previous experiments carried out in the 
Department of Chemistry, it was known that ACP can run on a SDS-PAGE gel 
with a lower apparent weight. The band corresponding to the ACP is indeed located 
below the 6.5 kDa band of the molecular markers. 
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Figure 6.15 ACP ion exchange purification. Chromatogram (A) and gel (B) after 
the ion exchange column. A) The arrow indicates when ACP is eluted. UV 
absorbance is shown in blue, the gradient of buffer B in red. B) SDS-PAGE gel 
corresponding to the ACP peak. M: Molecular weights; F: fractions of apo-ACP 
from the related peak. 
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In addition, more than one band can be observed, probably due to protein 
oligomerization (Figure 6.16 B). The addition of DTT resulted in a decrease in the 
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Figure 6.16 ACP gel filtration purification. Chromatogram (A) and SDS-PAGE 
gel (B) after ACP gel filtration. ACP is the last peak (A), and is very pure after this 
chromatography step (B). MW: molecular weights; F: fractions containing the pure 
apo-ACP eluted between 74 and 85 mL. 
6.3.3 Activation of holo-ACP 
The phosphopantetheinylation of apo-ACP can be achieved by incubating AcpS 
and ACP together in the presence of CoA and magnesium [61,73] (chapter 3.6.9). 
This simple experiment is very useful to produce holo-ACP, which can be 
separated from the AcpS by gel filtration. Firstly a sample of purified ACP was 
tested by mass spectroscopy, to confirm that it was apo-ACP (Figure 6.17 A). As 
can be seen from the spectrum, the sample was quite homogeneous, with an 
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experimental molecular weight of 9094.8 Da (expected molecular weight for apo- 
ACP is 9101 Da). This apo-ACP had lost its methionine, as confirmed by N- 
terminal sequencing. After incubation with AcpS and gel filtration, holo-ACP can 
be harvested. As can be seen from the chromatogram and related gel (Figure 6.18), 
3 peaks can be identified: the first one for the AcpS trimer of a molecular weight of 
approximately 45 kDa, the second for holo-ACP (molecular weight of about 9400 
kDa), and the last one probably corresponding to 3', 5'-ADP, the product of the 
pantetheine transfer from CoA. For the last peak, no bands were observed in the 
SDS-PAGE gel, and ADP can indeed absorb UV at 280 nm. To check if the 
activation had happened successfully, a sample of holo-ACP was checked again by 
mass spectroscopy (Figure 6.17 B), which confirmed the transfer. A peak with 
experimental molecular weight of 9461.2 Da (holo-ACP calculated molecular 


















Figure 6.17 Mass spectra obtained for the apo-ACP (A) and holo-ACP (B). All 
errors are within ±9 kDa. 
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Figure 6.18 Activation of holo-ACP. Chromatogram (A) and SDS-PAGE gel (B) 
for the activation of holo-ACP. As can been seen from the gel, the first peak is 
AcpS, while the second one is holo-ACP. MW: molecular weights; Al-A2: 
fractions from the first A peak; B1-B7: fractions from the second B peak. Peak C 
corresponds to ADP. 
6.3.4 Purification trials of the AcpS-ACP complex 
To try to purify the S. coe/icolor AcpS: ACP complex, AcpS and apo-ACP at a 1: 1 
ratio, with the presence of CoA, were incubated together, in a similar way as for the 
activation of the holo-ACP (chapter 3.6.9). The same buffer conditions under which 
Kd was measured (50 mM Tris pH 8.8,10 mM MgCl2,5 mM DTT), were used to 
equilibrate the gel filtration column. Unfortunately, no activation complex can be 
observed after gel filtration. The resulted chromatogram and gels shows exactly the 
same peaks and bands that are obtained when apo-ACP is activated to holo-ACP 
(Figure 6.18). A peak is observed for both AcpS and ACP, but none for a putative 
complex (expected molecular weight of 72K, it should be a trimer of dimers). The 
same experiment was carried out incubating AcpS and the holo-ACP, since the 
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bolo-ACP Kd is 2 µM, compared to apo-ACP Kd of 1.1 µM. Again, no complex was 
observed under conditions of gel filtration. 
6.3.5 Crystallization trials 
In parallel with the purification trials, AcpS and holo-ACP, at a ratio of 1: 1, for a 
final concentration of 10 mg/mL, were also incubated together in a crystal drop, in 
order to co-crystallize the complex. Crystal trials at 18°C were carried out using the 
Clear Strategy Screen I and II, pH 6.5 (MDL), and the PEG/Ion Screen (Hampton). 
The presence of sodium cacodylate buffer with pH 6.5 was essential for the AcpS 
crystal growth, so it was chosen also for the co-crystallization trials hoping that it 
would help ACP to crystallize with the AcpS. The PEG/Ion Screen was chosen 
because the B. subtilis complex was crystallized using the same screen [86] and 
because again several conditions resulted in AcpS crystals. The best crystals, about 
0.8x0.1 x0.1 mm (Figure 6.19), were obtained in potassium bromide and sodium 
acetate (Table 6.2). 
Salt Buffer PEG 
0.2 M potassium bromide 0.1 M Sodium Cacodylate pH 6.5 25% PEG 2K MME 
0.2 M potassium bromide 0.1 M Sodium Cacodylate pH 6.5 15% PEG 4K 
0.2 M potassium bromide 0.1 M Sodium Cacodylate pH 6.5 10% PEG 8K + 1K 
0.2 M potassium bromide 0.1 M Sodium Cacodylate pH 6.5 8% PEG 20K + 550 MME 
0.3 M sodium acetate 0.1 M Sodium Cacodylate pH 6.5 15% PEG 4K 
0.3 M sodium acetate 0.1 M Sodium Cacodylate pH 6.5 10% PEG 8K + 1K 
0.3 M sodium acetate 0.1 M Sodium Cacodylate pH 6.5 8% PEG 20K + 550 MME 
Table 6.2 Co-crystallization conditions for AcpS and holo-ACP. 
Several crystals from both conditions were tested at the beamline 10.1 in 
Daresbury. Unfortunately, they turned out to be apo-AcpS crystals. As can be seen 
from Figure 6.19, these crystals are very similar to the apo-AcpS one. In order to 
check if both proteins were present, the worst diffracting crystals, with a difficult 
space group determination and data processing, were also resuspended in the 
crystallization buffer and the sample was run on an SDS-PAGE gel. As expected, 
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the gel showed the presence of only AcpS, suggesting that these crystals did not 
contain the ACP. 
A) B) 
Figure 6.19 Crystals obtained after co-crystallization of AcpS and holo-ACP. A) 
Crystals obtained using 0.3 M sodium acetate, 0.1 M sodium cacodylate pH 6.5 and 
15% PEG 4K as precipitant. B) Crystals obtained using 0.2 M potassium bromide, 
0.1 M sodium cacodylate pH 6.5 and 15% PEG 4K as precipitant. 
6.3.6 Thrombin cleavage of AcpS 
The polyhistidine tag may affect the binding of ACP to AcpS, possibly even 
interacting with the negative helix a2 of ACP (the tag can have a positive charge in 
solution, depending on pH). It was observed that the polyhistidine tags come 
together at the top of the trimer axis in AcpS, and are close to helix al, the 
proposed ACP binding site. It was also observed that in the case of B. subtiles, it 
was not possible to form a complex with native tagged or untagged AcpS. So, due 
to the expected similarity between the S. coelicolor and B. subtilis complexes, it 
was tried to remove the polyhistidine tag. The pET-15b-AcpS DNA contains a 
thrombin cleavage site, so attempts to cut the polyhistidine tag were carried out at 
two different temperature, 18°C and 37°C (chapter 3.6.6). As can be seen from the 
SDS-PAGE gel (Figure 6.20), a complete cut was obtained after 2 days for the 37°C 
experiment and after 4 days for the 18°C one. Unfortunately, the untagged protein 
precipitates. Only 0.3 mg from the initial 5 mg of protein could be recovered in the 
soluble fraction. The untagged AcpS was then purified from the his-AcpS (chapter 
3.6.6) and it was incubated with apo- or holo-ACP, but again after gel filtration no 
complex was purified, and the corresponding chromatograms were similar to the 
one shown in Figure 6.18. This corresponds to what Parris observed [86]. It is 
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therefore possible that removing the histidine tag is not sufficient to isolate the 
AcpS: ACP complex. 
37°C 
MW 0 15h 24h 2d 3d 4d 0 6h 15h 24h 2d 3d 4d 
Figure 6.20 Thrombin cleavage of AcpS histidine tag. The SDS-PAGE gel was 
loaded with fractions collected after different amounts of time. Complete cleavage 
of the tag is obtained after 4 days at 18°C and 2 days at 37°C. 
6.3.7 Conclusions 
Several attempts to purify and crystallize in vitro the complex between AcpS and 
apo- or holo-ACP were carried out. Unfortunately, these experiments were not 
successful. The co-crystallization of the apo-AcpS and holo-ACP resulted in apo- 
AcpS like crystals, which contained only the AcpS. It was observed that AcpS helix 
al, that interacts with ACP, moves in presence of CoA. This suggests that, in order 
to form a complex, holo-AcpS should be used. In addition, to facilitate the 
crystallization of a stable ternary complex of AcpS, CoA and ACP, the active serine 
in the ACP can be mutated to an alanine, or alternatively, a non-hydrolyzable CoA 
analogue can be used. 
To avoid any aspecific interaction between the histidine tag of AcpS and helix a2 
of ACP, attempts to cut the tag with thrombin cleavage were also carried out. 
Unfortunately, the untagged AcpS precipitates in solution, and a very small amount 
of soluble protein could be recovered. In order to increase the solubility of the 
untagged protein, different stabilizing buffers can be explored. Despite numerous 
attempts, Parris et al. managed to isolate the B. subtilis AcpS: ACP complex only 
when using a mutated AcpS that did not contain a histidine tag [86]. So, this 
approach can also be investigated for the S. coelicolor AcpS. 
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Chapter 7 
Structure and activity of AcpS mutants 
In this chapter the structure and activity of two mutants of the AcpS active site were 
investigated. The activity was measured by analysing the conversion of apo-ACP to 
holo-ACP. The binding of CoA of these mutants was also measured by ITC. 
7.1 Generation of AcpS mutants 
As discussed in chapter 6, for the B. subtilis AcpS mechanism it was proposed that 
a water molecule, called activating water, is involved at the beginning of the 
phosphopantetheine transfer, deprotonating the conserved ACP serine. 
Two residues, His 110 and Asp 111, were identified in the S. coelicolor AcpS to be 
the possible catalytic residues responsible for direct deprotonation of the ACP 
serine, or base catalysts in the deprotonation of a water molecule. These residues 
are placed on either side of the ß-phosphate of CoA, and after inspection of the B. 
subtilis AcpS: ACP complex and S. coelicolor model, it is possible to suggest that 
they could both reach the ACP serine and deprotonate it. 
At the pH where the phosphopantetheinylation occurs, the carboxyl group of the 
aspartate side chain is deprotonated, and its oxygens highly electronegative can 
remove a proton from the hydroxyl group of the serine. Asp 111 could act in a 
similar way to the B. subtilis ACP Asp35 [86], but allowing less specific binding to 
promote a broader specificity for ACP recognition, without the need of an 
additional base contributed by ACP which would require precise positioning. In 
addition, Asp 111 is the residue that has the greatest change in position on CoA 
binding. Whilst the aspartate residue is not completely conserved among all the 
other AcpS, the histidine 110 is highly conserved (Figure 7.1). The basic nitrogen 
of the imidazole ring of histidine is usually involved in a quick proton shuttle, and 
it can remove a proton from serine, threonine or cysteine residues activating them 
as nucleophiles. 
To explore their role during catalysis, these two residues were mutated to alanines 
by site-directed mutagenesis, and the correspondent proteins were expressed, 
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purified and crystallized. Finally, their structures were solved by molecular 
replacement with the wild type. ITC was also used to calculate Ka of CoA binding. 
S. coelicolor AcpS 
B. subtilis AcpS 
S. pneuminiae AcpS 
K. radiotolerans AcpS 
L. xyli AcpS 
D. hafniense AcpS 
B. halodurans AcpS 
S. erythraea AcpS 
S. avermitilis AcpS 
T. denticola AcpS 
D. desulfuricans AcES 
15 22 29 110 
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Figure 7.1 Alignment of multiple polyketide synthesis and fatty acid synthesis 
Acyl carrier protein Synthase sequences. 
7.2 Primers design and cloning 
The Stratagene QuickChange II Site-Directed Mutagenesis kit was used for the 
generation of the plasmids containing the single mutation. This kit was chosen for 
its simplicity of use and for the relatively short time it requires. The only change to 
the protocol provided with the kit (chapter 3.4.4) was the addition of DMSO. Due 
to the high GC content (more than 75%), GC hairpins in the DNA could be formed, 
and DMSO was essential to destroy this base pairing and allow PCR reaction to 
occur. E. coli BL21 (DE3) cells were transformed with the new plasmids, and after 
miniprep the mutated vector was sent for sequencing, to confirm the presence of the 
single mutation. As can be seen from Figure 7.2, the site-directed mutagenesis was 
successful and the Asp] 11 or the His 110 were substituted with alanine residues, 
and no other mutations occurred into the gene or the histidine tag. 
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Figure 7.2 Alignments between the wild type AcpS and the D111A (A) or HI1OA 
(B) mutant. Nucleotide sequences after sequencing were translated with Translate 
(available at the expasy website [149]), then aligned with ClustalW [148] ("*" 
means identical residue). 
7.3 Expression and purification of H110A and D111A mutants 
Both mutants were expressed and purified using the same protocol as the wild type 
AcpS: a nickel affinity chromatography (chapter 3.6.3), an optional gel filtration 
column (chapter 3.6.5) and desalting (chapter 3.6.8). Apart from the fact that both 
mutants are eluted at a slightly higher imidazole concentration, about 300 mM from 
the nickel column, no further differences in comparison with the wild type were 
observed (Figure 7.3). About 10 mg of pure protein were obtained from 1L of 
bacterial culture. 
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Figure 7.3 Purification of AcpS mutants. Examples of affinity (A), gel filtration 
chromatography (B) and SDS-PAGE gel (C) for Hl lOA and Dl 1 IA AcpS mutants. 
UV absorbance is shown in blue, the gradient of the elution buffer in red. Mutants 
are eluted at a slightly higher concentration of imidazole, and no further differences 
are observed during their purification in comparison to the wild type. 
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7.4 Investigation of AcpS mutant activities on ACP by mass spectroscopy 
Each mutant was incubated with the polyketide S. coelicolor ACP and a standard 
phosphopantetheine transfer reaction was set up in vitro (chapter 3.6.9). Each 
reaction was carried out using the same amount of protein and time (1h). The 
resulting ACP was then purified by gel filtration (Figure 7.4) and mass 
spectroscopy was used as initial investigation to determine whether these mutants 
were still capable of phosphopantetheinylation (apo- and holo-ACP differs by 300 
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Figure 7.4 Purification of holo-ACP by gel filtration. AcpS and ACP were 
incubated together at 1: 100 ratio with the presence of CoA. 
A control reaction with wild type AcpS was also carried out. If activity was 
preserved, ACP should be present in its holo form. As can be seen from the mass 
spectra, the incubation with wild type AcpS led to the formation of holo-ACP. On 
the contrary, with the aspartate mutant, by comparing the intensity of the peaks, 
about 55% of holo-ACP seems to be present in solution, with 45% reduction in 
activity (Figure 7.5). The histidine mutation seemed to cause a greater effect on 
catalysis. The activity was reduced by approximately the 85%. So, it is evident that 
both mutants cause a reduction of the phosphopantetheine transfer, but with this 
analysis it is not possible to determine if this loss in activity is due to a catalytic 
role for these residues, or because CoA was not bound, suggesting a structural role 
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for them. To investigate the role of the His110 and Asp l11 further, their crystal 
structures were solved in the presence of CoA for comparison to the wild type 
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Figure 7.5 Activation of ACP by mutants. ACP Mass spectra measured on ACP 
samples obtained after phosphopantetheinylation reaction with wild type AcpS, 
D1IIA and HI OA mutants. All errors are within 19 kDa, and several sodium ions 
are bound to the ACPs. 
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7.5 Determination of AcpS D1IIA structure 
7.5.1 AcpS D111A crystallization 
Solutions from the MDL Clear Strategy Screen I and II, at pH 6.5, and the 
Hampton PEG/Ion Screen, with a protein concentration of 10 mg/mL and in the 
presence of 5 mM CoA, were screened at 18°C for D11 IA crystals (chapter 3.8.1). 
These screens were chosen because they gave the best results for the wild type 
AcpS. The best crystals, measuring about 0.7x0.6x0.3 mm (Figure 7.6) were 
obtained in the conditions shown in Table 7.1: 
Salt Buffer PEG 
0.15 M potassium thiocyanate 0.1 M sodium cacodylatc pH 6.5 15% PEG 4K 
0.2 M potassium bromide 0.1 M sodium cacodylate pH 6.5 15% PEG 4K 
0.2 M potassium thiocyanate 0.1 M sodium cacodylate pH 6.5 
8% PEG 20K + 
8% PEG 550 MME 
0.2 M tri-lithium citrate none 20% PEG 3350 
0.2 M lithium decahylate none 20% PEG 3350 








Figure 7.6 Example of D 11 IA AcpS crystal (A) and its diffraction image (B). One 
of the CCDs of the detector was not working during data collection at 102 in 
Diamond. This area was excluded during integration. Crystals were obtained in 0.2 
M potassium thiocyanate, 0.1 M sodium cacodylate pH 6.5,8% PEG 20K + 8% 
PEG 550 MME. 
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7.5.2 Data collection and processing 
Several datasets were collected from each condition at beamline 102 in Diamond. 
The best crystal, which diffracted to a resolution of approximately 1.4 A, was 
obtained in 0.2 M potassium thiocyanate, 0.1 M sodium cacodylate pH 6.5,8% 
PEG 20K + 8% PEG 550 MME. Glycerol was added to the same reservoir for a 
final concentration of 15% v/v, and this solution was used as cryoprotectant. The 
crystal was a bit icy as can be seen in picture 7.6 (presence of the characteristic ice 
ring at about 3.2 A), but this did not affect data collection and processing. The 
crystal belonged to the P213 space group with a=b=c=72.8 A. 
7.5.3 Molecular replacement and refinement 
One molecule per asymmetric unit was found. The structure was solved by 
molecular replacement using Phaser [ 136,137] and the holo-AcpS as search model. 
Inspection of the difference map clearly showed the presence of the mutation 
(Figure 7.7). The aspartate was then mutated to an alanine in Coot [142] and the 
refinement was carried out with Refmac5 [133] (chapter 3.8.6). 
A) B) 
Figure 7.7 Electron density corresponding to the D11 IA mutation. Examination of 
the difference map (DELFWT, DELPHWT) related to the DI 1IA mutant (A) 
clearly show the mutation. B) Density map corresponding to the alanine residue in 
the final model. The density map is contoured at 1 a, while the difference map at 36. 
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The model contains 123 residues, 2 magnesiums with 0.5 occupancy each, 2 
molecule of CoA with 0.5 occupancy each, I sodium and 208 water molecules. 
Inspection of the electron density at the CoA binding site after refining the model 
with a full occupancy cofactor in a orientation similar to that one of the holo-AcpS 
(Figure 7.8 A), and the presence of two magnesium ions, suggested that CoA was 
bound in two alternative conformations, that begin to diverge from the a- 
phosphates. Whilst the electron density for the adenine rings of both CoAs, 
including the a- and ß-phosphates, and their related magnesium ions was very clear, 
the density for the phosphopantetheine arms was not well defined and the model 
building for that part of the CoA was difficult (Figure 7.8). 
mii 
Figure 7.8 Possible alternative conformations of CoA bound to DIIIA AcpS. 
Difference maps (DELFWT, DELPHWT) related to the model refined without the 
cofactor (A), and related to the model refined with one molecule of cofactor with 
full occupancy (B). C) Electron density map (FWT, PHWT) and difference map 
(DELFWT, DELPHWT) of the final orientations of CoAs. The electron density 
map is contoured at 1.26, the difference map at 36. In figure 7.8 A and B the final 
model is shown as bonds. 
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The final model represents the clearly defined alternative positions of the adenine 
ring and phosphate for both CoAs, and for each model, the position for the 
phosphopantetheine chain was chosen which resulted in the least negative electron 
density. However there is evidence for other possible orientations of the 
phosphopantetheine chain portion, in contrast with the wild type structure where 
the density for the adenine base and the phosphopantetheine chain was all well 
defined. The presence of two binding sites for the cofactor was also proved by ITC 
experiment, as described in chapter 7.9. One molecule of CoA resulted to be bound 
in a similar way as in the holo-AcpS, while the second one to adopt a completely 
new conformation and is located in a different hydrophobic pocket. The refinement 
led to a structure model with R-factor an Rfrý, values of 0.19 and 0.21 respectively. 
Statistics for data processing and refinement are shown in Table 7.2. 
D111A AcpS 
Wavelength (A) 0.953 




Completeness (%) 99.6 (96.4) 
N unique reflections 25707 
Redundancy 7.9 (2.9) 
UvI 34.7 (1.5) 
R. merge 0.05 (0.51) 
Mosaicity (°) 0.21 
Rfree 0.21 
R-factor 0.19 
RMS bond (A) 0.08 
RMS angle (°) 1.271 
Table 7.2 Data processing and refinement statistics for D111A AcpS mutant. Data 
corresponding to the highest resolution shell are in brackets. 
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7.5.4 Geometry and B-factor analysis 
The geometry and the conformation were checked using MolProbity [ 145,146] 
The Ramachandran plot is presented in Figure 7.9. All 123 residues are in the most 
favoured region. Only HisI10 was recognized to have a slightly unusual rotamer 
(0.4%). The imidazole ring is coordinated to the 3'-phosphates of the two 
alternative conformations of the cofactor. The 08 oxygens of these phosphates are 
0.7 A apart. So, the electron density related to the histidine is an average of two 
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Figure 7.9 Ramachandran plot related to D111A mutant made by MolProbity. A) 
general case; B) glycine; C) proline; D) pre-proline. 
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An analysis of the average B-factor of the main chains was also performed with 
Baverage [143]. The average B-factor is 16 A2, while the average temperature 
factor for the mobile areas is higher: 21 A2 (MH 1), 30 A` (ML 1) 17 A2 (MI-2) and 
28 A2 (ML3). The loop containing the Aspl 11, shifted from the apo-position, has 
also higher average B-factor: 19 A2. This B-factor analysis and a comparison with 
the wild type AcpS are shown in Figure 7.10. The B-factor of this mutant is lower 
than the wild type one, but its pattern is very similar, with higher temperature factor 
values for mobile loops. 
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Figure 7.10 DI 1IA B-factor analysis. Average B-factor values for the main chain 
of D11 IA mutant and its comparison with the wild type AcpS. 
7.6 Determination of AcpS HI IOA structure 
7.6.1 AcpS HI1 OAA crystallization 
The MDL Clear Strategy Screen I and 11, at pH 6.5, and the Hampton PEG/Ion 
Screen were used to obtained H 111 OA crystals in the presence of 5 mM CoA 
(chapter 3.8.1). The best conditions, which gave the more regular and bigger 
crystals measuring approximately 0.8x0.6x0.3 mm at 18°C (Figure 7.11), are 




10 19 28 37 46 55 64 73 82 91 100 109 118 
residue number 
Chapter 7 Structure and activity of AcpS mutants 
Salt Buffer PEG 
0.3 M sodium acetate 0.1 M sodium cacodylate pH 6.5 25% PEG 2K MME 
0.15 M potassium thiocyanate 0.1 M sodium cacodylate pH 6.5 18% PEG5K MME 
5 mM Nickel chloride 0.1 M sodium cacodylate pH 6.5 20% PEG 4K 
0.2 M magnesium chloride hexahydrate none 20% PEG 3350 
0.2 M tri-lithium citrate tetrahydrate none 20% PEG 3350 
Table 7.3 Crystallization conditions for the H 11 OA AcpS mutant. 
7.6.2 Data collection and processing 
Crystals from each condition were tested at beamline BM 10.1 at the Synchrotron 
Radiation Source (SRS), Daresbury, and 102 and 103 at the Diamond Light source 
(DLS). It was noted that, the bigger the crystal was, the worse its diffraction was, 
probably due to problems while freezing. In addition, the best cryosolutions were 
proved to contain l0%-15% v/v glycerol or PEG 400, while higher concentrations 
destroyed the crystals. The best dataset was collected at station 10.1 in Daresbury, 
from a crystal obtained in 0.3 M sodium acetate, 0.1 M sodium cacodylate pH 6.5, 
25% PEG 2K MME with the presence of 10% PEG 400 as cryoprotectant. The 









Figure 7.11 Example of Hl l0A AcpS crystal (A) and its diffraction image (B). 
Crystals were obtained in 0.3 M sodium acetate, 0.1 M sodium cacodylate pH 6.5, 
25% PEG 2K MME. 
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7.6.3 Molecular replacement and refinement 
The structure was solved by molecular replacement using Phaser [136,137] and the 
wild type holo-AcpS as search model. Examination of the difference map showed 
the presence of the mutation, even though this identification was not immediate, 
due to the fact that a water molecule took the position of the histidine side chain. 
One molecule per asymmetric unit was found. The model contains 123 residues, 1 
magnesium, I molecule of CoA and 237 water molecules. The refinement led to a 
structure model with R-factor an Rte, values of 0.18 and 0.20 respectively. Data 
processing and refinement statistics are shown in Table 7.4. 
H110A AcpS 
Wavelength (A) 1.117 




N unique reflection 28420 
Completeness (%) 99.3 (99.3) 
Redundancy 9.3 (2.1) 
Val 32 (2.5) 
R. merge 0.07 (0.22) 
Mosaicity (°) 0.41 
Rf 0.20 
R-factor 0.18 
RMS bond (A) 0.007 
RMS angle 0 1.229 
Table 7.4 Data processing and refinement statistics for D111A AcpS mutant. Data 
corresponding to the highest resolution shell are in brackets. 
7.6.4 Geometry and B-factor analysis 
The geometry and the conformation were checked using the tool of programs 
MolProbity [145,146]. The Ramachandran plot is presented in picture 7.12. All 
123 residues are in the most favoured region. G1u42 was recognized to have a 
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slightly unusual rotamer (0.7%). The fact that the electron density for the carboxyl 
group is not extremely clear could have contributed to refine it in a not particular 
common rotamer. An analysis of the average B-factor of the main chains was also 
2 performed with Baverage [143]. The average B-factor is 13 A , while the average 
temperature factor for the mobile areas is higher: 17 A2 (MH 1), 23 A2 (ML 1) 14 A2 
(ML2) and 22 A2 (ML3). The loop containing the Aspl ll has also a higher average 
B-factor: 18 A2. The temperature factor analysis and the comparison with the wild 
type AcpS are shown in Figure 7.13. Again, the B-factor of this mutant is lower 
than the wild type one, but its pattern is very similar, with the mobile loops 
characterized by a higher temperature factor. 
A) 
F. 

















Figure 7.12 Ramachandran plot related to Dl1 IA mutant made by MoiProbity. A) 
general case; B) glycine; C) proline; D) pre-proline. 
163 
Chapter 7 Structure and activity of AcpS mutants 
Average B factor for the main chain 
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Figure 7.13 H1l OA B-factor analysis. Average B-factor values for the main chain 
of HII OA mutant and its comparison with the wild type AcpS. 
7.7 Analysis of the crystal structure of the D111A AcpS mutant 
The mutation of Asp 111 to alanine gave a very interesting result. The structure of 
the D111A mutant contains 2 alternative conformations for the CoA, each of them 
coordinated to its own magnesium ion (Figure 7.14). 
CoA 
S CoA 
Figure 7.14 D 111 A AcpS crystal structure. The ribbon representation of D 111 A 
AcpS is shown, with monomers A and B coloured in magenta and cyan. CoAs are 
shown as sticks and coloured according to atom type. CoAs in the D 111 A AcpS are 
coloured in yellow, the cofactor present in the holo-AcpS in green. Magnesium ions 
are shown as grey spheres. 
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The RMSD after Ca superimposition between the mutant to the wild type is 0.20 A. 
The N-terminal region is more disordered and the polyhistidine tag has a different 
arrangement in comparison with the wild type, explaining the fact that this mutant 
is eluted at a higher concentration of imidazole from the nickel column. Mobile 
loops are slightly displaced and in the same conformation. Whilst the adenine rings 
of CoA are placed in the same position, the phosphopantetheine chains are located 
in a different area. Two possible positions for the phosphopantetheine chain were 
identified. These orientations were chosen to reflect their best and more likely 
positions in the model. The first one is similar to the active one in the wild type, 
with the phosphopantetheine arms that begin to diverge after the carbon C9. After 
this atom, CoA in the mutant structure seems to assume a more contracted 
conformation in comparison to a more linear disposition of the chain in the wild 
type. The alternative CoA lies near sheet 03 until carbon C9, then is surrounded by 
helices al and a2 of another monomer. The alternative phosphopantetheine arm lies 
on a hydrophobic pocket that is defined by the aliphatic portion of the side chain of 
Argl5, and by the side chains of Phe16, Leu26, Leu30, Phe53 and Trp71 of a 
symmetry related subunit. Moreover, additional bits of electron density suggested 
that the phosphopantetheine tail is mobile, and other locations, especially one that 
is very similar to the one of CoA in the wild type protein, can also be seen, in 
particular for the portion after the 2 phosphates. The magnesium coordination 
sphere seems to be conserved, apart from the fact that some water molecules are 
missing, probably due to the complexity of this active site and the presence of the 2 
alternative conformations of CoA. 
7.8 Analysis of the crystal structure of the H110A AcpS mutant 
The overall structure of the H11OA mutant is very similar to the wild type AcpS, 
with clear electron density for the alanine that substitutes His110 (Figure 7.15). The 
RMSD after Ca superimposition between the H11OA mutant and the wild type is 
0.22 A. The N-terminal region is more similar to the aspartate mutant than to the 
wild type AcpS. It is more disordered than the wild type, with a different 
arrangement. Small displacements can be observed for the mobile loops 
(approximately between 0.4 A and 0.7 A for the Ca portion), which have the same 
conformation. The cofactor binding site is conserved. The most significant 
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difference is the orientation of the 06 oxygens of CoA, which are 1.43 A apart in 
mutant and wild type structure. The electron density around the 0-phosphate 
suggests that this portion of CoA is a bit more flexible than that one in the wild type 
structure. The coordination sphere of the magnesium ion is also conserved: the 3 
waters, the carboxyl group of Asp9 and the two phosphates of CoA. The side chain 
of Asp 111 is still capable of interaction with a magnesium-coordinating water via 
hydrogen bonds with another water molecule. Differently to the wild type AcpS, 
Glu57, residue that is very well conserved in other type I AcpSs, is coordinated to 
the [3-phosphate of CoA, in a conformation that is similar to that one observed in 
the B. subtilis AcpS, where the equivalent residue coordinates the calcium. This 
residue has been proposed to directly deprotonate the active ACP serine in type II 
human AcpSs [66]. 
Figure 7.15 The HII OA mutation in the corresponding crystal structure. Bonds 
representation of the alanine in the H1 l0A structure (coloured in yellow) and of the 
histidine 110 (in green) in the wild type AcpS. The electron density related (FWT, 
PH WT) to the HI1 OA protein is contoured at 1 a. 
7.9 Investigation of CoA binding with ITC 
The mutated proteins did not result to be 100% active. In particular, the histidine 
mutant resulted to be the most affected protein, with a drop of 85% of activity. 
Whilst an initial low resolution (approximately 4 A) structure of Hisl 10 did not 
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appear to have CoA present, the highest resolution shows its presence clearly. So, 
in order for AcpS to phosphopantetheinylate the substrate CoA, the CoA needs to 
bind, ACP needs to bind in the correct orientation and the active site needs to be 
organized in such a way that the correct chemistry can be catalyzed. In order to 
understand the role of substrate binding in the reduced activity of the mutants 
better, ITC was carried out to investigate the binding of CoA to both the wild type 
and the mutant enzymes (chapter 3.9). As can be seen from the graphs (Figure 
7.16), in the case of the histidine mutant, the affinity for CoA is very similar to the 
wild type one, and a molar ratio of approximately 1 was calculated (table 7.5). This 
suggests that the His 110 has a more active role in the catalysis or a structural role in 
the correct formation of the active site rather than in the cofactor binding. 
In the D111A crystal structure, 2 alternative conformations of CoAs, and 
consequently two binding sites, were identified per molecule. This was confirmed 
by ITC. A strong binding site, with an affinity similar to the wild type protein, was 
identified after a standard reaction, but the stoichiometry resulted to be either 0.6 or 
0.4, suggesting that 1 or 2 monomers per trimer were binding CoA, leaving some 
subunits available for CoA to occupy an alternative binding site. 
Wild type AcpS H110A D111A 
Kd (nM) 380 ± 20 450 ± 70 850 ± 40 
n 1.2 ± 0.1 0.98 ± 0.05 0.5 ± 0.1 
AH (caVmol) -4000 ± 400 -3500 ± 400 -7000 ± 1800 
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Figure 7.16 ITC graphs showing the presence of a strong binding site for CoA. A) 
Data related to the H1I OA mutant; B) data related to the D 111 A mutant. 
So, another experiment with a very high concentration of CoA was carried out, and 
a very weak binding site could be identified. Firstly, a normal ITC experiment was 
run (chapter 3.9). This showed an affinity for CoA similar to the wild type, but a 
stoichiometry of 1: 3 or 2: 3. So, at the end of this experiment and after complete 
saturation at that particular CoA concentration, another experiment was carried out 
with the same protein but with a very high concentration of cofactor (2.5 mM). 
From this second experiment a weaker binding site was recognized. A blank 
contained the same concentration of CoA was tested in the absence of the protein, 
to confirm that the weaker binding site was not a dilution effect. In addition, 
another experiment was carried out, with a starting CoA concentration of 1.5 mM 
(Figure 7.17 A). Again, after the first tight binding site and saturation, a weaker site 
could be identified. Due to the large difference of enthalpy between the two binding 
sites, it was not possible to determine accurately the Kd for the second binding, but 
its related graph shows clearly the presence of this weak site. A blank with the wild 
type protein and with the same volumes of injection was run to check if the peaks 
related to the weaker binding site were due to the different heat of dilutions (Figure 
7.17 B). As expected, the wild type AcpS with a very high concentration of CoA 
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reaches saturation very quickly, indirectly confirming that the peaks related to the 
aspartate mutant belong to the weaker site. Kd for this wild type blank was 537 nM, 
with a stoichiometry of 1.11, values that are very close to those of the wild type 
AcpS. For the weaker binding site of the aspartate mutant a Kd of 90 µM was 
calculated, but this value was affected by a big statistical error. The great error that 
affects the change in enthalpy reflects the fact that 2 different values were 
calculated: the first for a stoichiometry of 1: 3, the other for a 2: 3 ratio. 
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Figure 7.17 Discovering a second binding site for CoA for the aspartate mutant. A) 
After saturation of the tight binding site, a weaker site is recognized. B) Blank 
using the wild type AcpS to check if the AH characteristic of the second site was 
due to the heat of dilution. 
7.10 Role of the His110 and Aspl l1 in catalysis 
Both His110 and Asp I11 are located on either side of CoA, and may be in a 
position to deprotonate the active serine on ACP. Both mutant enzymes resulted in 
reduced activity, with the activity of the histidine mutant being most dramatically 
affected by its mutation to an alanine. ITC confirmed that the CoA binding is 
preserved. Structurally, for both enzymes only minor perturbations of the protein 
structure were noticed. The cofactor in the histidine mutant binds essentially in the 
same way of the cofactor in the wild type AcpS, with the exception that the f3- 
169 
Chapter 7 Structure and activity of AcpS mutants 
phosphate of CoA is slightly more variable. In the aspartate mutant, the major 
difference in comparison with the wild type is in the cofactor binding region, where 
the electron density shows clearly that the phosphopantetheine chain of CoA can 
occupy two alternative binding sites. This was confirmed by ITC experiments that 
allowed the identification of a second very weak binding site which may 
correspond to the second orientation of CoA that was observed in the crystal 
structure. 
7.10.1 Role of His110 
From the structural and ITC data it can be proposed that the His 110 residue may act 
as a base in deprotonation of the serine on ACP. The mutation to an alanine almost 
destroys the activity of the correspondent protein, but the affinity to CoA is not 
affected. Histidines are commonly present in various active sites and their basic 
nitrogen of the imidazole ring is used to remove a proton from serine, threonine or 
cysteine residues to activate them as nucleophiles. The remaining 10% of activity 
could be explained with the fact that a water molecule is placed at the position of 
the basic nitrogen of the imidazole ring, and it may act as a weaker base. 
Analysis of the structure reveals that a different conformation of the side chain of 
the histidine can be close either to the serine or to the equivalent of the activating 
water. If the histidine deprotonates the serine indirectly, an active water will be 
present in the active site. In order to self hydrolization of CoA to occur, this active 
water would have to deprotonate another water molecule form the bulk solvent 
since the distance between the water and the ß-phosphate is too great for it to attack 
it directly. 
If His110 is involved as base catalyst, it requires some conformational change to 
the side chain. This can be promoted by ACP binding, which would explain why 
the presence of the base in the active site in the absence of ACP does not promote 
self-hydrolysis. 
The observations of G1u57 in an alternative conformation close to that observed 
for 
the equivalent residues in B. subtilis and human AcpSs rather than coordinating the 
phosphopantetheine chain, suggests the possibility that this may act as a catalytic 
base as proposed for the human enzyme. 
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7.10.2 Role of AspI ll 
On the contrary, the aspartate 111 seems to have a different structural role during 
catalysis. D 111 A AcpS contains an alternative conformation of CoA. The 
negatively charged oxygens of the aspartate can repulse the negatively charged P09 
oxygen of the tail of the cofactor, and the A05 and A06 oxygens of the 0- 
phosphate of CoA, preventing the cofactor from binding in this alternative 




Figure 7.18 The alternative CoA conformation. Charged surface representation of 
the wild type Asp l11 and the alternative CoA in the D111A structure. CoA is 
shown as sticks and coloured in yellow, according to atom type. AcpS monomer A 
is coloured in magenta. Positive and negative regions are coloured in blue and red 
respectively. 
The loop containing Aspl ll is also very mobile, so it could also be possible that a 
particular conformation of this region will cause steric clash with the cofactor. 
Finally, this alternative orientation could also prevent the construction of an active 
site with the proper organization that allows the correct chemistry to be catalyzed. 
A model for the binding between the D 111 A mutant and the ACP was created in 
the same way as for the wild type (chapter 3.8.7). From Figure 7.19, it is evident 
that the first carbon atoms after the ß-phosphate can clash against the region 
containing the ACP Asp4l. The alternative conformation of the cofactor results to 
be located between ACP helix a2 and AcpS helix al, preventing the ACP Asp4l 
171 
Chapter 7 Structure and activity of AcpS mutants 
from interacting with AcpS Arg 15, and therefore not allowing the interaction that is 
supposed to be crucial for the beginning of the phosphopantetheinylation reaction. 
In addition, in this model the active serine clashes against the ß-phosphate of CoA. 
The other conformation of CoA, which is in a similar orientation as the wild type 
one, seems to permit the phosphopantetheinylation of the ACP, justifying the 
remaining 55% of activity that characterizes the aspartate mutant. 
These results suggest that Asp 111 does not have a role as a base in (in)direct 
deprotonation of Ser42. However, it seems to be necessary in organizing the active 
site for productive binding of CoA. 
Figure 7.19 Model for ACP binding to D 111 A mutant. The alternative 
conformation of CoA could prevent the interaction between ACP Asp4l and AcpS 
Arg 15. The cartoon representation of AcpS is shown in cyan, the modelled ACP in 
sand. CoA and the other side chains are shown as sticks. 
7.10.3 Catalysis revisited 
In conclusion, mutagenesis studies of Asp 111 suggest a structural role in the 
binding of CoA and not a catalytic role. The dramatic reduction in activity in the 
His l 10 mutant supports a role in catalysis, perhaps as the base in activation of the 
serine or a water molecule. Analysis of the HI I OA crystal structure reveals that 
G1u57, as proposed for the human AcpS, may be directly involved in serine 





The work presented in this thesis focuses on the type I actinorhodin acyl carrier 
protein synthase (AcpS) from Streptomyces coelicolor. The cofactor promiscuity 
and the interaction of AcpS with the acyl carrier protein (ACP), as well as the 
phosphopantetheinylation mechanism, were investigated. 
The crystal structures of the apo-AcpS and of the protein in complex with the 
cofactor coenzyme A (CoA) were solved at 2A and 1.6 A respectively. 
The biological unit is a trimer, with one active site at each interface between 2 
subunits. A magnesium ion is present in the electron density in the presence of 
CoA. This S. coelicolor holo-AcpS structure is the first type I AcpS that presents 
the essential magnesium ion in the active site. The adenine ring of CoA interacts 
with one monomer, while the phosphopantetheine arm binds to the adjacent 
monomer. The phosphopantetheine chain lies on a relatively large and well defined 
hydrophobic pocket. 
Four main flexible areas (ML1-3 and MH1) were recognized in the apo-AcpS. 
These regions are ordered in the holo model but displaced if compared to the apo 
one. In particular, ML1 surrounds the 3'-phosphate binding pocket, ML2 defines 
one side of the phosphopantetheine hydrophobic cavity and ML3 stacks against the 
adenine base of CoA. 
By superimposing the apo and the holo protein, it is possible to notice that helix al 
is displaced when CoA is present, indicating a change in the trimer arrangement in 
the active holo-protein, which results in an "opening up" at the top of the trimer. 
This displacement could be a signal for the ACP to bind and interact. 
Comparing the S. coelicolor AcpS to other type I and II AcpSs, it is possible to 
notice that ML2 is in different conformations. In particular, S. coelicolor ML2 
seems to be very open, while the equivalent region in the S. pneumoniae structure, 
which is not determined in the presence of 3'-5'-ADP, is very closed, in a 
conformation similar to the one assumed by the equivalent loop in the B. subtilis 
protein. In the human type II AcpS, the equivalent ML2 is in a intermediate 
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conformation between the B. subtilis and the S. coelicolor loops. The high 
flexibility of ML2 could explain the broader cofactor selection of S. coelicolor 
AcpS. ML2 could enlarge the cavity where the phosphopantetheine chain lies, 
allowing extended modified CoAs to bind in the active site. 
In order to investigate the cofactor promiscuity of AcpS, crystallization trials were 
performed in the presence of longer acyl-CoAs. The crystal structure of the S. 
coelicolor AcpS in complex with acetyl-CoA was solved at 1.5 A. This model is 
very similar to the holo-AcpS. ITC showed that CoA has a higher affinity than the 
acetyl-CoA for AcpS. 
The acetyl-CoA seems to adopt a more contracted conformation rather than causing 
conformational changes on ML2. All the residues that form the hydrophobic cavity 
that contains the phosphopantetheine arm are disposed in the same way and with 
the same conformations. So, the addition of just 3 atoms to the natural cofactor 
does not seem to cause any dramatic conformational changes. 
Several acyl-CoAs were also modelled into the holo-AcpS hydrophobic pocket. 
The models showed that the pocket was too small to contain these modified CoAs. 
However, ML2 could assume different conformations in vivo, thus enlarging the 
phosphopantetheine chain pocket. 
To investigate the S. coelicolor ACP binding to the AcpS, an AcpS: ACP complex 
model was made using holo-AcpS and a S. coelicolor apo-ACP NMR structure 
based on a known structure of B. subtilis FAS AcpS: ACP complex. 
The contacts between the two proteins are predominantly hydrophilic. Interactions 
between aspartate and glutamate residues on B. subtilis ACP helix a3 and arginine 
residues on B. subtilis AcpS helix al seem to be conserved in the S. coelicolor 
model. The affinity for apo-AcpS of several ACP mutants in these selected residues 
is within the same order of magnitude, suggesting that, even though the hydrophilic 
interactions are important for the interaction with the AcpS and are necessary to 
tune the precise location of ACP in the AcpS active site to allow catalysis, other 
hydrophobic interactions are also involved and participate to lock the ACP in the 
right position. The displacement of AcpS helix al and MH1 after CoA binding 
could also be a signal for ACP that AcpS is ready for catalysis. 
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The mutagenesis of the conserved ACP Asp41 into an alanine results in a 
significant change to binding affinity, and in complete inactivation of the 
phosphopantetheine transfer. The mutations of Asp41 to a glutamate affects the 
affinity only partially, and results in a 85% loss of activity. So, even if Asp41 is not 
involved in any chemical reaction, it could be important for locating the loop 
containing the activating ACP serine in the right position. 
After structural analysis of the AcpS: ACP model, it was proposed that the 
interaction between Asp4l in ACP and Argl5 in AcpS could lock ACP and more 
importantly the Ser42 into the right position. Asp4l is located in a region on ACP 
helix a2 that can undergo a conformational change, permitting the formation of the 
salt bond between Arg15 and Asp4l, thus bringing the Ser42 near the active site in 
a position where it could attack the ß-phosphate from either side of CoA. Ser42 can 
replace water Z183, which coordinates with Mg2+ and is also within hydrogen 
bonding distance from AcpS Asp 111, or water Z172 which is potentially within 
hydrogen bonding distance from AcpS His 110. After a small conformational 
change, the aspartate or the histidine residues may deprotonate the hydroxyl group 
of Ser42 directly or indirectly via an activating water. If an activating water is 
involved, the coordinated magnesium will have a catalytic role, in addition to its 
role in binding CoA. 
For the S. coelicolor AcpS, a preformed active site might be partially responsible 
for the promiscuity. These residues could be in situ as base to assist the reaction, 
without the need of an additional base contributed by ACP which would require 
precise positioning. 
AcpS mutants H110A and DI 1IA were characterized biochemically and their 
crystal structures in complex with CoA were solved at 1.3 A and 1.4 A 
respectively. 
D111A AcpS resulted with a 45% reduction in activity, while in the HI 1OA AcpS 
the activity was reduced by approximately 85%. ITC was carried out to determine 
the cofactor binding constant. The affinity for CoA of the histidine mutant is very 
similar to the wild type one, suggesting that His 110 has a more active role in the 
catalysis or a structural role in the correct formation of the active site rather than in 
the cofactor binding. 
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These experiments and analysis of the crystal structure Hl lOA AcpS suggest that 
His 110 could deprotonate the ACP serine directly or indirectly via an activating 
water. 
On the contrary, Asp 111 seems to have a different structural role during catalysis. 
Inspection of the electron density at the CoA binding site and ITC experiments 
suggested that CoA was bound in two alternative conformations in the DI 1IA 
AcpS mutant, one in a similar way as in the holo-AcpS, and a second one that 
adopts a completely new conformation and lies on a different hydrophobic pocket. 
The negatively charged oxygens of the aspartate could repulse the negatively 
charged oxygens of CoA, preventing the cofactor from binding in this alternative 
conformation. In addition, the loop containing Aspi !1 is also very mobile, so it 
could also be possible that a particular conformation of this region causes steric 
clash with the cofactor. So, these experiments suggest a structural role in the 
binding of CoA and not a catalytic role. 
In conclusion, the structure of AcpS from S. coelicolor has been determined in a 
catalytically competent complex which reveals a different location for the 13- 
phosphate in the active site compared to that observed in B. subtilis type I AcpS. In 
contrast to the model proposed for the B. subtilis type I AcpS, where a water 
molecule activated by another water or by a base on ACP is thought to deprotonate 
the ACP serine, in the promiscuous S. coelicolor AcpS a residue is proposed to 
deprotonate (in)directly the active serine on ACP, avoiding the precise positioning 
of a deprotonating residue located on ACP. This is similar to what has been 
proposed for the human type II AcpS. 
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Amino acid 3 letter code 1 letter code Structure 
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Glutamine Gln Q 
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Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
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Crystal Screens 1 and 2 (Hampton Research) 
Tube Salt Buffer Precipitant 
1 0.02 M Calcium chloride dihydrate 0.1 M Sodium acetate tnhydrate pH 4.6 30% v/v +l- -2-Meth l-2,4" entanediol 
2 None None 0.4 M Potassium sodium tartrate tetrahydrate 
3 None None 0.4 M Ammonium phosphate monobasic 
4 None 0.1 M Tns h rochlonde pH 85 2.0 M Ammonium sulfate 
5 0.2 M Sodium citrate (nbasic dih drate 0.1 M HEPES sodium pH 7.5 30% v/v +/" -2-Meth l-2,4- entanediol 
6 0.2 M Magnesium chlonde hexahydrate 0.1 M Tns h drochlonde pH 8.5 30% w/v Polyethylene glycol 4,000 
7 None 0.1 M Sodium cacodylate tnh drate pH 6.5 1.4 M Sodium acetate tnhydrate 
8 0.2 M Sodium citrate tribasic dihydrale 0.1 M Sodium cacodylate tnhydrate pH 6.5 30% vlv 2"Propanal 
9 0.2 M Ammonium acetate 0.1 M Sodium citrate tnbasic dihydrate pH 5.6 30% wlv Polyethylene glycol 4,000 
10 0.2 M Ammonium acetate 0.1 M Sodium acetate tnhydrate pH 4.6 30% w/v Polyethylene glycol 4,000 
11 None 0.1 M Sodium citrate tnbasic dehydrate pH 5.6 1.0 M Ammonium phosphate monobasic 
12 0.2 M Magnesium chloride hexah drate 0.1 M HEPES sodium pH 7.5 30%vlv 2-Propanol 
13 0.2 M Sodium citrate tnbasic dh drate 0.1 M Tns h drochloride pH 8.5 30% v/v Polyethylene I col 400 
14 0.2 M Calcium chlonde dehydrate 0.1 M HEPES sodium pH 7.5 28%v/v Polyethylene glycol 400 
15 0.2 M Ammonium sulfate 0.1 M Sodium cacodylate tnh drate pH 6.5 30% wlv Polyethylene glycol 8,000 
16 None 0.1 M HEPES sodium pH 7.5 1.5 M Lithium sulfate monohydrate 
17 0.2 M Lithium sulfate monohydrate 0.1 M Ins hydrochlonde pH 8.5 30% w/v Polyethylene glycol 4,000 
18 0.2 M Magnesium acetate tetrahydrate 0.1 M Sodium cacodylate trih drate pH 8.5 20% wlv Polyethylene glycol 8,000 
19 0.2 M Ammonium acetate 0.1 M Tns hydrochlonde pH 8.5 30% v/v 2-Propanol 
20 02M Ammonium sulfate 0.1 M Sodium acetate tnhydrate pH 46 25% w/v Polyethylene glycol 4,000 
21 0.2 M Magnesium acetate tetrahydrate 0.1 M Sodium cacodylate tnhydrate pH 6.5 30% v/v (+/-)"2-Methyl-2,4-pentanediol 
22 0.2 M Sodium acetate tnhydrate 0.1 M Tns hydrochloride pH 8.5 30% w/v Polyethylene glycol 4,000 
23 0.2 M Ma nesium chloride hexahydrate 0.1 M HEPES sodium pH 7.5 30% viv Polyethylene glycol 400 
24 0.2 M Calcium chlonde dihydrate 0.1 M Sodium acetate tnh drate pH 4.6 20% v/v 2-Pro and 
25 None 0.1 M Imidazole pH 6.5 1.0 M Sodium acetate tnhydrate 
26 0.2 M Ammonium acetate 0.1 M Sodium citrate tnbasic dihydrate pH 5.6 30% v/v (+l" 2-Methyl"2,4" ntanediol 
27 0.2 M Sodium citrate tnbasic dehydrate 0.1 M HEPES sodium pH 7.5 20% v/v 2-Propanol 
28 0.2 M Sodium acetate tnh drate 0.1 M Sodium cacodylate tnhydrate pH 65 30% w/v Polyethylene glycol 8,000 
29 None 0.1 M HEPES sodium pH 7.5 0.8 M Potassium sodium tartrate tetrahydrate 
30 0.2 M Ammonium sulfate None 30% w/v Polyethylene glycol 8,000 
31 0.2 M Ammonium sulfate None 30% wlv Polyethylene glycol 4,000 
32 None None 2.0 M Ammonium sulfate 
33 None None 4.0 M Sodium formate 
34 None 0.1 M Sodium acetate tnhydrate pH 46 2.0 M Sodium formate 
35 None 0.1 M HEPES sodium pH 7.5 0.8 M Sodium phosphate monobasic monohydrate 
0.8 M Potassium phosphate monobasic 





0.1 M Sodium acetate tnhydrate pH 4.6 
0.1 M HEPES sodium pH 7.5 
8% w/v Polyethylene glycol 4,000 
1.4 M Sodium citrate tnbasic dihydrate 
39 None 0.1 M HEPES sodium pH 7.5 2% v/v Polyethylene glycol 400 
2.0 M Ammonium sulfate 
40 None 0.1 M Sodium citrate tnbasic dehydrate pH 5.6 20% vlv 2-Propanot 
20% w/v Polyethylene glycol 4,000 
41 None 0.1 M HEPES sodium pH 7.5 10% vlv 2-Propanol 
20% w/v Polyethylene glycol 4,000 
42 0.05 M Potassium phosphate monobasic None 20% wlv Polyethylene glycol 8,000 
43 None None 30% wlv Polyethylene glycol 1,500 
44 None None 0.2 M Magnesium formate dihydrate 
45 0.2 M Zinc acetate dehydrate 0.1 M Sodium cacodylate tnhydrate pH 6.5 18% w/v Polyethylene glycol 8,000 
46 0.2 M Calcium acetate hydrate 0.1 M Sodium cacodylate tnhydrate pH 6.5 18%w/v Polyethylene glycol 8,000 
47 None 0.1 M Sodium acetate tnh drate pH 46 2.0 M Ammonium sulfate 
48 None 0.1 M Tns hydrochloride pH 8.5 2.0 M Ammonium phosphate monobasic 
49 1.0 M Lithium sulfate monohydrate None 2% wlv Polyethylene glycol 8,000 
50 0.5 M Lithium sulfate monohydrate None 15% w/v Polyethylene glycol 8,000 
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PEG/Ion Screen (Hampton Research) 
Tube Salt Polymer pH 
1 0.2 M Sodium fl uoride 20% w/v Polyethylene glycol 3,350 7.3 
2 0.2 M Potassium fluoride 20% w/v Polyethylene glycol 3,350 7.3 
3 0.2 M Ammonium fl uoride 20% w/v Polyethylene glycol 3,350 6.2 
4 0.2 M Lithium chloride 20% w/v Polyethylene glycol 3,350 6.8 
5 0.2 M Magnesium chloride hexahydrate 20% w/v Polyethylene glycol 3,350 5.9 
6 0.2 M Sodium chloride 20% w/v Polyethylene glycol 3,350 6.9 
7 0.2 M Calcium chloride dihydrate 20% w/v Polyethylene glycol 3,350 5.1 
8 0.2 M Potassium chloride 20% w/v Polyethylene glycol 3,350 7.0 
9 0.2 M Ammonium chloride 20% w/v Polyethylene glycol 3,350 6.3 
10 0.2 M Sodium iodide 20% w/v Polyethylene glycol 3,350 7.0 
11 0.2 M Potassium iodide 20% w/v Polyethylene glycol 3,350 7.0 
12 0.2 M Ammonium iodide 20% w/v Polyethylene glycol 3,350 6.2 
13 0.2 M Sodium thiocyanate 20% w/v Polyethylene glycol 3,350 6.9 
14 0.2 M Potassium thiocyanate 20% w/v Polyethylene glycol 3,350 7.0 
15 0.2 M Lithium nitrate 20% w/v Polyethylene glycol 3,350 7.1 
16 0.2 M Magnesium nitrate hexahydrate 20% w/v Polyethylene glycol 3,350 5.9 
17 0.2 M Sodium nitrate 20% w/v Polyethylene glycol 3,350 6.8 
18 0.2 M Potassium nitrate 20% w/v Polyethylene glycol 3,350 6.8 
19 0.2 M Ammonium nitrate 20% w/v Polyethylene glycol 3,350 6.2 
20 0.2 M Magnesium formate dihydrate 20% w/v Polyethylene glycol 3,350 7.0 
21 0.2 M Sodium formate 20% w/v Polyethylene glycol 3,350 7.2 
22 0.2 M Potassium formate 20% w/v Polyethylene glycol 3,350 7.3 
23 0.2 M Ammonium formate 20% w/v Polyethylene glycol 3,350 6.6 
24 0.2 M Lithium acetate dihydrate 20% w/v Polyethylene glycol 3,350 7.9 
25 0.2 M Magnesium acetate tetrahydrate 20% w/v Polyethylene glycol 3,350 7.9 
26 0.2 M Zinc acetate dihydrate 20% w/v Polyethylene glycol 3,350 6.4 
27 0.2 M Sodium acetate trihydrate 20% w/v Polyethylene glycol 3,350 8.0 
28 0.2 M Calcium acetate hydrate 20% w/v Polyethylene glycol 3,350 7.5 
29 0.2 M Potassium acetate 20% w/v Polyethylene glycol 3,350 8.1 
30 0.2 M Ammonium acetate 20% w/v Polyethylene glycol 3,350 7.1 
31 0.2 M Lithium sulfate monohydrate 20% w/v Polyethylene glycol 3,350 6.0 
32 0.2 M Magnesium sulfate heptahydrate 20% w/v Polyethylene glycol 3,350 6.0 
33 0.2 M Sodium sulfate decahydrate 20% w/v Polyethylene glycol 3,350 6.7 
34 0.2 M Potassium sulfate 20% w/v Polyethylene glycol 3,350 6.8 
35 0.2 M Ammonium sulfate 20% w/v Polyethylene glycol 3,350 6.0 
36 0.2 M Sodium tartrate dibasic dihydrate 20% w/v Polyethylene glycol 3,350 7.3 
37 0.2 M Potassium sodium tartrate tetrahydrate 20% w/v Polyethylene glycol 3,350 7.4 
38 0.2 M Ammonium tartrate dibasic 20% w/v Polyethylene glycol 3,350 6.6 
39 0.2 M Sodium phosphate monobasic monohydrate 20% w/v Polyethylene glycol 3,350 4.7 
40 0.2 M Sodium phosphate dibasic dihydrate 20% w/v Polyethylene glycol 3,350 9.1 
41 0.2 M Potassium phosphate monobasic 20% w/v Polyethylene glycol 3,350 4.8 
42 0.2 M Potassium phosphate dibasic 20% w/v Polyethylene glycol 3,350 9.2 
43 0.2 M Ammonium phosphate monobasic 20% w/v Polyethylene glycol 3,350 4.6 
44 0.2 M Ammonium phosphate dibasic 20% w/v Polyethylene glycol 3,350 8.0 
45 0.2 M Lithium citrate tribasic tetrahydrate 20% w/v Polyethylene glycol 3,350 8.4 
46 0.2 M Sodium citrate tribasic dihydrate 20% w/v Polyethylene glycol 3,350 8.3 
47 0.2 M Potassium citrate tribasic monohydrate 20% w/v Polyethylene glycol 3,350 8.3 
48 0.2 M Ammonium citrate dibasic 20% w/v Polyethylene glycol 3,350 5.1 
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Clear Strategy Screen I (MDL) 
2 3 4 5 6 
0.3 M NaAcetate 0.2 M Li2SO4 0.2 M MgCI2 0.2 M KBr 0.2 M KSCN 0.8 M NaFormate 
25% PEG 2K 25% PEG 2K 25% PEG 2K 25% PEG 2K 25% PEG 2K 25% PEG 2K 
MME MME MME MME MME MME 
7 8 9 10 11 12 
0.3 M NaAcetate 0.2 M Li2SO4 0.2 M MgCI2 0.2M KBr 0.2 M KSCN 0.8 M NaFormate 
15% PEG 4K 15"% PEG 4K 15% PEG 4K 15% PEG 4K 15% PEG 4K 15% PEG 4K 
13 14 IS 16 17 18 
0.3 M NaAcetate 0.2 M Li2SO4 0.2 M MgCI2 0.2 M KBr 0.2 M KSCN 0.8 M NaFormate 
10%PEG8K+ 10%PEG8K+ 10%PEG8K+ 10%PEG8K+ 10%PEG8K+ 10%PEG8K+ 
10% PEG IK 10% PEG IK 10% PEG IK 10% PEG IK 10% PEG IK 10% PEG IK 
19 20 21 22 23 24 
0.3 M NaAcetate 0.2 M Li2SO4 0.2 M MgCI2 0.2 M KBr 0.2 M KSCN 0.8 M NaFormate 
8% PEG 20K+ 8% PEG 20K+ 8% PEG 20K+ 8% PEG 20K+ 8% PEG 20K+ 8% PEG 20K+ 
8% PEG550 MME 8% PEG550 MME 8% PEG550 MME 8% PEG550 MME 8% PEG550 MME 8% PEG550 MME 
Clear Strategy Screen II (MDL) 
1 2 3 4 5 6 
1. SM (NH SO4 0.8M Li2SO4 2M NaFormate 0.5 M KH2PO4 25% PEG 2KMME 15% PEG 4K 
0.2 M CaAcetate 0.2 M CaAcetate 
7 8 9 10 11 12 
2.7M (NH42SO4 I. SM Li2SO4 4M NaFonnate 1.0 M KH2PO4 10% PEG 8K 8% PEG 20K 
+10% PEG IK +8% PEG550MME 
0.2 M CaAcetate 0.2 M CaAcetate 
13 14 IS 16 17 18 
40% v/v MPD 40'/e v/v Butanediol 20% PEG 4K 20% PEG 550 MME 20% PEG 600 20'/o PEG I. 5K 
5 mM CdCI2 0.1 5M KSCN 0.15 M KSCN 0.1 5M KSCN 
19 20 21 22 23 24 
35% v/v Isopropanol 30% v/v Jeffamine 20% PEG 4K 18% PEG 3350 18% PEG 5K MME 15% PEG 6K 
600M 5mM NiCI2 0.1 5M KSCN 0.15 M KSCN 0.15 M KSCN 
Buffers (IM): Sodium Acetate pH 4.5, pH 5.5; Sodium Cacodylate pH 6.5; Tris pH 7.5,8.5. 
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Structure Screen I and 1196 HT (MDL) 
tube salt buffer pH precipitant 
Al 0.02 M calcium chloride 0.1 M Na acetate 4.6 30 % v/v MPD 
A2 0.2 M ammonium acetate 0.1 M Na acetate 4.6 30 % w/v PEG 4000 
A3 0.2 M ammonium sulfate 0.1 M Na acetate 4.6 25 % w/v PEG 4000 
A4 None 0.1 M Na acetate 4.6 2.0 M sodium formate 
AS None 0. l M Na acetate 4.6 2.0 M ammonium sulfate 
A6 None 0.1 M Na acetate 4.6 8% w/v PEG 4000 
A7 0.2 M ammonium acetate 0.1 M Na citrate 5.6 30 % w/v PEG 4000 
A8 0.2 M ammonium acetate 0.1 M Na citrate 5.6 30 % v/v MPD 
A9 None 0.1 M Na citrate 5.6 20 % v/v 2-propanol, 
20 % w/v PEG 4000 
A10 None 0.1 M Na citrate 5.6 1.0 M ammonium 
dih dro gen phosphate 
All 0.2 M calcium chloride 0.1 M Na acetate 4.6 20 % v/v 2-propanol 
A12 None 0.1 M Na cacodylate 6.5 1.4 M sodium acetate 
B1 0.2 M sodium citrate 0.1 M Na cacodylate 6.5 30 % v/v 2-propanol 
B2 0.2 M ammonium sulfate 0.1 M Na cacodylate 6.5 30 % w/v PEG 8000 
B3 0.2 M magnesium acetate 0.1 M Na cacodylate 6.5 20 % w/v PEG 8000 
B4 0.2 M magnesium acetate 0.1 M Na cacodylate 6.5 30 % v/v MPD 
B5 None 0.1 M imidazole 6.5 1.0 M sodium acetate 
B6 0.2 M sodium acetate 0.1 M Na cacodylate 6.5 30 % w/v PEG 8000 
B7 0.2 M zinc acetate 0.1 M Na cacodylate 6.5 18 % w/v PEG 8000 
B8 0.2 M calcium acetate 0.1 M Na cacodylate 6.5 18 % w/v PEG 8000 
B9 0.2 M sodium citrate 0.1 M Na HEPES 7.5 30 % v/v MPD 
BIO 0.2 M magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v 2-propanol 
1311 0.2 M calcium chloride 0.1 M Na HEPES 7.5 28 % v/v PEG 400 
B12 0.2 M magnesium chloride 0.1 M Na HEPES 7.5 30 % v/v PEG 400 
C1 0.2 M sodium citrate 0.1 M Na HEPES 7.5 20 % v/v 2-propanol 
C2 None 0.1 M Na HEPES 7.5 0.8 M K/Na tartrate 
C3 None 0.1 M Na HEPES 7.5 1.5 M lithium sulfate 
C4 None 0.1 M Na HEPES 7.5 0.8 M sodium dihydrogen phosphate 
0.8 M potassium dihydrogen phosphate 
C5 None 0.1 M Na HEPES 7.5 1.4 M tri-sodium citrate 
C6 None 0.1 M Na HEPES 7.5 2% v/v PEG 400, 
2.0 M ammonium sulfate 
C7 None 0.1 M Na HEPES 7.5 10 % v/v 2-propanol, 
20 % w/v PEG 4000 
C8 None 0.1 M Tris 8.5 2.0 M ammonium sulfate 
C9 0.2 M magnesium chloride 0.1 M Tris 8.5 30 % w/v PEG 4000 
CIO 0.2 M sodium citrate 0.1 M Tris 8.5 30 % v/v PEG 400 
C11 0.2 M lithium sulfate 0.1 M Tris 8.5 30 % w/v PEG 4000 
C12 0.2 M ammonium acetate 0.1 M Tris 8.5 30 % v/v 2-propanol 
D1 0.2 M sodium acetate 0.1 M Tris 8.5 30 % w/v PEG 4000 
D2 None 0.1 M Tris 8.5 8% w/v PEG 8000 
D3 None 0.1 M Tris 8.5 2.0 M ammonium 
dih dro en phosphate 
D4 None None None 0.4 M K/Na tartrate 
D5 None None None 0.4 M ammonium 
dih dro en phosphate 
D6 0.2 M ammonium sulfate None None 30 % w/v PEG 
8000 
D7 0.2 M ammonium sulfate None None 30 % w/v PEG 4000 
D8 None None None 2.0 M ammonium sulfate 
D9 None None None 4.0 M sodium formate 
D10 0.05 M potassium dihydrogen 
phosphate 
None None 20 % w/v PEG 8000 
D11 None None None 30 % w/v PEG 1500 
D12 None None None 0.2 M magnesium formate 
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El 0.1 M sodium chloride 0.1 M Bicine 9.0 30 % v/v PEG 550 MME 
E2 None 0.1 M Bicine 9.0 2.0 M magnesium chloride 
E3 2% v/v dioxane 0.1 M Bicine 9.0 10 % w/v PEG 20,000 
E4 0.2 M magnesium chloride 0.1 M Tris 8.5 3.4 M 1,6-hexanediol 
ES None 0.1 M Tris 8.5 25 % v/v tert-Butanol 
E6 0.01 M nickel chloride 0.1 M Tris 8.5 1.0 M lithium sulfate 
E7 1.5 M ammonium sulfate 0.1 M Tris 8.5 12 % v/v glycerol 
E8 0.2 M ammonium phosphate 
monobasic 
0.1 M Tris 8.5 50 % v/v MPD 
E9 None 0.1 M Tris 8.5 20 % v/v ethanol 
E JO 0.01 M nickel chloride 0.1 M Tris 8.5 20 % w/v PEG 2000 MME 
Ell 0.5 M ammonium sulfate 0.1 M Na HEPES 7.5 30 % v/v MPD 
E12 None 0.1 M Na HEPES 7.5 10 % w/v PEG 6000, 
5% v/v MPD 
F1 None 0.1 M Na HEPES 7.5 20 % v/v Jeffamine M-600 
F2 0.1 M sodium chloride 0.1 M Na HEPES 7.5 1.6 M ammonium sulfate 
F3 None 0.1 M Na HEPES 7.5 2.0 M ammonium formate 
F4 0.05 M cadmium sulfate 0.1 M Na HEPES 7.5 1.0 M sodium acetate 
F5 None 0.1 M Na HEPES 7.5 70 % v/v MPD 
F6 None 0.1 M Na HEPES 7.5 4.3 M sodium chloride 
F7 None 0.1 M Na HEPES 7.5 10 % w/v PEG 8000, 
8% v/v ethylene I col 
F8 None 0.1 MMES 6.5 1.6 M magnesium sulfate 
ry u. i m soaium amyarogen pnospnate 
0.1 M potassium dihydrogen 
phosphate 
U. 1 M MEN Ö. ) 2.0 M sodium chloride 
F 10 None 0.1 M MES 6.5 12 % w/v PEG 20,000 
FI l 1.6 M ammonium sulfate 0.1 M MES 6.5 10 % v/v dioxane 
F12 0.05 M caesium chloride 0.1 M MES 6.5 30 % v/v Jeffamine M-600 
G1 0.01 M cobalt chloride 0.1 MMES 6.5 1.8 M ammonium sulfate 
G2 0.2 M ammonium sulfate 0.1 M MES 6.5 30 % w/v PEG 5000 MME 
G3 0.01 M zinc sulfate 0.1 MMES 6.5 25 % v/v PEG 550 MME 
G4 None 0.1 M Na HEPES 7.5 20 % w/v PEG 10,000 
G5 0.2 M K/Na Tartrate 0.1 M Na citrate 5.6 2.0 M ammonium sulfate 
G6 0.5 M ammonium sulfate 0.1 M Na citrate 5.6 1.0 M lithium sulfate 
G7 0.5 M sodium chloride 0.1 M Na citrate 5.6 4% v/v polyethyleneimine 
G8 None 0.1 M Na citrate 5.6 35 % v/v tert-Butanol 
G9 0.01 M ferric chloride 0.1 M Na citrate 5.6 10 % v/v Jeffamine M-600 
G10 0.01 M manganese chloride 0.1 M Na citrate 5.6 2.5 M 1,6-hexanediol 
Gil None 0.1 M Na acetate 4.6 2.0 M sodium chloride 
G12 0.2 M sodium chloride 0.1 M Na acetate 4.6 30 % v/v MPD 
H1 0.01 M cobalt chloride 0.1 M Na acetate 4.6 1.0 M 1,6-hexanediol 
H2 0.1 M cadmium chloride 0.1 M Na acetate 4.6 30 % v/v PEG 400 
H3 0.2 M ammonium sulfate 0.1 M Na acetate 4.6 30 % w/v PEG 2000 MME 
H4 2.0 M sodium chloride None None 10 % w/v PEG 6000 
H5 0.01 M CTAB None None 0.5 M sodium chloride 
0.1 M magnesium chloride 
H6 None None None 25 % v/v ethylene glycol 
H7 None None None 35 % v/v dioxane 
H8 2.0 M ammonium sulfate None None 5% v/v 2-propanol 
H9 None None 7.0 1.0 M imidazole 
HIO None None None 10 % w/v PEG 1000, 
10% w/v PEG 8000 
HII 1.5 M sodium chloride None None 10 % v/v ethanol 
H12 None None 6.5 1.6 M sodium citrate 
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PACT premiere 96 HT (MDL) 
tube salt buffer pH PEG 
Al 0.1 M SPG buffer None 4.0 25 % w/v PEG 1500 
A2 0.1 M SPG buffer None 5.0 25 % w/v PEG 1500 
A3 0.1 M SPG buffer None 6.0 25 % w/v PEG 1500 
A4 0.1 M SPG buffer None 7.0 25 % w/v PEG 1500 
AS 0.1 M SPG buffer None 8.0 25 % w/v PEG 1500 
A6 0.1 M SPG buffer None 9.0 25 % w/v PEG 1500 
A7 0.2 M sodium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
A8 0.2 M ammonium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
A9 0.2 M lithium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
A10 0.2 M magnesium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
All 0.2 M calcium chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
A12 0.01 M zinc chloride 0.1 M sodium acetate 5.0 20 % w/v PEG 6000 
BI 0.1 M MIB buffer None 4.0 25 % w/v PEG 1500 
B2 0.1 M MIB buffer None 5.0 25 % w/v PEG 1500 
B3 0.1 M MIB buffer None 6.0 25 % w/v PEG 1500 
B4 0.1 M MIB buffer None 7.0 25 % w/v PEG 1500 
B5 0.1 M MIB buffer None 8.0 25 % w/v PEG 1500 
B6 0.1 M MIB buffer None 9.0 25 % w/v PEG 1500 
B7 0.2 M sodium chloride 0.1 M MES 6.0 20 % w/v PEG 6000 
B8 0.2 M ammonium chloride 0.1 M MES 6.0 20 % w/v PEG 6000 
B9 0.2 M lithium chloride 0.1 M MES 6.0 20 % w/v PEG 6000 
B 10 0.2 M magnesium chloride 0.1 M MES 6.0 20 % w/v PEG 6000 
1311 0.2 M calcium chloride 0.1 M MES 6.0 20 % w/v PEG 6000 
B 12 0.01 M zinc chloride 0.1 MMES 6.0 20 % w/v PEG 6000 
C1 0.1 M PCTP buffer None 4.0 25 % w/v PEG 1500 
C2 0.1 M PCTP buffer None 5.0 25 % w/v PEG 1500 
C3 0.1 M PCTP buffer None 6.0 25 % w/v PEG 1500 
C4 0.1 M PCTP buffer None 7.0 25 % w/v PEG 1500 
C5 0.1 M PCTP buffer None 8.0 25 % w/v PEG 1500 
C6 0.1 M PCTP buffer None 9.0 25 % w/v PEG 1500 
C7 0.2 M sodium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
C8 0.2 M ammonium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
C9 0.2 M lithium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
CIO 0.2 M magnesium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
CII 0.2 M calcium chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
C12 0.01 M zinc chloride 0.1 M HEPES 7.0 20 % w/v PEG 6000 
D1 0.1 M MMT buffer None 4.0 25 % w/v PEG 1500 
D2 0.1 M MMT buffer None 5.0 25 % w/v PEG 1500 
D3 0.1 M MMT buffer None 6.0 25 % w/v PEG 1500 
D4 0.1 M MMT buffer None 7.0 25 % w/v PEG 1500 
D5 0.1 M MMT buffer None 8.0 25 % w/v PEG 1500 
D6 0.1 M MMT buffer None 9.0 25 % w/v PEG 1500 
D7 0.2 M sodium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
D8 0.2 M ammonium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
D9 0.2 M lithium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
D10 0.2 M magnesium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
D11 0.2 M calcium chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
D12 0.002 M zinc chloride 0.1 M Tris 8.0 20 % w/v PEG 6000 
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E1 0.2 M sodium fluoride None 20 % w/v PEG 3350 
E2 0.2 M sodium bromide None 20 % w/v PEG 3350 
E3 0.2 M sodium iodide None 20 % w/v PEG 3350 
E4 0.2 M potassium thiocyanate None 20 % w/v PEG 3350 
to u. L M soaium nitrate None 20 % w/v PEG 3350 
E6 0.2 M sodium formate None 20 % w/v PEG 3350 
E7 0.2 M sodium acetate None 20 % w/v PEG 3350 
E8 0.2 M sodium sulfate None 20 % w/v PEG 3350 
E9 0.2 M potassium/sodium tartrate None 20 % w/v PEG 3350 
ElO 0.02 M sodium/potassium phosphate None 20 % w/v PEG 3350 
Ell 0.2 M sodium citrate None 20 % w/v PEG 3350 
E12 0.2 M sodium malonate None 20 % w/v PEG 3350 
Fl 0.2 M sodium fluoride 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F2 0.2 M sodium bromide 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F3 0.2 M sodium iodide 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F4 0.2 M potassium thiocyanate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F5 0.2 M sodium nitrate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F6 0.2 M sodium formate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F7 0.2 M sodium acetate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F8 0.2 M sodium sulfate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F9 0.2 M potassium/sodium tartrate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F10 0.02 M sodium/potassium phosphate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F11 0.2 M sodium citrate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
F12 0.2 M sodium malonate 0.1 M Bis Tris propane 6.5 20 % w/v PEG 3350 
GI 0.2 M sodium fluoride 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G2 0.2 M sodium bromide 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G3 0.2 M sodium iodide 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G4 0.2 M potassium thiocyanate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G5 0.2 M sodium nitrate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G6 0.2 M sodium formate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G7 0.2 M sodium acetate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G8 0.2 M sodium sulfate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G9 0.2 M potassium/sodium tartrate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G 10 0.02 M sodium/potassium phosphate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
Gil 0.2 M sodium citrate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
G12 0.2 M sodium malonate 0.1 M Bis Tris propane 7.5 20 % w/v PEG 3350 
HI 0.2 M sodium fluoride 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H2 0.2 M sodium bromide 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H3 0.2 M sodium iodide 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H4 0.2 M potassium thiocyanate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H5 0.2 M sodium nitrate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H6 0.2 M sodium formate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H7 0.2 M sodium acetate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H8 0.2 M sodium sulfate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H9 0.2 M potassium/sodium tartrate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H 10 0.02 M sodium/potassium phosphate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H II 0.2 M sodium citrate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
H12 0.2 M sodium malonate 0.1 M Bis Tris propane 8.5 20 % w/v PEG 3350 
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JCSG-plus 96 HT (MDL) 
B9 None 0.1 M Na citrate 5.0 20 % w/v PEG 6K 
BIO 0.2 M magnesium chloride 0.1 M sodium cacodylate 6.5 50 % v/v PEG 200 
B11 None None 6.5 1.6 M tn-sodium citrate 
B12 0.2 M tri-potassium citrate None - 20 % w/v PEG 3350 
C1 0.2 M sodium chloride 0.1 M phosphate/citrate 4.2 20 % w/v PEG 8K 
C2 1.0 M lithium chloride 0.1 M Na citrate 4.0 20 % w/v PEG 6K 
C3 0.2 M ammonium nitrate None - 20 % w/v PEG 3350 
C4 None 0.1 M HEPES 7.0 10 % w/v PEG 6K 
C5 None 0.1 M Na HEPES 7.5 0.8 M sodium dihydrogen phosphate 
0.8 M potassium dihydrogen phosphate 
C6 None 0.1 M phosphate/citrate 4.2 40 % v/v PEG 300 
C7 0.2 M zmc acetate 0.1 M sodium acetate 4.5 IO % w/v PEG 3K 
C8 None 0.1 M Tris 8.5 20 % v/v Ethanol 
C9 None 0.1 M Na/K phosphate 6.2 25 % v/v 1,2-propanediol 
10 % v/v Glycerol 
CIO None 0.1 M Bicine 9.0 10 % w/v PEG 20,000/ 2% v/v Dioxane 
CII None 0.1 M sodium acetate 4.6 2.0 M ammonium sulfate 
C12 None None 10 % w/v PEG 1000/ 10 % w/v PEG 8000 
Dl None None 24 % w/v PEG 1500120 % v/v Glycerol 
D2 0.2 M magnesium chloride 0.1 M Na IJEPES 7.5 30 % v/v PEG 400 
D3 0.2 M sodium chloride 0.1 M Na/K phosphate 6.2 50 % v/v PEG 200 
D4 0.2 M lithium sulfate 0.1 M sodium acetate 4.5 30 % w/v PEG 8K 
D5 None 0.1 M HEPES 7.5 70 % v/v MPD 
D6 0.2 M magnesium chloride 0.1 M Tris 8.5 20 % w/v PEG 8K 
D7 0.2 M lithium sulfate 0.1 M Tris 8.5 40 % v/v PEG 400 
D8 None 0.1 M Ths 8.0 40 % v/v MPD 
D9 0.17 M ammonium sulfate None - 25.5 % w/v PEG 4K/ 15 % v/v Glycerol 
DI O 0.2 M calcium acetate 0.1 M Sodium cacodylate 6.5 40 % v/v PEG 300 
DI I 0.14 M calcium chloride 0.07 M Sodium acetate 4.6 14 % v/v 2-propanol/ 30 % v/v Glycerol 
D12 0.04 M potassium dihydrogen phosphate None 16 % w/v PEG 8K/ 20 % v/v Glycerol 
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EI None 0.1 M sodium cacodylate 6.5 1.0 M tn-sodium citrate 
E2 0.2 M sodium chloride 0.1 M sodium cacodylate 6.5 2.0 M ammonium sulfate 
E3 0.2 M sodium chloride 0.1 M HEPES 7.5 10 % v/v 2-propanol 
E4 0.2 M lithium sulfate 0.1 M Tns 8.5 1.26 M ammonium sulfate 
ES None 0.1 M CAPS 10.5 40 % v/v MPD 
E6 0.2 M zmc acetate 0.1 M imidazole 8.0 20 % w/v PEG 3K 
E7 0.2 M zmc acetate 0.1 M sodium cacodylate 6.5 10 % v/v 2-propanol 
E8 None 0.1 M sodium acetate 4.5 1.0 M di-ammonium hydrogen phosphate 
E9 None 0.1 M MES 6.5 1.6 M magnesium sulfate 
E10 None 0.1 M Bicine 9.0 10 % w/v PEG 6K 
Ell 0.16 M calcium acetate 0.08 M sodium cacodylate 6.5 14.4 % w/v PEG 8K/ 20 % v/v glycerol 
E12 None 0.1 M imidazole 8.0 10 % w/v PEG 8K 
FI 0.05 M caesium chloride 0.1 M MES 6.5 30 % v/v Jeffamme M-600 
F2 None 0.1 M Na Citrate 5.0 3.2 M ammonium sulfate 
F3 None 0.1 M Tns 8.0 20 % v/v MPD 
F4 None 0.1 M HEPES 7.5 20 % v/v Jeffamine M-600 
FS 0.2 M magnesium chloride 0.1 M Tns 8.5 50 % v/v ethylene glycol 
F6 None 0.1 M Btcine 9.0 10% v/v MPD 
F7 None None 7.0 0.8 M succimc acid 
F8 None None 7.0 2.1 M Dl-malte acid 
F9 None None 7.0 2.4 M sodium malonate 
FlO 1.1 M sodium malonate 0.1 M HEPES 7.0 0.5 % v/v Jeffamme ED-2001 
F11 1.0 M succmtc acid 0.1 M HEPES 7.0 1% w/v PEG 2000 MME 
F12 None 0.1 M HEPES 7.0 30 % v/v Jeffamine M-600 
G1 None 0.1 M HEPES 7.0 30 % v/v Jeffamine ED-2001 
G2 0.02 M magnesium chloride 0.1 M HEPES 7.5 22 % w/v polyacrylic acid 5100 sodium salt 
G3 0.01 M cobalt chloride 0.1 M Tns 8.5 20 % w/v polyvinylpynolidone KIS 
G4 0.2 M tn-methylamme N-oxide 0.1 M Tris 8.5 20 % w/v PEG 2K MME 
G5 0.005 M cobalt chloride 
0.005 M cadmium chloride 
0.005 M magnesium chloride 
0.005 M nickel chloride 
0.1 M HEPES 7.5 12 % w/v PEG 3350 
G6 0.2 M sodium malonate None 7.0 20 % w/v PEG 3350 
G7 0.1 M succmtc acid None 7.0 15 % w/v PEG 3350 
G8 0.15 M DL- malic acid None 7.0 20 % w/v PEG 3350 
G9 0.1 M potassium thiocyanate None None 30 % w/v PEG 2K MME 
G 10 0.15 M potassium bromide None None 30 % w/v PEG 2K MME 
Gil None 0.1 M Bis Tns 5.5 2.0 M ammonium sulfate 
G12 None 0.1 M Bis Tns 5.5 3.0 M sodium chloride 
HI None 0.1 M Bis Tns 5.5 0.3 M magnesium formate 
H2 1.0 M ammonium sulfate 0.1 M Bis Iris 5.5 1% w/v PEG 3350 
H3 None 0.1 M Bis Tris 5.5 25 % w/v PEG 3350 
H4 0.2 M calcium chloride 0.1 M Bis Tns 5.5 45 % v/v MPD 
H5 0.2 M ammonium acetate 0.1 M Bis Tns 5.5 45 % v/v M PD 
H6 0.1 M ammonium acetate 0.1 M Bis Tns 5.5 17 % w/v PEG IOK 
H7 0.2 M ammonium sulfate 0.1 M Bis Tns 5.5 25 `/o w/v PEG 3350 
H8 0.2 M sodium chloride 0.1 M Bis Iris 5.5 25 %w/v PEG 3350 
H9 0.2 M lithium sulfate 0.1 M Bis Tns 5.5 25 % w/v PEG 3350 
H 10 0.2 M ammonium acetate 0.1 M Bis Ins 5.5 25 % w/v PEG 3350 
H11 0.2 M magnesium chloride 0.1 M Bis Tns 5.5 25 % w/v PEG 3350 
H12 0.2 M ammonium acetate 0.1 M HEPES 7.5 45 % v/v MPD 
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